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Julie Kristin Hurt 
 
Chair: George A. Garcia 
Shigella flexneri is a human enteropathogen that invades the intestinal 
mucosa and results in severe bacillary dysentery.  With the emergence of 
multiantibiotic-resistant strains, the development of novel therapeutics against 
critical S. flexneri target proteins promises a more effective treatment regimen for 
shigellosis.  VirF is the positive regulator of transcription in the Shigella spp. 
virulence cascade, and #virF mutant strains of S. flexneri are avirulent.  Although 
many cellular factors are associated with expression of the VirF protein (i.e., 
temperature, pH), previous studies demonstrated that the concentration of VirF 
protein is decreased by 60% in #vacC mutant strains of S.flexneri.  VacC is 
tRNA-guanine transglycosylase (TGT), an RNA-modification enzyme that 
catalyzes the incorporation of the modified nucleoside queuosine (Q) in substrate 
xii 
tRNA.  We have studied the VirF protein as a novel antibacterial target in 
Shigella flexneri, with a focus on both modulation of VirF expression by TGT and 
expression and activity of the VirF protein itself. 
We hypothesized that TGT modulates VirF protein expression through 
queuine modification at both the level of tRNA and the virF mRNA.  We report 
that the modification state of tRNA with queuine and the Q-cognate codon usage 
(NAU versus NAC codons) in the target mRNA alters the rate of protein 
expression.  VirF mRNA contains an overall bias of 80% for the NAU Q-cognate 
codons, and it is conceivable that the subtle decrease in VirF protein expression 
in the S. flexneri (#vacC) mutant results from the absence of queuine-modified 
tRNA.  In addition, we report that the virF mRNA is itself a substrate for the 
eubacterial TGT in vitro.  Modification of RNA sequences (termed riboswitches) 
with small molecule metabolites has been shown to modulate either transcription 
or translation of the target RNA. 
To measure VirF activity in the presence of small molecules, we report the 
development of a high-throughput cell-based reporter assay using a virB 
operator-"-galactosidase fusion.  We have screened approximately 42,000 small 
molecules and report the identification of 7 compounds with low to mid-
micromolar IC50 values in the VirF – "-galactosidase assay.  Further studies are 











The prevalence of infectious diseases represents a continuing threat that 
disproportionately plagues many third world countries [1].  Responsible for one-
third of all deaths, infectious diseases claim the lives of 15 million people each 
year, including 2 million children.  Among those diseases considered to be most 
preventable are the diarrheal diseases, which are the cause of 15-34% of all 
deaths.  The prevalence of such diseases is based on several unregulated 
components of the environment in third world countries, including access to clean 
drinking water, hygiene, and sanitation.  Infections of the gastrointestinal tract are 
commonly caused by food- and water-borne pathogens (i.e., enteroinvasive E. 
coli, Shigella, Salmonella, Listeria, etc.).  These pathogens have developed 
complex regulatory mechanisms to infect host cells and initiate an immune 
response that triggers severe inflammation and cell death [2, 3].  Current 
treatments for bacillary dysentery include re-hydration therapy and development 
of a multivalent vaccine containing antigens from the following bacterial species: 
Campylobacter, Shigella and Enterotoxigenic Escherichia coli [1].  With the 
recent emergence of many antibiotic-resistant strains of these food- and water-
borne pathogens, there is an increasing need for identification of novel agents as 




Shigella flexneri and Shigellosis 
 
Shigella flexneri is a severe enteropathogen that plagues more than one 
million victims per year worldwide, leading to severe dysentery in humans [1].  
The complex mechanism by which Shigella infects the host cells of the 
gastrointestinal tract has been the subject of much research, and was recently 
reviewed [2].  In the initial stages of infection, Shigella cross the epithelial layer in 
the gastrointestinal tract by way of M cells.  The initial host inflammatory cascade 
is induced following invasion and subsequent lysis of macrophages, which 
release cytokines and elicit an immune response.  The bacteria then invade the 
mucosal cells of the epithelium from the basolateral side following expression of 
the type III secretion system (TTSS), a bacterial virulence determinant that 
facilitates transfer of key virulence proteins (i.e., ipa proteins) from the pathogen 
into the host cells [4, 5].   
The pathogenicity of Shigella is controlled in large part by approximately 
70 virulence genes encoded on a large molecular weight plasmid [6, 7].  The so-
called entry region contains 37 A+T-rich open reading frames, and the protein 
products of these key virulence genes serve as the structural components of the 
TTSS as well as key regulator proteins (i.e., VirB) [8].  All other virulence genes 
are located elsewhere on the ~220 kb plasmid [9].  There are two proteins 
associated with global regulation of the virulence genes: the positive regulator, 
VirF, and the negative regulator, H-NS (VirR) [10-13].  Figure I-1 presents a 





Figure I-1: Model of Shigella Pathogenesis.  Infection of the intestinal mucosal 
cells is facilitated by the transcriptional activator, VirF.  The 
secondary activator, VirB, is positively regulated by VirF and 
negatively regulated by H-NS (which also represses virf 
transcription).  Several of the key downstream virulence proteins are 
also highlighted. 
 
VirF is an AraC-type transcriptional activator that directly regulates 
transcription of the secondary positive regulator, VirB, and the actin-polymerizing 
enzyme, VirG (IcsA) [14-19].  H-NS, on the other hand, is a bacterial DNA-
binding protein that forms an oligomeric structure (homodimer or -tetramer) that 
binds to the promoter region of many virulence genes, including virf and virb, 
which alters the DNA structure to a transcriptionally inactive confirmation [20, 21].  
Ultimately, VirB activates transcription of many of the key downstream virulence 
genes (i.e., ipaBCD, virG(icsA), mxiD) [22, 23].  As the master regulator of 
positive transcriptional activation, VirF is of particular interest as a novel target in 
the treatment of shigellosis. 
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Regulation of VirF Expression 
Expression of VirF in Shigella flexneri is tightly regulated.  There are 
several environmental factors that promote the translation of VirF, including 
oxygen and iron limitation, temperature regulation, and posttranscriptional RNA 
modification [24].  Transcriptional repression of the virF and virB mRNAs by H-
NS is regulated by temperature [25].  Full virulence gene expression is observed 
at 37°C, but at 30°C the H-NS oligomer binds the promoter of each gene and 
inhibits transcription.  In the case of virB, there is a conformational change at 
37°C that results in dissociation of H-NS and allows VirF to bind and recruit the 
transcriptional machinery [26].  In addition to repression by H-NS, transcription of 
the virf gene is positively regulated in a pH-dependant manner by the two-
component regulatory system CpxA/CpxR [11, 27]. 
The modification state of several tRNAs have also been shown to play a 
role in translational regulation of the VirF protein [24].  One form of RNA 
modification is performed by the enzyme tRNA-guanine transglycosylase (TGT), 
which catalyzes the exchange of guanine for the modified nucleoside queuine in 
eukaryl and eubacterial tRNAAsp, Asn, His, Tyr [28]. In vivo, eubacterial organisms 
synthesize queuine from its chemical precursor, preQ1, whereas eukaryl species 
must acquire queuine from external routes such as diet.  The structures of the 





Figure I-2: Heterocyclic Substrates of TGT. A) guanine, B) preQ1 (7-
aminomethyl-7-deazaguanine), C) queuine ([7-(4,5-cis-dihydroxy-1-
cyclopenten-3-yl-aminomethyl)-7-deazaguanine). 
 
In each organism, although by different pathways, TGT catalyzes the exchange 
of guanine for queuine in the wobble position (34) of these cognate tRNA 
molecules with the common anticodon sequence G34U35N36 [29]. Biochemical 
experiments have primarily focused on the characterization of TGT and other 
enzymes in the queuosine biosynthetic pathway in eubacteria [30-32].  Though 
much is known, and continuing to unfold about this pathway, the biological 
relevance of queuine-modified tRNA has not yet been fully elucidated.  The E. 
coli (!tgt) mutant has been characterized as exhibiting no observable defective 
phenotype under optimal growth conditions, and in fact the cells grow to mid-log 
phase slightly faster than wildtype [33].  The E. coli (!tgt) mutant does exhibit 
growth defects under stress (particularly oxidative) conditions.  Studies have also 
shown that while there is the potential for leaky read-through of the UAG stop 
codon by tRNATyr-G34, Q-modified tRNATyr does not mistranslate this codon [34].  
Interestingly, the extent of queuine modification in eukaryotic tRNA populations 
has also been linked to several cancers [35, 36]. 
Durand and colleagues [24, 37] have demonstrated a correlation between 
virF and tgt by characterizing vacC (tgt) mutant S. flexneri strains.  In these 
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mutants, the production of VirF is markedly reduced (VirF expression is ~40% 
relative to concentration in wildtype Shigella) and the bacteria are less virulent.  
When monitoring the production of the downstream virulence genes (i.e., 
ipaBCD), their expression was also reduced by approximately 50% in 
comparison to wildtype protein levels.  Addition of an inducible copy of the virf 
gene in trans (tac-based plasmid) restored both VirF expression and virulence in 
the !vacC Shigella flexneri mutant.  Taken together, these results suggest that 
the presence of Q34-modified tRNA has a specific effect on the translation of the 
VirF protein.  In order to probe this interaction between TGT and VirF, we 
propose two models of regulation for translation of the virF mRNA: 1) the 
modification state of queuine-cognate tRNA effects VirF expression, or 2) the virF 
mRNA is itself directly modified with queuine. 
Investigating How Queuine-cognate Codon Usage Alters the Rate of Protein 
Expression (Chapter II). 
The role modified nucleosides play in the recognition of transfer RNA at 
the ribosome has been an issue of ongoing investigation.  Several in vitro studies 
have been conducted to monitor binding of tRNA to the ribosome-mRNA 
complex [38, 39].  Uhlenbeck and coworkers found that association for various 
tRNA species was similar, but the rate of dissociation from the ribosome was 
increased for unmodified tRNA versus their fully-modified counterparts [38].  
While the rate of dissociation was faster overall for unmodified tRNAs, the rates 
varied depending on position in the ribosome (i.e., A-site versus P-site) and the 
state of aminoacylation.  Of the Q-cognate tRNAs tested, tRNAHis demonstrated 
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the most notable sensitivity to the presence of global modifications, with a 
dissociation rate 60-fold higher for unmodified tRNA in the P-site.  Conversely, 
the koff for tRNAHis was only 3-fold higher for unmodified tRNA in the A-site when 
compared to the fully modified tRNAHis.  The authors conclude that there are 
several unique interactions between each tRNA and the ribosome-mRNA 
complex, and the overall effect is to equalize the thermodynamics of each 
binding event to achieve a normalized rate of protein synthesis. 
To determine the specific codon bias of Q-modified substrate tRNA (i.e., 
NAU versus NAC), a cell-based approach was performed using X. laevis oocytes 
[40].  Under competitive conditions, tRNAHis-G34 and tRNAHis-Q34 from Drosophila 
melanogaster were esterified with radiolabeled histidine, and the translation of 
His codons in a model mRNA sequence was studied following cyanogen bromide 
cleavage of the protein product.  When tRNAHis-G34 was labeled, the authors 
observed that peptide fragments translated from the CAC histidine codon 
demonstrated higher levels of radioactivity in comparison to the CAU-translated 
fragments (64:36, respectively).  Radiolabeled tRNAHis-Q34, however, did not 
show a significant preference for one codon over the other in comparison to the 
control experiment. 
This apparent preference for NAC codons by Q-cognate tRNA-G34 was 
also studied computationally [41].  Molecular modeling experiments were 
conducted based on the crystal structure of tRNAAsp and the recognition of the 
modified/unmodified anticodon with both GAU- and GAC-containing mRNA.  
Queuine and several Q-precursors (guanine, 7-deazaguanine, preQ1) were 
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modeled in position 34 of the tRNA anticodon loop.  For both guanine and 7-
deazaguanine, the interaction with the GAC codon was facilitated through three 
full Watson-Crick hydrogen bonds, while only two H-bonds were predicted with 
the GAU codon.  The presence of preQ1 and queuine in the anticodon loop 
altered the hydrogen bonding capability of the purine carbonyl moiety (O6) due to 
an energetically favorable intramolecular interaction with the amine side chain in 
each modified nucleoside.  Interestingly, queuine was further predicted to alter 
the flexibility of the anticodon through an increased hydrogen bonding network, 
with contacts between the cyclopentendiol hydroxyl groups and the backbone of 
U33, as well as an intraloop hydrogen bond between U33 and C36 (Figure I-3).  
This interaction between U33 and C36 was first observed in molecular modeling 
experiments with tRNAAsp-G34, but the lifetime was shorter in the absence of 
queuine or preQ1 [42, 43].  The authors postulate that this increased rigidity 
aligns the anticodon loop of the Q-modified tRNA such that only two hydrogen 
bonds are formed with both NAU and NAC codons, whereas tRNA-G34 makes 
preferential hydrogen bonding contact (i.e., Watson-Crick hydrogen bonding) with 




Figure I-3: Hydrogen-bonding Interactions in the Anticodon Loop of tRNAAsp.  A) 
Anticodon stem-loop sequence of tRNAAsp-G34 (nucleotides 27-43 
illustrated).  B) Hydrogen-bonding parameters determined by x-ray 
crystallography of the tRNAAsp anticodon loop between uridine 33 
(U33) and cytosine 36 (C36).  From Auffinger et al. (1996), Journal of 
the American Chemical Society, 118(5): 1181-1189. 
 
Recently, a manuscript was published that sought to address the issue of 
codon bias in vivo using gfp as a model mRNA sequence [44].  A library was 
constructed of randomly altered gfp sequences, where the global degenerate 
codon usage of each template was changed by mutation of the third nucleotide 
position in each codon.  The authors observed a significant variation in 
fluorescence among the constructs, suggesting the possibility that changes in 
codon usage directly affected the levels of GFP protein expressed.  However, 
their primary conclusions implicate mRNA secondary structure and stability as 
the more influential factors on protein synthesis.  Though the authors conclude 
that tRNA populations (i.e. rare tRNAs/isoforms) did not have a dramatic effect 
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on protein expression, it has been shown, in the case of S. flexneri VirF, that a 
subtle decrease in protein expression (40% in comparison to wild type levels) 
was sufficient to decrease activation of the virulence cascade [24].  In Chapter II, 
studies to probe the differential codon recognition model are presented. 
Investigating Modification of virF mRNA by TGT (Chapter III)   
The role of modified nucleosides in RNA structure and stability has been 
well-studied [45-47].  Agris and coworkers have identified key interactions 
between modified nucleosides and magnesium ions essential to the secondary 
structure of tRNA, in addition to facilitating key RNA-protein interactions [48].  
Mandal and Breaker have characterized binding of small molecules and 
metabolites to RNA motifs termed “riboswitches” [49, 50]. 
 
Figure I-4: Structure of the Class I PreQ1 Riboswitch in B. subtilus queC.  In the 
absence of preQ1, the queC RNA forms a transcriptionally active 
hairpin confirmation.  When preQ1 is bound, however, the RNA 
structure changes to a terminator sequence.  Taken from Kang et al., 
Molecular Cell (2009), 33(6): 784-790.  
 
Riboswitches are structural motifs in mRNAs (often in the 5' untranslated region 
and extending into the start of the open reading frame) that can exist in at least 
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two stable conformations.  One of these conformations is stabilized by binding to 
a small molecule, thus altering the equilibrium between the conformations.  One 
conformation supports translation of the protein while with the other 
conformation, translation is blocked.  In this way, binding of the small molecule 
changes the conformation of the RNA and modulates its translation.  
Riboswitches have also been characterized as regulators of transcription, with 
the formation of a transcription terminator complex dependent on the 
concentration of the bound metabolite [51].  In addition to the 5' untranslated 
region (UTR) of prokaryotic mRNAs, riboswitches have also been found in the 3' 
UTR and introns in several eukaryotic species [52].  Interestingly, several groups 
have reported the discovery of two classes of riboswitches that respond to the 
queuine precursor, preQ1, and appear to regulate the expression of the four 
genes that are involved in preQ1 biosynthesis [53-56].  In the case of a preQ1 
riboswitch identified in the queuosine biosynthetic gene, queC, solution NMR 
structures revealed that preQ1-bound RNA formed a transcription terminator 
pseudoknot structure (Figure I-4) [56].  It certainly seems possible that base 
modification of an mRNA could modulate a similar conformational change.  It 
therefore is feasible that such a control mechanism for gene expression might be 
involved in regulating the expression of virulence factors in pathogenic 
organisms, as is apparently seen with VirF. 
The incorporation of modified nucleosides has been characterized more 
fully for tRNA (and some other RNAs, e.g., rRNA & snRNA), than for mRNA [57-
59].  The most common example of post-transcriptional processing in mRNA is 
 
 12 
the eukaryotic 7-methylguanosine 5' cap structure, which aids in the binding to 
the small ribosomal subunit and is essential for the efficient synthesis of 
eukaryotic proteins [60-62].  To date, the only known function of TGT is to 
catalyze the modification of tRNA with queuine.  Previous work has shown that 
the eubacterial TGT will recognize a U-G-U sequence in the loop of an RNA 
hairpin structure that corresponds to the anticodon stem-loop of its cognate 
tRNAs [63, 64].  The eubacterial TGT will also recognize a U-G-U containing 
hairpin in the context of a dimeric form of a cognate tRNA [65].  It is conceivable 
that an mRNA may also be modified directly by TGT provided the mRNA 
contained the appropriate recognition elements.  In Chapter III, in vitro kinetic 
analyses of E. coli TGT and various virF mRNA substrates will be discussed. 
The VirF Protein – A Novel Drug Target in Shigella 
In addition to monitoring the regulation of VirF expression, our second aim 
is to study VirF function.  VirF is a member of the AraC family of transcriptional 
regulators [66].  There are three classes of AraC-type regulators: chemically-
modulated, physically-modulated, and monomeric [67].  AraC itself is a member 
of the first class and is modulated by arabinose [68].  VirF is a member of the 
second class and is modulated by temperature, pH and osmolarity [69].  MarA is 
a member of the third class of monomeric regulators that lack the amino terminal 
dimerization domain [70, 71].  In general, a high degree of sequence similarity is 
exhibited in the C-terminal domain of AraC-family members, but very little 
sequence homology is observed in the N-terminus (where applicable).  Figure I-5 
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shows a 1.6 Å crystal structure solved for AraC in the L-arabinose-bound and 
unbound states [68].   
 
 
Figure I-5: Crystal Structure of AraC from E. coli. A) In the presence of L-
arabinose, the DNA-binding domains of the AraC monomers are held 
in close proximity for binding of adjacent sites in the downstream 
promoters.  B) In the absence of arabinose, the DNA-binding 
domains are bound to opposing regions of the promoter DNA, and 
transcription initiation is halted.  Taken from Soisson et al. Science, 
(1997), 276(5311): 421-425. 
 
In most cases, AraC-family members function as transcriptional activators; 
however, AraC is unique in that the homodimer acts as both a repressor and an 
activator of the araBAD operon.  In the absence of L-arabinose, AraC binds 
opposing sites in the araBAD operon and creates a DNA loop that prevents 
transcription from occurring [72, 73].  In the presence of L-arabinose, however, 
the AraC dimer binds an adjacent site in the operon, releasing the DNA loop and 
adopting a conformation favorable for transcription initiation. 
Many bacterial pathogens utilize AraC-type regulators to activate transcription 
of key virulence genes (i.e., Shigella (VirF), Enterotoxigenic E. coli (CfaD), 
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Salmonella (SprA), Vibrio (ToxT), Pseudomonas (ExsA)) [69, 74-77].  The 
relatively widespread distribution of VirF and VirF-homologous systems suggests 
that the investigation of VirF as a novel antibiotic target in Shigella may extend to 
other important human pathogens.  However, many attempts to express and 
purify recombinant AraC-family members have failed due to the insoluble nature 
of the overexpressed DNA-binding proteins [16, 78].  Due to increased solubility, 
the monomeric class of transcriptional activators has been studied more 
extensively [70, 71].   
 
Figure I-6: Crystal Structures of Monomeric AraC-type Proteins Rob and MarA 
with DNA Bound.  Rob binds to the micF promoter making primary 
contacts with one of the HTH motifs.  MarA (bound to the mar 
promoter) facilitates DNA-binding with both HTH motifs characteristic 
of the AraC family, creating a bend in the DNA.  Taken from Kwon et 




Figure I-6 shows the crystal structures of Rob and MarA bound to their DNA 
promoter sequences (micF and mar respectively), with the critical protein-DNA 
interactions made through the conserved helix-turn-helix motif (HTH) 
characteristic to the AraC family.  Although much information has been obtained 
from DNA-binding analyses of this monomeric class, many of the AraC-type 
regulators involved in bacterial virulence function as homodimers of multi-domain 
proteins (i.e., contain both dimerization and DNA-binding domains).  In an 
attempt to gain more knowledge of the virulence factor, VirF from S. flexneri, we 
propose 1) study of the recombinant VirF protein in vitro with various molecular 
biology manipulations in an attempt to improve expression, and 2) expression in 
a cell-based reporter assay as a high-throughput screen for potential inhibitors. 
Expression and Purification Trials with the VirF Protein (Chapter IV) 
 Discovery of new methods for expressing “problematic” or “toxic” proteins 
in vitro and in vivo is an ongoing area of research.  In some cases, expression is 
studied through alteration of the protein induction conditions in a host strain 
(typically E. coli).  One standard method for increasing protein solubility is the 
expression of recombinant proteins with fusion tags and has been the subject of 
several recent reviews [79-81].  Fusion tags are selected based on optimal 
characteristics of protein solubility and ease of expression.  Among the most 
commonly used fusion tags are MBP (maltose-binding protein), GST 
(glutathione-S-transferase), Trx (thioredoxin) and NusA (N-utilization substance) 
[79].  Although in some cases these protein partners can result in improved 
solubility, the effects of each fusion tag are different depending on the candidate 
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protein of interest.  Other methods for altering the induction conditions in E. coli 
include lower growth temperatures and over expression of specific tRNAs for 
expression of proteins with rare codon usage [82]. 
 Protein insolubility is often linked to aggregation of the recombinant 
protein in E. coli and the formation of inclusion bodies [83].  Some evidence 
suggests that expression of insoluble proteins can be overcome with use of more 
tightly regulated bacterial promoters, such as the araBAD promoter from E. coli 
[84].  Molecular chaperones have also been used to direct protein folding when 
co-expressed with the target protein.  Several heat shock proteins with 
chaperone function have been identified in prokaryotic species (i.e., GroEL, 
GroES, DnaK, GrpE) [85, 86].  If solubility cannot be regulated under native 
expression conditions, some success has come from denaturing the protein of 
interest in the presence of high concentrations of a chemical denaturant (i.e., 
urea or guanidinium chloride).  Protein re-folding is then conducted with gradual 
dialysis to remove the denaturant and exchange the protein into a proper buffer 
to monitor recovery of activity.  Though much is known about troubleshooting this 
issue of protein solubility, expression of the recombinant VirF protein in E. coli 
has historically proven difficult [16, 87].  In Chapter IV, a presentation of efforts to 
express recombinant VirF in vivo and in vitro will be discussed. 
Development of a High-throughput Reporter Assay to Screen Small Molecule 
Inhibitors of VirF Activity (Chapter V) 
Recently, there has been increased interest in development of novel 
antibiotics that target virulence factors [88-90].  Though the prevalence of AraC-
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type transcriptional activators make them an attractive target for treatment of a 
wide range of bacterial pathogens, the pharmaceutical industry has historically 
focused on development of bactericidal antimicrobial agents (i.e., inhibitors of 
DNA/RNA, protein, or cell wall synthesis).  Though many potent drugs have been 
designed against these fundamental bacterial targets, the use of antibiotics in the 
food industry and everyday household products has lead to the emergence of 
antibiotic-resistant strains of medically-relevant bacteria [91].  Because 
expression of virulence factors is not required for cell viability, there should be 
less selective pressure for the pathogens to develop resistance to inhibitors of 
such targets.  Though the study of AraC family members has thus far focused on 
identification of downstream virulence targets and protein-DNA interactions, there 
is increasing interest in developing functional assays to screen for potential 
inhibitors. 
Researchers at Paratek Pharmaceuticals have studied several members 
of the AraC family related to bacterial virulence in vitro [92, 93].  Using a coupled 
approach with in silico screening of small molecules and solved crystal structures 
of three AraC members from E. coli (MarA, SoxS and Rob) and an in vitro DNA-
binding assay, researchers identified a promising class of AraC-type DNA-
binding inhibitors: hydroxybenzimidazole derivatives [93].  Though the 
compounds demonstrated inhibition of DNA-binding in vitro with IC50 values in 
the low micromolar range, this study only addresses one aspect of AraC-type 
regulator function.  Recently, the same group reported activity of a similar 
compound set (N-hydroxbenzimidazoles) against LcrF in Yersinia spp. [92].  LcrF 
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is a Mar-like protein that activates transcription of the type III secretion system.  
Following synthesis of various analogues, compounds were validated in a cell-
based cytotoxicity assay as well as DNA-binding analysis with an LcrF 
homologue (ExsA from Salmonella) and an unrelated transcriptional activator 
(SlyA from Salmonella) to establish specificity.  In the case of VirF, there are at 
least three steps in the gene activation process (although the order is not clearly 
understood): DNA binding, dimerization, and recruitment of the transcription 
complex.  In Chapter V, we describe a primary cell-based functional assay, which 
would screen for inhibition of any of these processes, with more specific 
secondary assays to both validate the hits and to probe their mechanisms of 
action. 
Research Objectives 
VirF from Shigella flexneri is the key transcriptional activator of the 
virulence cascade.  Though some details of VirF activity and specificity are 
known (i.e., DNA-binding sites, primary targets for activation, activators and 
repressors of protein expression), the specific mechanism by which VirF 
activates transcription is unclear.  One interesting point of regulation in the VirF 
lifecycle was discovered by Durand and colleagues, demonstrating a link 
between RNA modification by TGT and protein expression [24, 94].  To better 
understand this master virulence regulator, the approach for this dissertation 
research is two-fold: 1) characterize the mechanism by which RNA modification 
with queuine alters VirF protein expression, and 2) study the VirF protein directly 
to gain structural and functional information about the bacterial transcription 
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factor.  The primary questions addressed in each chapter of this dissertation are 
listed below. 
RNA Modification and VirF Expression 
• Chapter II: Does the queuosine modification in substrate tRNA and 
degenerate codon usage alter the rate of protein expression? 
• Chapter III: Does the virF mRNA serve as a substrate for queuosine 
modification by TGT? 
Functional/Structural Characterization of the VirF Protein 
• Chapter IV: Can the issue of recombinant VirF solubility in E. coli be 
overcome by molecular manipulation? 
• Chapter V: Can we study VirF in vivo as a means to screen small 
molecule inhibitors of the bacterial transcription factor? 
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tRNA Wobble Base Modification Modulates Translation via a Redundant 
Codon Bias Mechanism 
 
The genetic code provides multiple synonymous codons for 18 of the 20 
naturally occurring amino acids (excluding methionine and tryptophan).  For 
many of these amino acids, there are several tRNA isoforms that recognize a 
particular codon or subset of codons.  Codon usage varies between species, and 
the implications of codon bias were recently reviewed [1].  Many factors are 
involved in protein synthesis, including the concentration of appropriate tRNA 
isoforms, the post-transcriptional modification state of tRNA and the energetics of 
tRNA binding to the mRNA-ribosome complex [2, 3].  Though the occurrence of 
degenerate codon usage has been well documented, there is little direct 
evidence measuring the biological relevance of this phenomenon. 
Recently, a study was published that sought to address the effect of codon 
bias on protein translation in vivo using gfp as a model mRNA [4].  The author’s 
primary conclusions implicate mRNA secondary structure and stability as the 
more influential factors on protein synthesis.  Although these authors observed 
that tRNA populations (i.e., rare tRNAs/isoforms) did not have a dramatic effect 
on protein expression, it has been shown that the modification state of tRNA can 
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affect not only protein synthesis but bacterial virulence as well in the case of a 
!vacC (tgt homologue) mutant of Shigella flexneri [5].  In this mutant strain, a 
subtle decrease in protein expression of the positive transcriptional regulator, 
VirF (40% in comparison to wild type levels) was sufficient to decrease activation 
of the virulence cascade. 
tRNA-guanine transglycosylase (TGT) is an RNA modification enzyme 
that catalyzes the incorporation of the non-cannonical nucleoside, queuosine (Q), 
into the wobble position of four substrate tRNAs (Asn, Asp, His, Tyr) [6].  For 
each of these four amino acids, there is a single tRNA that decodes two 
synonymous codons (NAC and NAU, where N is any of the canonical 
nucleosides).  Interestingly, the virF mRNA exhibits a bias of "90% for NAU 
codons of Asp, His, and Tyr, with an overall bias of 80% toward the NAU Q-
cognate codons.  In this study, we aim to address the biological relevance of the 
queuine modification in substrate tRNA as it relates to protein synthesis.  With 
DNA microarray analysis comparing the gene expression profiles of wild-type E. 
coli K12 and a K12(!tgt) mutant, we report several key cellular mRNAs with 
altered expression levels, relative to wild-type, in the absence of this unique RNA 
modification.  Computational analysis of the protein-coding sequences in the 
genomes of E. coli and S. flexneri revealed similar trends in protein classes with 
biased queuine-cognate codon usage.  Finally, we show with detailed kinetic 
analyses that both tRNA-G34 and tRNA-Q34 demonstrate apparent preferential 




Materials and Methods 
Reagents 
Unless otherwise specified, all reagents were from Sigma or Aldrich.  DNA 
oligonucleotides, agarose, dithiothreitol (DTT), T4 DNA ligase, IPTG, 
SuperScriptIII™ reverse transcriptase, RNaseOUT RNase inhibitor, and DNA 
ladders were from Invitrogen.  All restriction enzymes and Vent! DNA 
polymerase were from New England Biolabs.  The deoxyribonucleic acid 
triphosphates (dNTPs) were from Promega.  Low-melting Seaplaque agarose 
was from Cambrex.  Gelase" Enzyme Prep, ScriptGuard™ RNase inhibitor, and 
MasterPure™ RNA Purification Kit were from Epicentre.  BugBuster® Protein 
Extraction Reagent, Lysonase™ Bioprocessing Reagent, and pET21b were from 
Novagen.  Epicurian coli! XL2-Blue ultracompetent cells were from Stratagene.  
Gene Pulser electroporation cuvettes were purchased from BioRad.  Amicon 
Ultra Centrifugal Filter Devices were from Millipore.  Whatman GF/C Glass 
Microfibre Filters and carbenicillin were from Fisher Scientific.  The QIAPrep! 
Spin Miniprep Kit was from Qiagen.  The GeneChip Ecoli_ASv2 and data 
analysis program were from Affymetrix.  Synthetic gfp plasmid constructs were 
prepared by GenScript.  The CybrGreen master mix, real-time PCR reagents and 
data analysis software were from Applied Biosystems. 
DNA Microarray Analysis 
E. coli K12 was from ATCC and K12(!tgt) was received as a gift from Dr. 
Klaus Reuter (University of Marburg, Germany) [7].  Liquid cultures (100 mL 
2xTY) were inoculated with starter culture for each cell line (1:100) and grown at 
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37°C with shaking.  Aliquots (1 mL) were removed every 30 minutes from each 
sample to monitor bacterial growth by UV-Vis (OD600).  Total RNA was isolated 
from both K12 and K12(!tgt) at mid-log and stationary phases using the 
MasterPure™ RNA Purification Kit according to the vendor’s protocol.  
Generation of cDNA and microarray experiments were performed by the 
Molecular Biology Core Facility (Dental School, University of Michigan).  The 
gene expression profile in each sample was analyzed with the GeneChip 
Ecoli_ASv2 according to the vendor’s protocol. 
Computational Genomic Analysis 
The complete genomes for E. coli K12 (substrain MG1655, NC_000913) 
and S. flexneri 2a (substrain 301, NC_004337), as well as the Shigella virulence 
plasmid, pWR501 (NC_002698), were obtained from the NCBI database.  The 
synonymous codon usage for each protein-coding open reading frame was 
tabulated with the computational tool CodonW [8].  The data was analyzed for 
pronounced codon bias in the queuine-cognate codons (NAC and NAU) as 
determined by the following criteria: 1) NAC = NAC/(NAC+NAU) " 0.75, or 2) 
NAU = NAU/(NAC+NAU) " 0.8 in at least three of the four Q-cognate codons.  
Candidate open reading frames were cross-referenced with the NCBI database 
to determine the function (known or predicted) of each protein-coding sequence 
identified. 
Determining the Rate of GFP Expression 
Construction of codon-biased gfp vectors 
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The sequence for wild-type gfp DNA was obtained from the NCBI 
database (U50963).  The gfp transcript consists of 239 codons, 51 of which are 
queuine-cognate.  Synthetic gfp constructs corresponding to the wild-type 
sequence and gfp with engineered Q-cognate codon bias (GFP(C) and GFP(U)) 
were prepared by GenScript.  GFP(C) contains 100% NAC codons and GFP(U) 
contains 100% NAU codons.  Each sample was constructed with restriction 
enzyme sites for recognition by EcoRI (3’) and HindIII (5’) for cloning into 
pET21b.  Each gfp open reading frame and the pET21b vector were treated in a 
double restriction enzyme digestion with EcoRI and HindIII (40 U each, 20 #L 
reaction) for 1 h at 37°C.  All samples were gel-purified from Seaplaque agarose 
gel with Gelase™ according to the vendor’s protocol.  Each gfp insert was 
subcloned into pET21b (5:1 volume ratio, respectively) with T4 DNA ligase (2 U, 
20 #L reaction) at 17°C overnight.  The ligation products (10 #L) were 
transformed into chemically competent E. coli TG2 cells (JM101 derivative) and 
grown on L-Carb plates (100 #g/mL carbenicillin) at 37°C.  Liquid 2xTY cultures 
(3 mL with carbenicillin) were inoculated with individual colonies and grown at 
37°C with shaking.  Plasmid DNA was isolated from each sample with the 
QIAprep Spin Miniprep Kit according to vendor’s protocol.  The resultant GFP 
expression vectors (pET21b-gfp(wt), gfp(C), and gfp(U)) were confirmed by DNA 
sequencing (University of Michigan DNA Sequencing Core Facilities). 
Kinetic analysis of GFP expression 
Electrocompetent E. coli K12(DE3) and K12(!tgt, DE3) cells were 
prepared and transformed with each pET21b-gfp sample according to the 
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MicroPulser Electroporation protocol (BioRad).  Cells were grown overnight at 
37°C on L-Carb plates.  Individual colonies were isolated for growth in 10 mL 
2xTY (with 100 #g/mL carbenicillin), and each construct was assayed in replicate 
(n=6).  All samples were incubated at 37°C with shaking to mid-log phase (OD600 
= 0.6-0.7).  Aliquots (1 mL) were removed from each sample to a pre-tared 
microcentrifuge tube as an uninduced control.  Samples were induced with IPTG 
(1 mM) and divided in half, with one set of replicates induced at 37°C with 
shaking and the other set at 30°C.  Aliquots (1 mL) were removed at each hour of 
the 4 h induction period, and the cells were harvested by centrifugation.  
Following aspiration of the media, the pellets were weighed and subsequently 
resuspended in BugBuster® Protein Extraction Reagent (120 #L) supplemented 
with Lysonase™ Bioprocessing Reagent (1 #L) and PMSF (100 mM) for 5 min. at 
room temperature.  Each sample (100 #L) was added to a black, flat-bottom 
microtiter plate (Corning), and GFP expression was monitored by fluorescence 
(F485/518 nm).   
The rate of expression for GFP(wt), GFP(C), and GFP(U) in both E. coli 
K12(DE3) and K12(!tgt, DE3) was determined from a plot of F(485/518 nm) / mg cell 
pellet versus time (h).  The data were fit by linear regression using the first four 
data points; the 4 h time point was not used in the rate calculation because in 
most cases it was outside of the linear range.  The average rate of protein 
synthesis from each Q-cognate codon biased gfp transcript was determined from 
the six replicate samples and presented with the corresponding standard 
deviation.  The expression of each GFP construct was reported relative to 
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GFP(wt) in wild-type K12(DE3) at each temperature.  The standard deviation is a 
measure of the relative error between samples calculated by the following 
equation: when y = a/b, then !y = ((!a/a)-(!b/b))!y, where “y” is the relative 
expression, “a” is the rate of expression in the test sample, and “b” is the rate of 
expression in GFP(wt) in K12(DE3). 
Quantification of gfp mRNA levels 
Isolation of total RNA from induced cultures 
All pET21b-gfp constructs were assayed in both E. coli K12(DE3) and 
K12(!tgt, DE3) in duplicate according to the above protocol with some 
modifications.  Upon induction with IPTG, the samples were incubated in parallel 
at 37°C and 30°C for 3 h.  Aliquots (1 mL) were removed from each sample and 
placed in pre-tared microcentrifuge tubes, and the cells were harvested by 
centrifugation.  The total RNA (with induced gfp mRNA) was extracted from the 
cell pellets as described previously.  The final RNA pellet was resuspended in TE 
Buffer (25 #L) with ScriptGuard™ RNase Inhibitor (40 U).  The final concentration 
of RNA was determined by UV-Vis using the NanoDrop spectrophotometer 
(Thermo Scientific). 
Northern Blot (Passive Diffusion) 
 The method for Northern blot analysis of 32P-labeled gfp mRNA is a 
modified denaturing agarose gel/passive transfer protocol developed by Katrin 
Karbstein and colleagues (Young and Karbstein, unpublished).  The method and 





Gfp cDNA was synthesized from each duplicate total RNA preparation 
using a modified procedure from Invitrogen.  16S rRNA was chosen as a 
reasonable endogenous control for standardization of RNA content and stability.  
Total RNA (10 #g) was incubated with antisense primers for either gfp (test RNA) 
or 16S rRNA (endogenous control) in parallel (4 pmol each): gfp REV: 5’–
CACTTGTACAGCTCGTCCATGCCAAG–3’, and 16S REV: 5’–
CATGGCTGCATCAGGCTTGCGC–3’.  Briefly, reactions containing total RNA, 
gene-specific oligos, and dNTP mix (0.5 mM each NTP) in a total volume of 26 
#L were denatured at 65°C for 5 min. and cooled immediately on ice for 1 min.  
The following components were added to each sample (final volume of 40 #L): 
first-strand buffer (250 mM Tris!HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2), DTT 
(5 mM), SuperScriptIII™ reverse transcriptase (200 U), RNaseOUT™ RNase 
Inhibitor (40 U), and DMSO (10%).  Samples were incubated at 55°C for 1 h for 
efficient first-strand synthesis. 
Real-time PCR 
All samples were submitted for real-time PCR analysis at the Molecular 
Biology Core Facility (Dental School, University of Michigan).  HPLC-purified 
oligos were purchased for amplification of gfp and 16S cDNA (see REV primers 
above): gfp FWD: 5’–GAGCAAGGGCGAGGAACTGTTCACTG–3’, and 16S 
FWD: 5’–GAAGAGTTTGATCATGGCTCAG–3’.  Amplification of both nucleic 
acids was monitored in the ABI PRISM® 7700 Sequence Detection System 
thermocycler with CybrGreen Master mix (Applied Biosystems).  Briefly, 
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detection of gfp cDNA was monitored from samples containing reverse 
transcription (RT) product (1 #L) and gfp HPLC-purified oligos (5 pmol each) in a 
total volume of 30 #L.  Reactions were tested in replicate (n=4) and incubated 
according to the following temperature sequence: 40 cycles – 95°C for 15 sec., 
60°C for 30 sec., and 72°C for 30 sec.  For detection of 16S rRNA, samples 
containing RT product (1 #L, 100-fold dilution) and 16S HPLC-purified oligos (15 
pmol each) in a total volume of 30 #L.  Reactions were tested in replicate (n=4) 
and incubated according to the following temperature sequence: 40 cycles – 
95°C for 15 sec., 60°C for 30 sec., and 72°C for 45 sec. 
Statistical Analysis 
 The average threshold cycle (CT) for gfp and 16S cDNA synthesis in each 
sample was determined.  The expression of each gfp codon-biased construct 
was measured by averaging the CT data for duplicate biological samples, and 
reporting gfp cDNA expression relative to the levels of gfp(wt) expression in wild-
type K12(DE3) at each corresponding temperature.  The standard deviation was 
calculated according to the same equation described for the GFP protein 
analysis.  Statistical significance was determined with the Student’s t-test. 
Results 
DNA Microarray Analysis 
 To probe the physiological roles of tRNA-guanine transglycosylase in E. 
coli, the global gene expression profiles in both wild-type E. coli K12 and E. coli 
K12(!tgt) (hereafter termed K12 and K12(!tgt)) were detremined via DNA 
microarray analyses.  A comparison of the expression patterns at both mid-log 
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and stationary phase revealed key differences in mRNA transcript levels that 
were reduced or increased in K12(!tgt) relative to wild-type K12 (Table II-1).  
Patterns in biological function of affected transcripts emerged.  Most notably, five 
of the most reduced RNA transcripts in K12(!tgt) at mid-log phase belong to the 
fim operon, responsible for synthesis of type-1 fimbrial proteins.  Of the ten 
genes with the most significant increase in mRNA concentration at mid-log 
phase, five encode for enzymes that prepare biologically relevant substrates for 
glycolysis and the citric acid cycle.  In addition, several transcripts related to 
carbohydrate-utilizing enzymes and tRNAs were shown to have a differential 
expression pattern in K12(!tgt) in comparison to wild-type K12 over the growth 
cycle.  The relationship in biological function of affected transcripts was less 
apparent in stationary phase, with the appearance of hypothetical and predicted 
proteins becoming more predominant.  For these genes identified by DNA 
microarray analysis, no pronounced bias in the queuine-cognate codons was 
observed (as defined in Materials and Methods).  In general, genes with 
decreased expression in K12(!tgt) did exhibit a bias for NAU in one or two of the 
cognate codons, and genes with increased expression demonstrated a bias for 
NAC in one or two of the cognate codons. 
Genome Analysis for Queuine-Cognate Codon Usage in E. coli and S. 
flexneri 
Although a strong codon bias was not observed for genes identified by 
microarray, genes necessary for their activation/function may show a pronounced 
bias. To probe this possibility, the protein-coding sequences of the E. coli K12 
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and S. flexneri 2a genomes were analyzed with the biophysical tool CodonW [8].  
The algorithm in CodonW tabulates the codon usage patterns of degenerate 
codons for each of the twenty amino acids.  The data were sorted to identify 
genes with a strong bias in at least three of the four queuine-cognate codons to 
more closely match the bias seen in virF (Figure II-3).  The bias for NAU (NAU 
codons / (NAU+NAC codons)) and NAC (NAC codons / (NAU+NAC codons)) Q-
cognate codons were determined for each species, and the results were grouped 
according to biological function as described by homology sequence alignments 
in the NCBI protein database (Figure II-1, full list of genes found in Appendix II-
3).  The threshold for pronounced bias of 80% was initially chosen because this 
is the observed bias for virF.  This was maintained for the NAU-biased genes, but 
the threshold was set to 75% in the case of NAC-biased genes because the 
number of hits was much smaller at a threshold of 80%. 
As seen with the DNA microarray data, interesting trends in protein 
functional classes emerged.  Open reading frames demonstrating a strong NAU-
bias in both E. coli and S. flexneri aligned with the biological functions we 
observed as being down-regulated in the K12(!tgt) mutant: fimbrial proteins and 
membrane-associated proteins (Figure II-1A and C, respectively).  Also, genes 
involved in the biosynthesis of lipopolysaccharides were identified, which 
comprise key structural membrane components in bacterial species.  Several 
components of the phosphotransferase system involved in sugar uptake 
(referenced in the “enzymes” functional class) were also identified as having a 
pronounced NAU-bias.  It should be noted that of the 20 NAU-biased genes  
 
 39 
Table II-1: DNA Microarray Global Gene Expression Profile of E. coli K12 and 
K12 (!tgt).  The top results for genes with differential expression in 
the presence or absence of tgt are highlighted. 
Mid-log phase: E. coli K12 ("tgt) versus 
E. coli K12 
Stationary phase: E. coli K12 ("tgt) 
versus E. coli K12 
Gene 
ID 




Gene Description Fold 
Change 
Genes with Decreased Expression Genes with Decreased Expression 
fimI Fimbrial protein, type-
1 pilus biosynthesis 
-140.10 b2656 Hypothetical protein -180.06 
fimA Major type 1 subunit 
fimbrin (pilin) 
-85.39 yrhA Hypothetical protein -171.00 
glyY Glycine tRNA3 -60.05 b1471 Hypothetical protein -151.67 
fimD Outer membrane 
usher protein, type-1 
fimbrial synthesis  
-43.20 agaB N-
acetylgalactosamine-
specific enzyme IIB 
component of PTS 
-111.89 
argX Arginine tRNA3 -42.08 proM Proline tRNA3 -109.98 
fimC Pilin chaperone, 
periplasmic 




-29.91 ycgW Predicted protein -104.75 
fimF Minor component of 
type-1 fimbriae 





glpK Glycerol kinase -20.73 yedN Hypothetical protein -94.97 
glpT Sn-glycerol-3-
phosphate transporter 
-19.70 b2857 Hypothetical protein -91.32 
Genes with Increased Expression Genes with Increased Expression 




betB Betaine aldehyde 
dehydrogenase 
126.39 ssrS 6S RNA, interacts 
with holo RNAP 
26.37 
narG Nitrate reductase I, 
alpha subunit 
105.86 ymfM Hypothetical protein 24.60 










83.50 b1145 E14 prophage; 
repressor protein 
19.00 
b0370 Hypothetical protein 73.50 lacA Thiogalactoside 
acetyltransferase 
18.33 
aceB Malate synthase A 69.15 glpF Glycerol facilitator 17.82 
yahO Predicted protein 68.82 yahM Hypothetical protein 17.76 
glcB Malate synthase G 64.87 rpsM 30S ribosomal 




identified as nucleic acid-binding proteins in E. coli, 11 were classified as DNA-
binding transcriptional regulators (same functional class as VirF).  A number of 
predicted/hypothetical proteins were also identified as NAU-biased genes in both 
genomes, though the percentage is larger in S. flexneri.  This is most likely due 
to the fact that the E. coli genome has been more carefully annotated. 
As with the NAU-biased analysis, genes identified with a pronounced 
NAC-bias clustered into various functional classes.  Nearly 30% of the genes 
identified as having a strong NAC-bias in both E. coli and S. flexneri are 
ribosomal protein subunits or other components of the translational machinery 
(Figure II-1B and D, respectively).  One ribosomal open reading frame (rpsM) 
demonstrated increased expression in K12(!tgt) by microarray.  Although more 
ribosomal subunits were not listed, four additional ribosomal subunits (rpsGKLN) 
are found among the top 20 transcripts with increased expression in K12(!tgt). 
The genes encoded on the 230 kb virulence plasmid from S. flexneri were 
also analyzed for Q-cognate codon bias (Figure II-2).  Only 2 genes were 
identified as having a pronounced bias toward NAC codons (tnpR and tnpA, 
related to the Tn501 transposition processes).  Of the nearly 300 virulence 
genes, 24 were identified with bias of " 80% toward NAU codons.  VirF was the 
only transcriptional regulator to demonstrate such a strong bias.  The genes 
identified belong predominantly to open reading frames responsible for synthesis 






Figure II-1: Comparison of Queuine-Cognate Codon Bias in the E. coli and S. 
flexneri Genomes.  Protein-coding sequences were analyzed for bias 
in at least three of the four Q-cognate codons as described in the 
materials and methods.  Genes demonstrating bias are presented 





Figure II-2: Queuine-Cognate Codon Bias in the S. flexneri Virulence Plasmid. 
Protein-coding sequences were analyzed for bias in at least three of 
the four Q-cognate codons.  The genes demonstrating bias are 
presented according to biological function, number of genes, and 
percentage of total genes.  
 
 
Analysis of Protein Expression from Engineered Biased Constructs 
  The genes identified by DNA microarray and genomic analyses belong to 
functional protein classes that made experimental expression studies and assays 
relatively difficult (i.e., membrane-associated proteins, large molecular weight 
protein complexes).  A suitable model protein was found in green fluorescent 
protein (GFP), which was initially selected based on the ease of assay and the 
distribution and ratio of queuine-cognate codons (Figure II-3).  The wild-type gfp 
mRNA contains a slight bias for NAC codons over NAU codons (63%, Table II-2).  
Three open reading frames for gfp (wild-type, 100% NAU and 100% NAC in all 
51 Q-cognate codons; gfp(wt), gfp(U) and gfp(C), respectively) were engineered 
by GenScript.  Each construct was expressed in K12(DE3) and K12(!tgt, DE3) at 
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both 30°C and 37°C.  Determination of GFP concentration in cell lysates was 
measured by fluorescence over a 4 h incubation period and normalized for the 
weight of the resuspended cell pellet. 
 
Figure II-3: Queuine-Codon Distribution in virF and gfp mRNA.  Positioning of the 
NAU and NAC codons are highlighted in red. 
 
Table II-2:  Comparison of Codon Usage in virF and gfp mRNA. 
 
Samples were assayed in replicates of 6, and the data were fit by linear 
regression (see Figure II-A3-A in Appendix II-2, inset for a representative set).  
The average rate of expression for each GFP sample is shown in Figure II-A3-A 
and Table II-3.  The deviation observed is reflective of the variability in GFP 
expressed from individual colonies, and not the variability within a given sample.  
The expression of each gfp construct at 30°C demonstrated slightly less 
variability between independent cultures (average percent error in 37ºC samples 










virF 263 9 35 6 




Figure II-4:  Relative Expression of Biased-GFP.  A) Expression of GFP protein in 
E. coli K12(DE3) versus K12(!tgt, DE3) at 37ºC and 30ºC relative to 
GFP(wt) in K12(DE3) at each temperature.  B) Expression of gfp 
cDNA by real-time PCR in E. coli K12 (DE3) versus K12(!tgt, DE3) 
at 37ºC and 30ºC relative to gfp(wt) in K12(DE3) at each 
temperature.  Statistical significance determined by Student’s t-test: 
(*) p < 0.05, (**) p < 0.01, (***) p < 0.001.  
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Table II-3:  Comparison of Biased-GFP Expression.  The rate of expression for 
each GFP construct (GFP(wt), C-biased, and U-biased) is listed for 
both the wildtype K12 (DE3) and K12 ($tgt, DE3) E. coli strains.  The 
average rate of GFP expression is presented with the standard 
deviation in parentheses. 
 
expression relative to GFP(wt) in K12(DE3) at each temperature are represented 
graphically in Figure II-4A.  At both 30°C and 37°C, the rate of GFP expression 
for either biased open reading frame was approximately 35% slower in the 
mutant K12(!tgt, DE3) relative to wild-type K12(DE3).  The rate of GFP 
translation from each codon-biased construct was slower in every case in 
comparison to wild-type GFP, with the exception of GFP(U) in K12(DE3), 
however this increased rate of synthesis was not found to be statistically 
significant (Figure II-4A).   
Real-time PCR Analysis of gfp mRNA 
 E. coli K12(DE3) and K12(!tgt, DE3) expressing GFP(wt), GFP(C), and 
GFP(U) were induced with IPTG as above.  Cells were harvested following a 3 h 




















Growth @ 37 °C 
GFP(wt) 376 (± 70) 354 (± 70) 0.94 1 0.94 (± 0.01) 
GFP(C) 198 (± 30) 124 (± 20) 0.63 0.53 (± 0.02) 0.33 (± 0.008) 
GFP(U) 433 (± 100) 289 (± 60) 0.67 1.2 (± 0.05) 0.77 (± 0.02) 
Growth @ 30°C 
GFP(wt) 138 (± 20) 137 (± 20) 0.99 1 0.99 (± 0.001) 
GFP(C) 112 (± 8) 79.8 (± 20) 0.71 0.81 (± 0.06) 0.58 (± 0.06) 
GFP(U) 157 (± 30) 104 (± 30) 0.66 1.1 (± 0.05) 0.76 (± 0.1) 
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induction period, and total RNA was isolated.  Using gene-specific primers, 
samples were treated with SuperScriptIII™ reverse transcriptase to generate gfp 
cDNA and 16S cDNA as an endogenous control.  Generation of gfp and 16S 
cDNA in the same sample was unsuccessful due to the high concentration of 
16S rRNA in each total RNA preparation.  The concentration of gfp cDNA in each 
sample was determined by averaging the CT data from each biological replicate, 
with the exception of gfp(wt) in K12(DE3) at 37ºC because one of the duplicate 
samples was deemed to be an outlier (Figure II-A3-B in Appendix II-2).  The 
concentration of codon-biased gfp cDNA was normalized to the concentration of 
gfp(wt) cDNA in K12(DE3) at each temperature (Figure II-4B).  The only 
statistically significant difference in gfp mRNA concentration was observed in 
gfp(wt) K12(!tgt, DE3) at 30ºC.  We conclude that the changes we observed in 
GFP protein expression are predominantly due to changes in the rate of protein 
synthesis rather than mRNA concentration. 
Discussion 
 The queuine modification is well conserved in eubacterial and eukaryl 
tRNA, yet the biological function of this modified nucleoside is poorly understood. 
It is generally believed that the presence of modified bases in tRNA (especially in 
the anticodon arm) serves to increase the fidelity of the tRNA-mRNA-ribosome 
interaction during protein synthesis.  While studies have been conducted 
monitoring changes in affinity for Q-cognate tRNAs with the mRNA-ribosome 
complex in the presence and absence of all modifications, little is known about 
the contributions made specifically by the queuine nucleoside [9].  It has been 
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suggested that modification with queuine at the wobble position of the cognate 
tRNAs leads to preferential codon recognition [10, 11].  However, definitive in 
vivo studies have yet to be conducted to elucidate the effect of queuine, and by 
extension TGT, in protein translation. 
The global expression profiles identified in K12 and K12(!tgt) by DNA 
microarray analysis provided insight into some of the functional protein classes 
affected by the absence of Q-modified tRNA.  The identification of trends in 
genes with decreased (i.e., fimbrial synthesis) and increased (i.e., ribosomal 
subunits) expression profiles suggests a potential link between queuine and 
translation of vital cellular components.  In rapidly dividing cells, loss of Q-
modified tRNA resulted in decreased expression of fimbrial proteins that are 
critical for cell-cell interaction and generally linked to virulence in pathogenic 
bacteria.  Although no pronounced queuine-cognate codon bias was observed 
for these open reading frames, the microarray does not necessarily reflect a 
direct effect on expression profile changes.  For example, tRNA-Q34 might not 
directly affect the expression of the fimbrial genes identified.  The !tgt mutation 
may instead directly impact expression of an upstream factor responsible for 
expression of these specific genes.  Similarly, perhaps an increased expression 
of ribosomal subunits in stationary phase reflects a cellular response to a deficit 
in global protein synthesis.  It has been demonstrated previously that growth of 
the E. coli (!tgt) mutant is challenged under hypoxic conditions [12]. 
 To identify genes with pronounced Q-cognate codon bias, the codon 
usage of genes in the E. coli and S. flexneri genomes was evaluated with the 
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biophysical tool CodonW [8].  Genes identified with a pronounced Q-cognate 
codon bias in E. coli and S. flexneri revealed a larger subset of genes closely 
related to those observed by microarray.  Interestingly, both the classes of 
fimbrial proteins and ribosomal subunits emerged in the genome analysis, with 
the fimbrial proteins biased heavily toward NAU codons and the ribosomal 
protein subunits containing a bias for NAC codons (Figure II-1).  In contrast to 
this function-specific codon usage, many functional protein classes were shared 
between the two groups, with several unrelated genes of similar function 
demonstrating either pronounced NAU- or NAC-bias (i.e., membrane-associated 
proteins, LPS biosynthesis proteins, and a variety of enzymes).  One pattern that 
was more pronounced in the NAU-bias analysis was the predominance of DNA-
binding transcriptional regulators in the category “nucleic acid-binding proteins“.  
This is interesting because VirF also belongs to this functional class, and it is 
possible that a slight decrease in expression of these proteins could result in 
more dramatic effects in expression of their downstream DNA targets. 
The bias observed in S. flexneri virulence genes for NAU codons is 
striking.  The majority of genes identified belonged to the mxi-spa operons, 
responsible for synthesis of the structural components of the type III secretion 
system (TTSS) in Shigella.  The TTSS is a key virulence determinant, and 
bacterial species deficient in this protein complex are non-invasive [13].  Several 
secreted proteins (classified as “invasion associated proteins”) were also 
characterized as strongly NAU-biased.  Like the structural TTSS complex, the 
secreted invasion proteins are also critical for virulence.  These results could 
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suggest a greater extent of regulation of the virulence cascade of S. flexneri, 
where several key components in the invasion process (including virF) are 
strongly NAU-biased and their expression is potentially regulated by the 
presence of Q-modified tRNA. 
To gain insight into the effect of Q-modified tRNA on translation of codon-
biased open reading frames, we decided to study expression of a gene with 
known differential expression in the absence of TGT in vivo.  We searched for a 
suitable model protein to study the effects of translation with tRNA-Q34 and -G34.  
Protein would be expressed from candidate mRNA in three forms: 1) with wild-
type codon usage, 2) engineered with 100% bias in NAC queuine-cognate 
codons, and 3) engineered with 100% bias in NAU queuine-cognate codons.  
Qualifications for a potential candidate included soluble protein, relatively simple 
quaternary structure, and a simple assay method to determine protein 
concentration.  VirF was a logical choice, as the virF mRNA has an overall bias 
of 80% for NAU queuine-cognate codons, and Durand and colleagues have 
demonstrated that expression of the VirF protein in the !vacC mutant (tgt 
homologue in Shigella) is reduced to ~40% of the concentration in wild-type 
Shigella [14].  Expression of VirF was very problematic in vivo and in vitro (see 
Chapter IV for details), and a suitable alternative gene with pronounced Q-
cognate codon bias was difficult to find in the above analyses.  While not 
endogenous to S. flexneri, green fluorescent protein (GFP), is widely used in 
molecular biology, similar in size to VirF and very easy to assay.  Although gfp 
mRNA exhibits no pronounced overall bias for Q-cognate codons, the overall 
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distribution and propensity for clustering of Q-cognate codons in gfp mRNA 
mimics that of the virF mRNA (Figure II-3).  Therefore GFP was chosen for our 
study. 
GFP expression from wild-type (gfp(wt)) and codon-biased constructs 
(gfp(C) and gfp(U))  was monitored by fluorescence (F485/518nm) and normalized to 
the weight of the cell pellet in each aliquot to account for differences in cell 
growth between samples.  The total protein content was determined by Bradford 
assay, and it was found that the amount of protein in each sample did not vary 
significantly between K12 and K12(!tgt) (data not shown).  This suggests that 
the differences in GFP expression between K12 and the K12(!tgt) mutant reflect 
different rates of GFP synthesis specifically and not overall protein translation.  
To account for the concern that IPTG-induction at 37°C could result in a 
dramatically enhanced rate of GFP expression relative to that in Shigella, growth 
at 30°C was performed to slow the overall rate of translation and more closely 
model a biologically relevant rate of protein synthesis.   
GFP expression in K12(DE3) (which contains tRNA-Q34) highlights 
differential rates of translation for NAC- and NAU-biased mRNA in the presence 
of Q-modified tRNA (Figure II-4A).  For GFP(U), the rate of protein expression is 
comparable to that observed for GFP(wt) in K12(DE3) at both temperatures.  
Alternatively, the rate of GFP(C) synthesis is reduced by approximately 45% in 
K12(DE3) at 37ºC.  The relative rates of GFP expression at 30ºC in K12(DE3) 
follow the same pattern; the rate of expression for GFP(U) % GFP(wt) > GFP(C).  
In K12(!tgt, DE3), a different pattern in relative GFP expression is observed.  At 
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both 37ºC and 30ºC, the rate of expression for GFP(wt) > GFP(U) > GFP(C) in 
the presence of tRNA-G34. 
With changes in codon usage of the gfp mRNA, we have also changed the 
G-C content and perhaps the structural dynamics and stability of the codon-
biased gfp mRNA.  To monitor the concentration of gfp mRNA following IPTG-
induction (3 h), real-time PCR was performed to probe the subsequent effects on 
RNA stability in each sample.  A period of 3 h was chosen because at this stage 
the variation in total GFP protein levels between samples is the highest, and it 
provides a direct correlation between mRNA concentration and the rate of 
translation.  The concentration of the endogenous control (16S rRNA) was too 
high, and subsequent dilution of the reverse transcription samples produced 
inconsistent data in the real-time PCR analysis (see Appendix II-2 for details).  
Alternatively, the concentration of codon-biased gfp cDNA was normalized to the 
concentration of gfp(wt) cDNA in K12(DE3) at each corresponding temperature 
(Figure II-4B).  This analysis provides for a direct comparison to the levels of 
GFP protein expressed in each cell line relative to GFP(wt) in E. coli K12 as it 
relates to the total gfp mRNA population (Figure II-4A).  In general, gfp mRNA 
expression levels are consistent between cell lines and constructs with altered 
codon usage, as the variability observed was not found to be statistically 
significant (Figure II-4B).  These results suggest that the observed differences in 
the rate of expression between GFP(wt) and the codon-based GFP proteins is 
due to changes in the rate of protein translation. 
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Few experiments have been conducted to directly assess the relevance of 
queuine-cognate codon bias.  In vivo analysis with Q-cognate tRNA concluded 
that tRNA-Q34 demonstrated no significant bias between the NAU and NAC 
codons under competitive conditions with tRNA-G34 [10].  A computational model 
of Q-cognate tRNA codon bias performed with tRNAAsp-Q34 and tRNAAsp-G34 
predicted the same result, suggesting that the same number of hydrogen-bonds 
(2) were formed between queuosine and either uridine or cytosine in the wobble 
position due to an increased hydrogen-bonding network and anticodon rigidity in 
the presence of queuine [11].   
 
Figure II-5: Predicted Hydrogen Bonding Interactions Formed with Guanine 
versus Queuine.  The four predicted interactions between tRNA-G34 
and -Q34 with cytosine versus uridine in the wobble position are 
illustrated with the key heterocyclic bases (G/Q with C/U).  The 
intramolecular hydrogen bond between the amino side chain of 
queuine (Q) and O6 was predicted by molecular dynamics Morris et 



























































However, the rate of GFP(U) expression in wild-type E. coli K12(DE3) is faster 
than the rate observed for GFP(C) (100% increase at 37ºC and 30% increase at 
30ºC). The observation that the rate of GFP(C) synthesis in K12(!tgt, DE3) is the 
slowest for all constructs tested is also in apparent conflict with the originally 
proposed “codon bias model,” which suggested tRNA-G34 preferentially 
recognizes the NAC codon as opposed to the NAU codon [10].  One might 
predict that if tRNA-G34 preferentially recognized the NAC codon, the rate of 
GFP(C) synthesis would be highest in the (!tgt) mutant strain.   
In some cases, the wobble base modification, or the nucleotide 3’ to the 
wobble position, also exhibits characteristics of codon context (i.e., the 
interaction between the A-site tRNA and the neighboring codon / P-site tRNA at 
the ribosome-mRNA complex that can lead to frameshifting) [15].  This 
phenomenon has been most well-characterized for the wyosine modification at 
G37 in tRNAPhe, which helps prevent frameshifting in recognition of the UUU 
codon [16, 17].  Using the same computational modeling parameters, Morris et 
al. found no such codon context for the queuine modification in tRNAAsp [11].  
Previous studies, however, have suggested an element of codon context with 
tRNA-Q34, as the tobacco mosaic virus tRNATyr (antidocon G&A) recognizes the 
UAG stop, but tRNATyr (antidocon Q&A) does not [18].  
Perhaps the issue of “preferential codon recognition” extends to both 
tRNA-G34 and -Q34.  At 30ºC, while the rate of GFP(C) expression in K12(DE3) is 
relatively indistinguishable from the rate of GFP(U) synthesis in K12(!tgt), there 
is a 2-fold difference in the rate of expression of each codon-biased construct in 
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the alternate cell line (Figure II-4A).  This observation suggests that the rate of 
translation of NAU-biased mRNA is specifically increased with tRNA-Q34, while 
the rate of translation for NAC-biased mRNA is specifically decreased with tRNA-
G34 in comparison to mRNA with equivalent usage of the degenerate Q-cognate 
codons. 
It is important to note that when measuring the rate of GFP expression, we 
are monitoring the overall rate of translation.  It is conceivable that preferential 
binding may relate to the stability of the tRNA-mRNA complex in the A-site or the 
E-site in the ribosome.  In the process of protein synthesis (following the initiation 
phase with binding of tRNAfMet), the appropriate aminoacylated tRNA binds to the 
corresponding codon in the A-site of the ribosome-mRNA complex [19].  Peptidyl 
transfer occurs where a new peptide bond is formed between the amino acid 
attached to the A-site tRNA and the carboxyl end of the polypeptide chain  
 
Figure II-6: Snapshot of the Prokaryotic Ribosome in Elongation Phase.  During 
protein translation, tRNA binds to the bacterial ribosome-mRNA 
complex in three sites: the A-, P-, and E-site.  In the elongation 
phase, the next required aminoacylated tRNA binds to the A-site.  
Peptidyl transfer occurs, followed by translocation of the ribosome.  




attached to the tRNA in the P-site.  The ribosomal subunits shift; the empty tRNA 
moves from the P-site to the E-site, while the A-site tRNA with the growing 
polypeptide chain shifts to the P-site (Figure II-6).  Once in the E-site, the tRNA 
dissociates from the ribosome-mRNA complex, and the cycle continues. 
If the interaction between tRNA and the cognate codon in the mRNA is too 
weak at the A-site, the increased on-off rate of the tRNA could halt translation 
and reduce protein synthesis [9].  Likewise, a strong tRNA-mRNA interaction in 
the E-site of the ribosome could prevent overall elongation of the polypeptide.  
Both cases could produce similar results in the total protein analysis, which 
measures only the end product of protein synthesis.  Previous in vitro kinetic 
analysis with tRNA in both fully-modified and fully-unmodified forms suggests 
that the ultimate role of modified nucleosides in tRNA is to normalize the 
interaction at the ribosome-mRNA complex [9].  It is conceivable that codon 
usage in a given mRNA performs the same function of normalization between the 
anticodon-codon interactions, and any changes in the already optimized process 
lead to unfavorable results.  Alternatively, the changes in queuine-cognate codon 
usage may alter the rates of translation in ways we do not fully understand under 
the current experimental protocol. 
Taken together, we propose a new interpretation of the queuine-cognate 
“codon bias” model.  Perhaps the strength of the anticodon-codon interaction 
(i.e., 3 full Watson-Crick hydrogen bond pairs or 2 hydrogen bonds) partially 
determines the rate of protein synthesis.  The slowest rate of protein expression 
at both 30°C and 37°C was observed in the only case where a full Watson-Crick 
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interaction at the wobble position is formed: GFP(C) expressed in K12(!tgt, 
DE3).  The similarity between rate of expression for GFP(U) with tRNA-G34 and 
GFP(C) with tRNA-Q34 may also suggest a component of codon preference.  
Two hydrogen bonds are formed in both cases, yet studies with Q-modified tRNA 
show an increased rate of translation for GFP(U) and GFP(wt) utilizing the same 
number of hydrogen bonds in the anticodon-codon interaction.  This result could 
be predicted if tRNA-Q34 formed an optimized interaction with NAU codons that 
was different from the interaction formed by tRNA-G34.  Although the effect in 
GFP expression is subtle, the result could be more dramatic for proteins that 
must maintain a specific cellular concentration for proper activity, as is the case 
with VirF. 
Conclusions 
The modification state of tRNA with queuine appears to have pronounced 
effects on global gene expression profiles in E. coli.  Although tRNA-G34 and -Q34 
can translate both degenerate Q-cognate codons (NAU and NAC), the rate of 
protein synthesis is altered with each tRNA-codon pair.  The presence of 
queuine/guanine in cognate tRNA may provide a different anticodon-codon 
interaction with each degenerate codon.  This effect could help explain the 
observation that S. flexneri VirF protein levels (translated from NAU-biased virF 
mRNA) are reduced in the (!vacC) mutant.  Further studies must be performed 
to explore the importance of Q-tRNA in the translation of other genes critical to 
virulence and cellular structure/growth. 
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Northern Blot Analysis of gfp mRNA 
Analysis of RNA has historically been performed by Northern blotting with 
single-stranded oligonucleotides that are antisense to the target RNA.  Using a 
modified protocol developed in the Karbstein lab (University of Michigan), I 
attempted to analyze the concentration of gfp mRNA by Northern blot using both 
an active and passive transfer method.  The active transfer of gfp mRNA (~700 
nt) from a denaturing acrylamide gel was unsuccessful, as the technique is best 
suited for RNA ( 500 nt in length.  For passive transfer, total RNA (10 #g) was 
loaded onto a 1.25% agarose gel (with 6.7% formaldehyde) in MESA buffer (20 
mM MOPS (pH 7), 8 mM sodium acetate, 1 mM EDTA).  Samples were run at 95 
V for 7 h.   Following electrophoresis, the gel was treated with 50 mM NaOH for 
20 min. at room temperature with shaking.  The gel was incubated in ethidium 
bromide solution (0.0001% EtBr in 0.5X TBE buffer (5 g Tris Base (pH 8.0), 2.8 g 
boric acid, 1 mM EDTA / 1 L dH2O) for 30 min. at room temperature followed by a 
destain solution (0.5X TBE) for an additional 30 min. to visualize the total RNA 
(Figure II-A1).   
The total RNA was transferred to the Hybond-N membrane in SSC buffer 
(3 M NaCl, 300 mM sodium citrate (pH 7)) overnight according to the vendor’s 
protocol (Amersham).  Oligonucleotide probes for gfp mRNA (5’–
CACTTGTACAGCTCGTCCATGCCAAG–3’) and 23S rRNA as an endogenous 




Figure II-A1: Denaturing Agarose Gel for gfp Northern Blot.  Ethidium bromide 
staining of total RNA with induced gfp mRNA.  All samples were run 
in duplicate: gfp(wt), gfp(C), and gfp(U) in K12(DE3) and K12(!tgt, 
DE3), induced at 37ºC and 30ºC.   
 
T4 polynucleotide kinase (PNK) according to the vendor’s protocol (New England 
Biolabs).  Free NTPs were removed with G25 microspin columns (GE 
Healthcare), and the specific activity was determined (1 #L probe) by scintillation 
counting.  The membrane was cross-linked, and treated with boiling 0.1% SDS 
(sodium dodecyl sulfate) at 65ºC with rotation for 10 min.  Pre-hybridization 
solution was added (16 mL total volume; Denhardt’s solution (0.15% Ficoll (type 
400), 0.15% polyvinylpyrrolidone, 0.15% BSA); SSPE buffer (750 mM NaCl, 50 
mM NaH2PO4 (pH 7.4), 6.25 mM EDTA); 0.1% SDS; boiled salmon sperm DNA 
(790 #L)) at 37ºC for 4 h with rotation.  The gfp probe (1 x 107 counts) was boiled 
with 500 #L pre-hybridization solution for 3 min., and the labeled probe was 
incubated with the membrane at 37ºC overnight. 
The membrane was washed with subsequent volumes of Solution 1 (25 
mL volume, SSPE buffer with 0.1% SDS) to strip unbound probe until the wash 




Figure II-A2: Northern Blot Analysis.  Total RNA samples probed with 32P-)-ATP 
labeled oligonucleotides for gfp mRNA and 23S rRNA.  23S rRNA 
control is fairly consistent, but inconsistent results obtained with gfp 
mRNA.  Possible lower molecular weight gfp degradation products 
also marked. 
dried and exposed to an x-ray screen for 8 h at room temperature.  The screen 
was analyzed by the Typhoon™ imager using ImageQuant™ software (GE 
Healthcare).  The gfp probe was stripped, and the 23S probe was annealed as 
described previously.  Representative membrane blots are shown in Figure II-A2.  
Detection of 23S rRNA was more successful due to the relative abundance of the 




Real-time PCR Analysis Raw Data 
Samples for analysis of gfp mRNA by real-time PCR were prepared in 
duplicate.  Experiments for detection of nucleic acids by CybrGreen dye were 
performed as described in Materials and Methods.  The raw expression data for 
the GFP protein in addition to the raw CT (threshold cycle) data for gfp and 16S 
RNA in each set of biological replicates is illustrated in Figure II-A3.  The 
concentration of 16S rRNA in four samples at 37ºC appears to be very dilute in 
comparison to the endogenous control in other samples (gfp(wt) K12-2, gfp(wt) 
K12(!tgt)-1, gfp(C) K12(!tgt)-1, gfp(U) K12-1) (Figure II-A3-C).  These samples 
were treated as outliers, but the relative consistency in 16S rRNA concentration 
among the other samples suggests that any variability in gfp mRNA conentration 
is not the result of inconsistent reverse transcription between samples.  The 
variability in threshold cycle for detection of 16S is most likely due to the 
alterations in protocol (i.e., dilution of RT sample, increased primer 
concentration) between the endogenous control and gfp analysis.  The reverse 
transcription reactions were optimized to the concentration of gfp mRNA, and 
does not account for the abundance of the 16S rRNA.  The inconsistency in the 
16S control masks the reproducibility in the gfp mRNA so the data measured 
from duplicate samples was instead averaged and reported as expression 
relative to gfp(wt) mRNA in wild-type K12(DE3) at each temperature (Figure II-4B 






Figure II-A3:  Relative Expression of Biased-GFP.  A) Expression of GFP protein in E. coli K12(DE3) versus K12(!tgt, 
DE3) at 37ºC and 30ºC relative to GFP(wt) in K12(DE3) at each temperature.  B) Expression of gfp cDNA 
by real-time PCR in E. coli K12 (DE3) versus K12(!tgt, DE3) at 37ºC and 30ºC relative to gfp(wt) in 
K12(DE3) at each temperature. 
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The one major discrepancy was the level of gfp(wt) in K12(DE3) at 37ºC, which 
had a representative standard deviation of approximately 10 CT between the 
duplicate samples (Figure II-A3-B).  Because the average of these samples 
would skew the normalization, and the gfp(wt)-2 concentration is likely an outlier, 
only the concentration of gfp(wt)-1 in K12(DE3) was used to normalize the codon 
biased gfp samples at 37ºC.  Overall, this method of normalization is a better fit 




Presentation of Genes Identified by Genome Analysis 
E. coli Genome (4149 protein-coding genes) 
NAU Codon Bias – 148 open reading frames 
Gene Locus Tag Gene ID Function/Description 
   
Membrane-associated Proteins 
b3921 yiiR Conserved inner membrane protein 
b3511 hdeD Acid-resistance membrane protein 
b1322 ycjF Conserved inner membrane protein 
b1607 ydgC Conserved inner membrane protein 
b1626 ydgK Conserved inner membrane protein 
b3563 yiaB Conserved inner membrane protein 
b3817 yigF Conserved inner membrane protein 
b0111 ampE Predicted inner membrane protein 
b1447 ydcZ Predicted inner membrane protein 
b2145 yeiS Predicted inner membrane protein 
b2668 ygaP Predicted inner membrane protein 
b3818 yigG Predicted inner membrane protein 
b2666 yqaE Predicted membrane protein 
b1615 uidC Predicted outer membrane porin 
b1038 csgF Predicted transport protein 
   
LPS Biosynthesis Proteins 
b2563 acpS Holo-ACP Synthase I 
b3623 waaU Lipopolysaccharide core biosynth. 
b3624 rfaZ Lipopolysaccharide core biosynth. 
b3629 rfaS Lipopolysaccharide core biosynth. 
b3622 rfaL O-antigen ligase 
b2035 rfc O-antigen polymerase 
b2371 yfdE Predicted CoA-transferase, NAD(P)- 
   
Nucleic Acid-binding Protein 
b1320 ycjW Predicted DNA-binding 
b1343 dbpA ATP-dependent 23s rRNA helicase 
b0546 ybcM DLP12 prophage, predicted DNA- 
b1399 paaX DNA-binding transcriptional 
b3512 gadE DNA-binding transcriptional 
b4046 zur DNA-binding transcriptional 
b3149 diaA DnaA initiator-associated factor for 
b2038 rfbC dTDP-4-deoxyrhamnose-3,5- 
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b3998 nfi Endonuclease V 
b3856 mobB Molybdopterin-guanine dinucleotide 
b0483 ybaQ Predicted DNA-binding 
b1434 ydcN Predicted DNA-binding 
b2398 yfeC Predicted DNA-binding 
b3060 ttdR Predicted DNA-binding 
b3507 dctR Predicted DNA-binding 
b3180 yhbY Predicted DNA-binding protein 
b0318 yahD Predicted transcriptional regulator 
b3889 yiiE Predicted transcriptional regulator 
b2573 rpoE RNA polymerase, sigma factor E 
b3627 rfaI UDP-D-galactose:(glycosyl) 
   
Fimbrial / Pilin proteins 
b1940 fliH Flagellar biosynthesis protein 
b1942 fliJ Flagellar protein 
b4320 fimH Minor component of type I fimbriae 
b0531 sfmC Pilin chaperone, periplasmic 
b1043 csgC Predicted curli production protein 
b0938 ycbQ Predicted fimbrial-like adhesion 
b2321 flk Predicted flagella assembly protein 
b1546 tfaQ Qin prophage, predicted tail fibre 
b1373 tfaR Rac prophage, predicted tail fibre 
   
Predicted/Conserved Proteins 
b0956 ycbG Conserved protein 
b1705 ydiE Conserved protein 
b1707 ydiV Conserved protein 
b1787 yeaK Conserved protein 
b1878 flhE Conserved protein 
b1976 mtfA Conserved protein 
b2012 yeeD Conserved protein 
b2073 yegL Conserved protein 
b2583 yfiP Conserved protein 
b3098 yqjD Conserved protein 
b3100 yqjK Conserved protein 
b3348 slyX Conserved protein 
b3596 yibG Conserved protein 
b3698 yidB Conserved protein 
b3717 cbrC Conserved protein 
b4594 ymgJ Hypothetical protein 
b4604 yojO Hypothetical protein 
b4621 yjbS Hypothetical protein 
b2301 yfcF Predicted enzyme 
b0329 yahO Predicted protein 
b0466 ybaM Predicted protein 
b0498 ybbC Predicted protein 
b1001 yccE Predicted protein 
b1058 yceO Predicted protein 
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b1112 bhsA Predicted protein 
b1167 ymgC Predicted protein 
b1455 yncH Predicted protein 
b1532 marB Predicted protein 
b1847 yebF Predicted protein 
b2085 yegR Predicted protein 
b2274 yfbO Predicted protein 
b2602 yflL Predicted protein 
b2757 ygcI Predicted protein 
b2758 ygcJ Predicted protein 
b2849 yqeK Predicted protein 
b2940 yqgC Predicted protein 
b3107 yhaL Predicted protein 
b3120 yhaB Predicted protein 
b3362 yhfG Predicted protein 
b4026 yjbE Predicted protein 
b4047 yjbL Predicted protein 
b4482 yigE Predicted protein 
b4555 yicS Predicted protein 
   
Amino Acid-binding Proteins 
b1325 ycjG L-Ala-D/L-Glu epimerase 
b2743 pcm L-isoaspartate protein  
b1838 pphA Serine/threonine-specific protein 
b0367 tauC Taurine transporter subunit 
b2851 ygeG Predicted chaperone 
 
Enzymes   
b2462 eutS Predicted carboxysome (carbon 
b1270 btuR Cob(I)alamin adenosyltransferase/ 
b1992 cobS Cobalamin 5'-phosphate synthase 
b1557 cspB Qin-prophage, cold-shock protein 
b1646 sodC Superoxide dismutase, Cu, Zn 
b2311 ubiX 3-octaprenyl-4-hydroxybenzoate 
b1538 dcp Dipeptidyl carboxypeptidase II 
b4367 fhuF Ferric iron reductase involved in  
b2091 gatD Galactitol-1-phosphate 
b2093 gatB Galactitol-specific enzyme IIB 
b3631 rfaG Glucosyltransferase I 
b0849 grxA Glutaredoxin 1, redox coenzyme w/ 
b1379 hslJ Heat-inducible protein 
b2259 pmrD Polymyxin resistance protein B 
b2844 yqeF Predicted acyltransferase 
b3765 yifB Predicted bifunctional enzyme and 
b2371 yfdE Predicted CoA-transferase, NAD(P)- 
b2301 yfcF Predicted enzyme 
b3953 frwD Predicted enzyme IIB component of 
b1710 btuE Predicted glutathione peroxidase 
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NAC Codon Bias – 95 open reading frames 
Gene Locus Tag Gene ID Function/Description 
   
Ribosomal Proteins 
b3165 rpsO 30S ribosomal subunit protein S15 
b0169 rpsB 30S ribosomal subunit protein S2 
b3314 rpsC 30S ribosomal subunit protein S3 
b3984 rplA 50S ribosomal subunit protein L1 
b2185 rplY 50S ribosomal subunit protein L25 
b3320 rplC 50S ribosomal subunit protein L3 
b3339 tufA Protein chain elongation factor EF-Tu 
b3980 tufB Protein chain elongation factor EF-Tu 
b0911 rpsA 30S ribosomal subunit protein S1 
b3342 rpsL 30S ribosomal subunit protein S12 
b2609 rpsP 30S ribosomal subunit protein S16 
b3311 rpsQ 30S ribosomal subunit protein S17 
b0023 rpsT 30S ribosomal subunit protein S20 
b3065 rpsU 30S ribosomal subunit protein S21 
b3230 rpsI 30S ribosomal subunit protein S9 
b3310 rplN 50S ribosomal subunit protein L14 
b3301 rplO 50S ribosomal subunit protein L15 
b2606 rplS 50S ribosomal subunit protein L19 
b1716 rplT 50S ribosomal subunit protein L20 
b3318 rplW 50S ribosomal subunit protein L23 
b3637 rpmB 50S ribosomal subunit protein L28 
b1089 rpmF 50S ribosomal subunit protein L32 
b1717 rpmI 50S ribosomal subunit protein L35 
b4147 efp Elongation factor EF-P 
b3340 fusA Protein chain elongation factor EF-G, 
b0170 tsf Protein chain elongation factor EF-Ts 
b0884 infA Translation initiation factor IF-1 
   
LPS Biosynthesis Proteins 
b3255 accB Acetyl CoA carboxylase, BCCP subunit 
b2207 napD Assembly protein for periplasmic nitrat 
b4093 phnO Pred. acyltransferase with acyl-CoA  
b0729 sucD Succinyl-CoA synthetase, NAD(P)-bind 
b4093 phnO Predicted acyltransferase with acyl-CoA 
 
Nucleic Acid-binding Proteins   
b2699 recA DNA strand exchange and recomb. 
b3560 glyQ Glycine tRNA synthetase, alpha subunit 
b3871 typA GTP-binding protein 
b4384 deoD Purine-nucleoside phosphorylase 
b3988 rpoC RNA polymerase, beta prime subunit 
b3783 rho Transcription termination factor 




b0814 ompX Outer membrane protein 
b3736 atpF F0 sector of membrane-bound ATP syn 
b3732 atpD F1 sector of membrane-bound ATP syn 
b3731 atpC F1 sector of membrane-bound ATP syn 
b2215 ompC Outer membrane porin protein C 
b0957 ompA Outer membrane protein A 
b1632 rsxE Predicted inner membrane NADH-quino 
b4354 yjiY Predicted inner membrane protein 
   
Amino Acid-binding Proteins 
b2796 sdaC Predicted serine transporter 
b4143 groL Cpn60 chaperonin GroEL, large subunit 
b3349 slyD FKBP-type peptidyl prolyl cis-trans iso. 
b0810 ginP Glutamine transporter subunit 
b3556 cspA Major cold shock protein 
b0441 ppiD Peptidyl-prolyl cis/trans isomerase rot. 
b0525 ppiB Peptidyl-prolyl cis/trans isomerase rot. 
b0436 tig Peptidyl-prolyl cis/trans isomerase 
b0161 degP Serine endoprotease (protease Do), 
b2551 glyA Serine hydroxymethyltransferase 
   
Enzymes 
b0605 ahpC Alkyl hydroperoxide reductase, C22 sub 
b0270 yagG CP4-6 prophage; predicted sugar trans. 
b0271 yagH CP4-6 prophage; predicted xylosidase/ 
b2935 tktA Transketolase 1, thiamin-binding 
b3919 tpiA Triosephosphate isomerase 
b4196 ulaD 3-keto-L-gulonate 6-phosphate decarb. 
b2296 ackA Acetate kinase A and propionate kinase 
b4101 phnG Carbon-phosphorus lyase complex sub. 
b2779 eno Enolase 
b2528 iscA FeS cluster assembly protein 
b2925 fbaA Fructose-bisphosphate aldolase, class II 
b1779 gapA Glyceraldehyde-3-phosphate dehydrog. 
b2023 hisH Imidazole glycerol phosphate synthase, 
b4226 ppa Inorganic pyrophosphatase 
b0116 lpd Lipoamide dehydrogenase, E3 compon. 
b1818 manY Mannose-specific enzyme IIC compon. 
b1850 eda Multifunctional 2-keto-3-deoxygluconat 
b2297 pta Phosphate acetyltransferase 
b2926 pgk Phosphoglycerate kinase 
b1207 prs Phosphoribosylpyrophosphate synthase 
b4565 sgcB Predicted enzyme IIB component PTS 
b0903 pflB Pyruvate formate lyase I 
b0008 talB Transaldolase B 
   




Predicted/Conserved Proteins   
b0471 ybaB Conserved protein 
b3096 yqjB Conserved protein 




S. flexneri Genome (4177 protein-coding genes) 
NAU Codon Bias – 111 open reading frames 
Gene Locus Tag Gene ID Function/Description 
   
Membrane-associated Proteins 
SF2171 yehB Putative outer membrane protein 
SF2676 smpA Small membrane protein A 
SF3545 hdeD Acid-resistance membrane protein 
   
LPS Biosynthesis Proteins 
SF2100 rfbE Polysaccharide biosynthesis protein 
SF2625 acpS 4'-phosphopantetheinyl transferase 
SF3665 waaY LPS core biosynthesis protein 
   
Nucleic Acid-binding Proteins 
SF1826 dbpA ATP-dependent RNA helicase DbpA 
SF3190 yraO DnaA initiator-associating protein 
SF3927 mobB Molybdopterin-guanine dinucleotide 
SF1326 ycjW Putative LACI-type transcriptional 
SF2906 ygfI Putative LYSR-type transcriptional 
SF2635 rpoE RNA polymerase sigma factor RpoE 
SF3220 yhbY RNA-binding protein 
SF2016 yedW Transcriptional regulatory protein 
   
Fimbrial/Pilin Proteins 
SF1891 -- Putative tail component of prophage CP-93 
SF1922 flhE Flagellar protein 
SF1987 fliJ Flagellar protein 
SF1895 -- Putative tail attachment protein 
SF1890 -- Putative tail component of prophage 
   
Predicted Proteins 
SF1005 yccE Hypothetical Protein SF1005 
SF1437 yeaK Hypothetical Protein SF1437 
SF3538 -- Hypothetical Protein SF3538 
SF4232 yjgN Hypothetical Protein SF4232 
SF0890 ybhH Hypothetical protein SF0890 
SF0913 ycaR Hypothetical protein SF0913 
SF0916 ycbC Hypothetical protein SF0916 
SF1065 yceO Hypothetical protein SF1065 
SF1116 ycfR Hypothetical protein SF1116 
SF1169 -- Hypothetical protein SF1169 
SF1278 -- Hypothetical protein SF1278 
SF1328 ycjF Hypothetical protein SF1328 
SF1333 -- Hypothetical protein SF1333 
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SF1336 -- Hypothetical protein SF1336 
SF1498 ydjO Hypothetical protein SF1498 
SF1524 -- Hypothetical protein SF1524 
SF1562 marB Hypothetical protein SF1562 
SF1628 ydgC Hypothetical protein SF1628 
SF1752 yddG Hypothetical protein SF1752 
SF1770 -- Hypothetical protein SF1770 
SF1858 yebF Hypothetical protein SF1858 
SF2071 yeeD Hypothetical protein SF2071 
SF2093 -- Hypothetical protein SF2093 
SF2136 -- Hypothetical protein SF2136 
SF2137 -- Hypothetical protein SF2137 
SF2230 -- Hypothetical protein SF2230 
SF2377 yfcF Hypothetical protein SF2377 
SF2438 yfdE Hypothetical protein SF2438 
SF2460 yfeC Hypothetical protein SF2460 
SF2486 -- Hypothetical protein SF2486 
SF2645 yfiP Hypothetical protein SF2645 
SF2662 yfiL Hypothetical protein SF2662 
SF2932 yqgB Hypothetical protein SF2932 
SF2987 -- Hypothetical protein SF2987 
SF3007 -- Hypothetical protein SF3007 
SF3141 yqjD Hypothetical protein SF3141 
SF3143 -- Hypothetical protein SF3143 
SF3149 yhaL Hypothetical protein SF3149 
SF3279 yhcO Hypothetical protein SF3279 
SF3366 slyX Hypothetical protein SF3366 
SF3381 yhfG Hypothetical protein SF3381 
SF3421 -- Hypothetical protein SF3421 
SF3500 -- Hypothetical protein SF3500 
SF3503 yhiI Hypothetical protein SF3503 
SF3541 yhiF Hypothetical protein SF3541 
SF3546 yhiE Hypothetical protein SF3546 
SF3607 yiaB Hypothetical protein SF3607 
SF3766 yidB Hypothetical protein SF3766 
SF3895 yigF Hypothetical protein SF3895 
SF3902 yigK Hypothetical protein SF3902 
SF3963 -- Hypothetical protein SF3963 
SF3965 yiiE Hypothetical protein SF3965 
SF4158 yjbL Hypothetical protein SF4158 
SF4179 yjbE Hypothetical protein SF4179 
SF4195 yjiC Hypothetical protein SF4195 
SF4417 -- Hypothetical protein SF4417 
   
Enzymes 
SF2387 ubiX 3-octaprenyl-4-hydroxybenzoate carboxylase 
SF1272 btuR Cob(I)yrinic acid a,c-diamide adenosyltransf. 
SF2060 cobS Cobalamin synthase 
SF2099 rfbF dTDP-rhamnosyl transferase 
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SF2096 rfbI Glycosyl translocase 
SF2625 acpS 4'-phosphopantetheinyl transferase 
SF1578 -- Aldolase 
SF0990 cspH Cold shock-like protein 
SF2101 rfbC dTDP-6-deoxy-L-mannose- 
SF2098 rfbG dTDP-rhamnosyl transferase 
SF4070 nfi Endonuclease V 
SF4400 fhuF Ferric iron reductase involved in ferr 
SF2150 gatR Galactitol utilization operon 
SF2151 gatD Galactitol-1-phosphate dehydrogena 
SF2155 gatB Galactitol-specific PTS system 
SF0802 grxA Glutaredoxin 1 
SF2096 rfbJ Glycosyl transferase 
SF1789 trg Methyl-accepting chemotaxis protei 
SF2766 pcm Protein-L-isoaspartate O-MTase 
SF4377 hpaA Putative 4-hydroxyphenylacetate 
SF2781 ygcM Putative 6-pyruvoyl tetrahydro- 
SF1521 btuE Putative glutathione peroxidase 
SF1331 ycjG Putative muconate cycloisomerase I 




NAC Codon Bias – 84 open reading frames 
Gene Locus Tag Gene ID Function/Description 
   
Ribosomal Proteins 
SF3206 rpsO 30S ribosomal protein S15 
SF3346 rpsC 30S ribosomal protein S3 
SF4057 rplA 50S ribosomal protein L1 
SF2272 rplY 50S ribosomal protein L25 
SF3352 rplC 50S ribosomal protein L3 
SF3357 tuf Elongation factor Tu 
SF4053 tuf Elongation factor Tu 
SF0907 rpsA 30S ribosomal protein S1 
SF3360 rpsL 30S ribosomal protein S12 
SF2669 rpsP 30S ribosomal protein S16 
SF3343 rpsQ 30S ribosomal protein S17 
SF3106 rpsU 30S ribosomal protein S21 
SF3270 rpsI 30S ribosomal protein S9 
SF4056 rplK 50S ribosomal protein L11 
SF3342 rplN 50S ribosomal protein L14 
SF2666 rplS 50S ribosomal protein L19 
SF1515 rplT 50S ribosomal protein L20 
SF3350 rplW 50S ribosomal protein L23 
SF3676 rpmB 50S ribosomal protein L28 
SF1093 rpmF 50S ribosomal protein L32 
SF1514 rpmI 50S ribosomal protein L35 
SF3333 rplO 50S ribosomal protien L15 
SF4303 efp Elongation factor P 
SF3358 fusA GTP-binding protein chain elong. Factor EF- 
SF0843 infA Translation initiation factor IF-1 
   
LPS Biosynthesis Proteins 
SF3293 accB Acetyl-CoA carboxylase biotin carrier protein 
SF2291 napD Assembly protein for periplasmic nitrate red. 
   
Nucelic Acid-binding Proteins 
SF4061 rpoC DNA-directed RNA polymerase subunit !' 
SF3603 glyQ Glycyl-tRNA synthetase subunit " 
SF4416 deoD Purine nucleoside phosphorylase 
SF2542 upp Uracil phosphoribosyltransferase 
   
Membrane-associated Proteins 
SF1706 lpp Murein lipoprotein 
SF0957 ompA Outer membrane protein A 
SF0765 ompX Outer membrane protein X 
SF0761 glnP Glutamine ABC transporter permease protein 
SF2299 ompC Outer membrane porin protein C 




SF1599 -- Hypothetical protein 
SF2274 yejL Hypothetical protein 
SF3139 yqjB Hypothetical protein 
SF1554 -- Hypothetical protein 
SF2967 -- Hypothetical protein 
   
Amino Acid-binding Proteins 
SF2810 sdaC Serine Transporter 
SF4297 groEL Chaperonin GroEL 
SF3850 ppiC Peptidyl-prolyl cis-trans isomerase C 
   
Enzymes 
SF3997 tpiA Triosephosphate isomerase 
SF2372 ackA Acetate kinase 
SF3816 atpF F0F1 ATP synthase subunit B 
SF3812 atpD F0F1 ATP synthase subunit beta 
SF3811 atpC F0F1 ATP synthase subunit epsilon 
SF0898 pflB Formate acetyltransferase 1 
Sf2910 fba Fructose-bisphosphate aldolase 
SF1444 gapA Glyceraldehyde-3-phosphate dehydrogenase 
SF1860 eda keto-hydroxyglutarate-aldolase/ 
SF2373 pta Phosphate acetyltransferase 
SF3729 pstA Phosphate transporter permease subunit 
SF2911 pgk Phosphoglycerate kinase 
SF1410 manY PTS enzyme IIC 
SF1904 -- Putative serine protease 
SF4024 -- Putative transaldolase 
SF2722 recA Recombinase A 
SF1210 prsA Ribose-phosphate pyrophosphokinase 
SF1657 ydgQ SoxR-reducing system protein RsxE 
SF2358 nuoH NADH dehydrogenase subunit H 




S. flexneri Virulence Plasmid (293 protein-coding genes) 
NAU Codon Bias – 24 open reading frames 
Gene Locus Tag Gene ID Function/Description 
   
TTSS Genes 
pWR501_p155 mxiA Invasion protein 
pWR501_p161 spaP 
Surface presentation of antigens protein 
SpaP 
pWR501_p147 mxiJ Type III secretion protien 
pWR501_p149 mxiL Hypotetical protein 
pWR501_p150 mxiM Hypotetical protein 
pWR501_p166 spa-orf11 Hypotetical protein 
pWR501_p154 mxiC Invasion protein 
pWR501_p158 spa13 Invasion protein 
pWR501_p151 mxiE Putative lipoprotein 
pWR501_p148 mxiK Type III secretion protein 
pWR501_p152 mxiD Type III secretion protein 
pWR501_p153 mxiD Type III secretion protein 
   
Invasion Proteins 
pWR501_p192 -- Adhesion protein, fragment 
pWR501_p142 ipgE Invasion-associated protein 
pWR501_p143 ipgF Invasion-associated protein 
pWR501_p237 mob9 Plasmid mobilization protein 
pWR501_p028 -- Putative transposase, fragment 
pWR501_p141 ipgD Secreted protein 
   
Nucleic Acid-binding Protein 
pWR501_p051 virF Transcriptional activator of virulence loci 
   
Hypothetical Proteins 
pWR501_p120 -- Hypotetical protein 
pWR501_p236 -- Hypotetical protein 
pWR501_p264 yigB Hypotetical protein 
pWR501_p290 -- Hypotetical protein 
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Site-specific Modification of Shigella flexneri virF mRNA by tRNA-guanine 
Transglycosylase in vitro 
 
Modified nucleosides have been shown to play a role in RNA structure 
and stability [1-3].  The incorporation of modified nucleosides has been 
characterized more fully for tRNA (and some other RNAs, e.g., rRNA & snRNA), 
than for mRNA [4-6].  Mandal and Breaker have characterized binding of small 
molecules and metabolites to RNA motifs termed “riboswitches,” which are often 
located in the untranslated regions (UTR) of target RNAs in both prokaryotic and 
eukaryotic species [7-9].  It has been shown that binding of the small molecule 
changes the conformation of the RNA and thereby modulates either transcription 
or translation of the target RNA [10]. 
Breaker and colleagues have reported the discovery of a riboswitch that 
responds to the queuine precursor, preQ1, and appears to regulate the 
expression of the four genes that are involved in preQ1 biosynthesis [11-13].  
Durand and colleagues have demonstrated a positive correlation between virF 
mRNA translation and the presence of active TGT (and presumably queuine 
modification) [14].  It certainly seems possible that base modification of an mRNA 
could modulate a similar conformational change observed with the preQ1 
riboswitch.  It therefore is feasible that such a control mechanism for gene 
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expression might be involved in regulating the expression of virulence factors in 
pathogenic organisms, as is apparently seen with VirF. 
 To date, the only known function of TGT is to catalyze the modification of 
tRNA with queuine; however, previous work has shown that the eubacterial TGT 
will recognize a U-G-U sequence in alternative RNA structures (i.e., minihelical 
stem-loop, dimeric cognate tRNA) [15-17].  It is conceivable that an mRNA may 
also be modified directly by TGT provided the mRNA contained the appropriate 
recognition elements.  As a first step towards probing the possibility that TGT 
may modulate the translation of VirF via modification of the virF mRNA, 
Michaelis-Menten kinetic analyses were conducted to probe this modification by 
TGT in vitro. 
Materials and Methods 
Reagents 
Unless otherwise specified, all reagents were from Sigma or Aldrich.  DNA 
oligonucleotides, agarose, dithiothreitol (DTT), T4 DNA ligase, and DNA ladders 
were from Invitrogen.  All restriction enzymes and Vent! DNA polymerase were 
from New England Biolabs.  The ribonucleic acid triphosphates (NTPs) and 
pyrophosphatase were from Roche Applied Sciences.  The deoxyribonucleic acid 
triphosphates (dNTPs) were from Promega.  Low-melting Seaplaque agarose 
was from Cambrex.  Gelase" Enzyme Prep, MasterAmp" High Fidelity RT-PCR 
Kit, and Scriptguard" RNase Inhibitor were from Epicentre.  Epicurian coli! 
XL2-Blue ultracompetent cells were from Stratagene.  Amicon Ultra Centrifugal 
Filter Devices were from Millipore.  Whatman GF/C Glass Microfibre Filters and 
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all bacterial media components were from Fisher.  The QIAPrep! Spin Miniprep 
Kit was from Qiagen.  Tris-HCl Buffer was from Acros Organics.  [3H]-PreQ1 was 
obtained from a custom synthesis by American Radiolabeled Chemicals, Inc.  T7 
RNA polymerase was isolated from E. coli BL21 cells containing the plasmid 
pBH161 according to the procedure of Prof. William McCallister, State University 
of New York, Brooklyn.  The E. coli TGT was isolated with an amino terminal his-
tag as previously described [18]. 
Synthesis of [3H] preQ1 
 
Figure III-1. Synthesis of Radiolabeled [3H] PreQ1. a) chloro(formyl)acetonitrile, 
NaOAc, H2O, 100°C; b) 3H2, Pd/C, MeOH, 50 psi.  Note that 
aqueous workup exchanges any tritium in the amine. 
 
The cyano precursor (preQ0, 2) was synthesized according to the method 
of Migawa and Townsend by the condensation of chloro(formyl)acetonitrile and 
pyrimidine 1 [19].   Reduction of the cyano precursor with tritium gas gave the 
desired radiolabeled substrate preQ1 (3) with a specific activity of 500mCi/mmol 
[20].  After aqueous workup, the tritium in the amine is exchanged out.  The 






Construction of pTZvirF 
The plasmid pBDG302, containing the virf gene, was received from Prof. 
Glenn Björk (Umeå University, Sweden).  The virf gene was amplified from the 
plasmid by polymerase chain reaction (PCR) under the following conditions: 
pBDG302 (500 ng), PCR primers (20 pmol each, see pTZvirF in Table III-1), 
Mg2+ (2 mM), dNTP mix (1 mM each NTP), Vent DNA polymerase (4 U), brought 
to a final volume of 50 µL with deionized water.  The sample was treated with 30 
PCR cycles of the following sequence: 94°C for 1 min., 50°C for 1 min., and 72°C 
for 2 min., followed by a final extension at 72°C for 5 min.  Following a double 
restriction enzyme digestion with PstI and EcoRI (40 U each, 20 #L reaction) for 
1 h at 37°C, the PCR product and vector were gel-purified from Seaplaque 
agarose with Gelase" according to the vendor’s protocol.  The purified virf gene 
was then ligated into digested pTZ19R (5:1 volume ratio, 20 #L reaction) 
following overnight incubation with T4 DNA ligase (2 U) at 17°C.  The ligated 
sample (10 #L) was transformed into 100 #L of Epicurian coli! XL2-Blue 
ultracompetent cells according to the Stratagene protocol. Cells were grown 
overnight at 37°C on L-Amp plates (50 #g/mL ampicillin).  Individual colonies 
were isolated, and 3-mL 2xTY (16 g bactotryptone, 10 g yeast extract, 5 g 
NaCl/liter of water with 50 #g/mL ampicillin) liquid cultures were inoculated at 
37°C with shaking.  Plasmid was isolated via miniprep, and the virf gene 
sequence was confirmed with DNA sequencing (University of Michigan DNA 




Table III-1. Oligonucleotide Sequences for pTZvirF.  Key restriction enzyme sites 
or nucleotides of interest are underlined. 
 
Sample Name Primer Name Primer Sequence (5’ – 3’) 
PstI FWD GACTGCAGATGATGGATATGGGAC 
pTZvirF 
EcoRI REV GAGAATTCTTAAAATTTTTTATG 
 G421A FWD GTTTAGCTTGCCTTTTATCAGCTAT- 
TTCTGATGAGGAAGCTTTATATAC pTZvirF(G421A) 
Quik-Change G421A REV GTATATAAAGCTTCCTCATCAGAAA- 
TAGCTGATAAAAGGCAAGCTAAAC 
 
In vitro Transcription 
In vitro transcription reactions with pTZvirF were conducted by first 
linearizing the plasmid at the end of the virf sequence with the restriction enzyme 
EcoRI (40 U/100 #L DNA, 500 #L reaction).  The sample was ethanol 
precipitated at -20°C, and the pellet was resuspended in 250 #L of deionized 
water.  In vitro transcription conditions were as follows (1 mL total volume): 
pTZvirF template (100 µL), transcription buffer (4 mM Tris-HCl, pH 8.0; 2 mM 
MgCl2, 0.5 mM DTT, 0.1 mM spermidine), NTP mix (4 mM each NTP), T7 RNA 
polymerase (2500 U), inorganic pyrophosphatase (2 U), and RNase inhibitor 
(200 U).  The reaction was incubated at 37°C for approximately 4 h, and stored 
at -20°C following transcription.  Best results were obtained when the 1-mL 
reaction was prepared and redistributed into 100 µL volumes prior to incubation 
at 37°C.  The MasterAmp" High Fidelity RT-PCR Kit was used according to 
vendor’s protocol to generate virf DNA, which was confirmed via sequence 




Mfold Analysis and Synthesis of virF MH 
Analysis of the energetically favorable secondary structures within the virF 
mRNA sequence was performed using the biophysical web tool Mfold [21].  
Sequences of approximately 10 nucleotides surrounding either side of the six 
possible recognition motifs were analyzed by the web tool, and the hairpin 
structure determined to be most favorable was found between nucleotides 410-
433 in the virF mRNA, which contains the potential recognition sequence 
U420G421U422 (Figure III-2).  The RNAture Oligonucleotide Analyzer web tool was 
used to predict a Tm of 71 °C for the virF minihelix hairpin.  An Expedite" 
Nucleic Acid Synthesis System was used to synthesize the 24-nucleotide 
sequence (5’-GGAGUAGUCUUUGUCGACUAUUUU-3’) using the vendor’s 
protocols for the synthesis of RNA at the 1 #mole scale.  The reagents were from 
Perkin-Elmer and the RNA amidites were from Glen Research.  The extinction 
coefficient determined for this RNA minihelix was #260=265.3 OD/mM. 
Characterization of TGT-virF mRNA Intermediate 
 Various concentrations of virF mRNA (1-20 #M) and E. coli TGT (500 nM-
20 #M) were incubated at 37°C overnight in transcription buffer supplemented 
with RNase inhibitor (40 U).  A previously characterized minihelical substrate, 
ECYMH (the anticodon stem-loop of E. coli tRNATyr), was studied as a positive 
control [16].  Samples were analyzed by SDS-PAGE under mild denaturing 
conditions as previously described [22].  Product virF mRNA containing an 
abasic site(s) in place of the substrate guanine base were analyzed by RT-PCR 
as previously described or by chemical cleavage following treatment with 
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spermidine and/or hydroxylamine.  Briefly, samples containing virF mRNA and E. 
coli TGT (5 #M each) were incubated in HEPES reaction buffer (100 mM 
HEPES, pH 7.3; 20 mM MgCl2; 5 mM DTT) in a total volume of 60 #L for 30 min. 
at 30°C.  Samples were treated with either hydroxylamine (420 mM), spermidine 
(4.2 #M), or a combination of the two for 30 min. at 37°C.  The samples were 
characterized on an ethidium bromide stained, 1.2% formaldehyde agarose gel. 
Generation of virF mRNA(G421A) 
The single nucleotide mutation of guanine 421 to adenine in the virF 
mRNA sequence was generated via QuikChange site-directed mutagenesis 
(Stratagene), producing the new vector pTZvirF(G421A).  The reaction conditions 
were as follows: pTZvirF(wt) template (800 ng), Quik-Change PCR primers (10 
pmol each, see pTZvirF(G421A) in Table III-1), dNTP mix (0.25 mM each NTP), 
and Vent DNA polymerase (2 U), brought to a final volume of 30 µL with 
deionized water.  The sample was treated with 25 PCR cycles of the following 
sequence: 94°C for 30 sec., 50°C for 1 min., and 72°C for 6.5 min.  The PCR 
product was treated for 2 h at 37°C with DpnI (40 U), and addition of NEBuffer 4 
(20 mM Tris-Acetate (pH 7.9), 50 mM K(CH3COO), 10 mM Mg(CH3COO)2, 1 mM 
DTT) was required for proper digestion of wildtype plasmid.  The digested 
sample (10 #L) was transformed into 100 #L of XL2-Blue ultracompetent cells 
according to vendor’s protocol (Stratagene).  Cells were grown overnight at 37°C 
on L-Amp plates (50 #g/mL ampicillin).  Individual colonies were isolated, and 3 
mL 2xTY liquid cultures (with 50 #g/mL ampicillin) were inoculated and incubated 
at 37°C with shaking.  Plasmid was isolated via miniprep (Qiagen), and the virF 
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mRNA(G421A) mutation was confirmed by DNA sequencing (University of 
Michigan DNA Sequencing Core Facilities). 
Kinetic assays 
Assays were conducted by monitoring the incorporation of radiolabeled 
substrate, [3H]-preQ1, into E. coli tRNATyr, dG34ECYMH (5$-
GGGAGCAGACUdGUAAAUCUGCUCCC-3$), and various virF mRNA 
substrates.  Samples generated by in vitro transcription were concentrated with 
Amicon Ultra Centrifugal Filters (10,000 MWCO).  The concentration of virF 
mRNA was determined with a Cary UV-Visible Spectrophotometer, where the 
approximate concentration of a single stranded RNA sample A260=1 OD is 40 
#g/mL and the molecular weight of virF mRNA is 252g/mmol virF mRNA.  In 
brief, kinetic assays were set up under the following conditions: RNA substrate 
(various concentrations), [3H]-preQ1 (10 µM, 296 mCi/mmol stock), TGT (100 or 
200 nM, as specified), and HEPES reaction buffer to a final volume of 400 µL.  
All samples were incubated at 37°C for 5 min. to allow for temperature 
equilibration.  Reactions were initiated by addition of TGT.  Aliquots (70 µL) were 
removed at various points throughout the reaction and quenched in 3 mL of 5% 
TCA for 1 h before filtering on glass-fiber filters.  Each filter was washed with 
three volumes of 5% TCA and a final wash of ethanol to dry the filter.  The 
samples were analyzed in a scintillation counter (Beckman) for radioactive 
decay, where counts were reported in DPM and later converted to pmol [3H]-
preQ1 by the following conversion (pmol = DPM x 0.00152, for the [3H]-preQ1 
stock with a specific activity of 296 mCi/mmol).  Initial velocities were determined 
VirG 













by converting the slopes of these plots (pmol/min) to units of sec-1, taking into 
account the concentration of the enzyme and aliquot size.  The individual data 
points from each trial were averaged, and the standard deviation was determined 
for each concentration of RNA substrate.  The average data points (with error 
bars representing their standard deviations) were plotted.  However, all of the 
individual data points were fit via nonlinear regression to the Michaelis-Menten 
equation and the line for that fit is displayed (Figure III-4).  All non-linear 
regression fits with the Michaelis-Menten equation were determined using 
Kaleidagraph (Abelbeck Software). 
For direct incorporation of queuine, virF mRNA was also incubated with 
the human TGT catalytic subunit (hTGTc).  Briefly, reactions containing virF 
mRNA (10 #M), hTGTc (1 #M), [3H]-queuine (20 #M), RNase inhibitor (200 U), 
and bicine buffer in a total volume of 400 #L were incubated at 37°C for 25 min.  
Aliquots (70 #L) were removed every 5 min, and the samples were prepared as 
described previously. 
Results 
Construction and In vitro Transcription of pTZvirF 
To provide micromolar quantities of virF mRNA for our studies, we 
generated an in vitro transcription clone for the virF mRNA.  The virf gene was 
subcloned from the plasmid pBDG302 containing the virf gene (a gift from 
Professor Glenn Björk, Umeå University, Sweden) into a plasmid suitable for in 
vitro transcription, generating pTZvirF.  VirF mRNA was synthesized via in vitro 
run-off transcription following digestion with EcoRI, linearizing pTZvirF at the end 
 
87 
of the virf gene sequence.  The virF mRNA was physically characterized on an 
ethidium bromide-stained, 1.2% formaldehyde agarose gel.  Reverse 
transcriptase / polymerase chain reaction (RT-PCR) was utilized to generate 
dsDNA from the in vitro transcription product using the same oligonucleotide 
primers initially designed for subcloning of the virf gene.  Examples of TAE 
agarose gels of the virF mRNA and the dsDNA from the RT-PCR reaction are 
shown in Figure III-3. 
 
Figure III-2. Nucleotide Sequence of virF mRNA.  Six UGU sequences are found 
in the sequence, and are highlighted in red. 
 
The single-stranded virF mRNA appears to run on the gel at approximately 500 
bp in comparison to the double-stranded DNA ladder.  The size of the virf gene is 
789 bp, and the corresponding mRNA is 789 nucleotides in length.  We 
hypothesize that the mRNA is running at a lower “apparent” molecular weight 
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due to the propensity of mRNA to adopt a variety of conformations, even in an 
agarose gel.  This would explain why the observed molecular weight is a little 
larger than one half the size of the double-stranded virf DNA.  The RT-PCR 
product (dsDNA) migrated to the anticipated molecular weight for a DNA sample 
of approximately 800 bp.  DNA sequencing of this product confirmed the RT 
product was the virf gene. 
 
Figure III-3. Transcription of virF mRNA.  A) In vitro transcription of virF mRNA 
visualized with ethidium bromide on a 1% TAE agarose gel.  The 
single-stranded mRNA ran at approximately 500 bp in comparison to 
the 100 bp DNA ladder (lane 1).  Lane 2: virF mRNA from a previous 
transcription reaction.  Lanes 4 and 5: virF mRNA from replicate 
transcription reactions.  B) RT-PCR samples visualized with 
ethidium bromide on a 1% TAE agarose gel.  RT-PCR was 
conducted using extracted mRNA from replicate samples (lanes 2 & 
3), electrophoresed in comparison to a 100 bp DNA ladder (lane 1).  
Each RNA sample produced the corresponding 800 bp DNA species 
indicative of the virf ORF. 
 
Kinetic Analysis of E. coli tRNATyr, ECYMH Minihelix with preQ1 
For comparison, Michaelis-Menten kinetic analyses were conducted with 
the natural RNA substrate E. coli tRNATyr (ECY) and the modified minihelix 
substrate dG34ECYMH (the anticodon stem-loop of E. coli tRNATyr where the 
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guanosine at position 34 contains a 2$-deoxyribose) with [3H] preQ1.  It has been 
shown previously that a minihelix RNA consisting of the anticodon arm and loop 
of a queuine-cognate tRNA is a sufficient substrate for TGT [15].  Aliquots were 
taken at various time points over a 15-minute incubation of 100 nM E. coli TGT, 
various concentrations of ECY (0.05-1.5 #M) or dG34ECYMH (0.05-5 #M), and 
saturating concentrations of [3H]-preQ1.  The kinetic constants determined for the 
incorporation of [3H]-preQ1 with ECY and dG34ECYMH are shown in comparison 
with the kinetic data for the virF substrates in Table III-2. 
Attempt at Characterization of TGT-virF mRNA Covalent Intermediate 
 TGT and virF mRNA were incubated for an increased period of time 
(overnight) in an attempt to visualize the formation of a covalent intermediate, 
which has been characterized previously with both tRNA and minihelical 
substrate RNA [22].  Visualization of the complex by SDS-PAGE and Coomassie 
Blue staining under mild denaturing conditions was unsuccessful.  Only the 45 
kDa unbound E. coli TGT was detected (data not shown).  In addition, chemical 
cleavage of the product mRNA with hydroxylamine/spermidine lead to 
degradation of the RNA species.  Due to issues with RNA integrity, the technique 
was unsuccessful in determining the site of queuine modification. 
Kinetic Analysis of virF mRNA, virF MH Minihelix with preQ1 
Using the same approach described above, Michaelis-Menten kinetic 
analyses were conducted with virF mRNA.  Aliquots were taken at various time 
points over a 1 h incubation of 200 nM TGT, various concentrations of virF 
mRNA (0.1-10 #M), and saturating concentrations of [3H]-preQ1 (Figure III-4A).  
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Higher concentrations of virF mRNA were tested to obtain an accurate kinetic 
profile by characterizing the reaction over a large range of concentrations.  In 
addition to characterizing the wildtype virF mRNA, a virF minihelix RNA (virF MH) 
corresponding to the 410-433 hairpin sequence (underlined in Figure III-2, 
structure in Figure III-4B) as well as a full-length virF mRNA mutant (G421A) were 
studied.  The kinetic analyses were performed with 100 nM E. coli TGT, various 
concentrations of virF MH (0.1-10 #M), and saturating concentrations of [3H]-
preQ1 (Figure III-4B).  The full-length virF mRNA(G421A) was incubated under the 
same conditions as the wildtype mRNA, but only at concentrations corresponding 
to KM and 5xKM, as determined from the kinetic constants of virF mRNA(wt) 
(Table III-2).  A “no RNA” control was also included to determine the background 
level of radioactivity present in the samples (Figure III-4C).  The data in Figures 
III-4A & B were fit by non-linear regression to the Michaelis-Menten equation and 
those in Figure III-4C by linear regression.   
Both the full-length virF mRNA(wt) and the virF minihelix exhibited RNA 
concentration-dependent incorporation of [3H]-preQ1 over time, and the 
Michaelis-Menten equation provided a good fit for the data.  The full-length virF 
mRNA(G421A), which is full-length mRNA with a single nucleotide mutation at 
guanine 421, was analyzed at both 2 #M (~ KM) and 10 #M (~ 5xKM) mRNA.  The 
virF mRNA(G421A) mutant showed no detectable activity greater than the “no 
RNA” control (Figure III-4C).  The kinetic constants determined for the virF 
mRNA substrates are shown in Table III-2.  Both the virF mRNA and virF MH 




Figure III-4.  Kinetic Characterization of virF mRNA Substrates with E. coli TGT 
and [3H] PreQ1.  A) and B) The individual data points were fit to the 
Michaelis-Menten equation by non-linear regression, and the 
average data points (with error bars representing the standard 
deviations of the averages) for each concentration of RNA 
substrate are depicted.  The study was performed with duplicate 
kinetic trials at saturating concentrations of [3H] preQ1.  The inset in 
B shows the structure of the RNA minihelix corresponding to bases 
410-433 of the virF mRNA.  C) The comparison of radioactive 
substrate incorporated over time in virF mRNA(wt) (blue), virF 
mRNA(G421A) (green), and a no RNA control (red), fit by linear 
regression.  Each virF mRNA substrate was analyzed at two 
concentrations: 2 #M and 10 #M.  The average of duplicate trials is 
shown. 
 
is lower than the corresponding values for the ECY substrates.  Attempts to 
modify virF mRNA with queuine using human hTGTc were unsuccessful.  We 
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now know that this is most likely due to an inactive preparation of human TGT 
(Chen & Garcia, unpublished). 
Table III-2.  RNA Kinetic Parameters with E. coli htTGT(wt) and [3H] PreQ1 at pH 
7.3. 
 
 KM (#M) kcat (10-4 s-1) kcat / KM (102 M-1 s-1) 
ECY 0.16 (0.03)a 40 (2) 250 (40) 
dG34ECYMH 0.26 (0.07) 70 (5) 270 (60) 
virF mRNA 1.8 (0.4) 1.1 (0.1) 0.60 (0.1) 
virF MH 0.87 (0.3) 3.3 (0.3) 3.8 (1) 
a Standard errors are in parentheses. 
 
Discussion 
VirF is a critical transcriptional regulator responsible for activating 
virulence genes in Shigella flexneri.  Durand and colleagues demonstrated the 
involvement of tRNA-guanine transglycosylase (TGT) in modulating the 
translation of VirF via the observation that a mutant strain of Shigella with an 
inactivated tgt gene (termed vacC) showed decreased virulence [23].  VirF 
protein levels were dramatically lower in the mutant as compared to wildtype, but 
the virF mRNA levels showed no detectable difference from wildtype S. flexneri.  
The lack of VirF resulted in a reduction of all downstream virulence gene 
expression, and thus exhibited a less virulent phenotype than that of the wildtype 
bacterium.  When transformed with a plasmid encoding the S. flexneri tgt gene, 
both VirF translation and virulence were restored in the vacC mutant.  It had 
previously been shown that the presence of modified nucleosides enhances 
translation [24, 25].  However, other studies have shown that growth rate and 
protein translation as a whole are not directly affected by a lack of queuine-
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modified tRNA [26].  While this interesting correlation between VirF translation 
and TGT activity has been known for some time, the exact role TGT plays in the 
translation of this primary virulence factor remains unclear. 
Our laboratory has previously demonstrated that TGT can modify 
substrates with more unusual structures than a canonical tRNA fold.  We 
reported that a dimeric form of the E. coli tRNATyr serves as a substrate for TGT, 
with a slightly higher KM and identical kcat, relative to the normal tRNA [17].  It had 
previously been shown from NMR studies that the anticodon arms of the dimer 
subunits were intact and pointing away from the center of the dimer [27]. 
Those studies demonstrate that TGT can recognize a minihelix containing 
the requisite U-G-U sequence even in the context of a larger RNA structure.  
TGT is not the first tRNA modification enzyme to demonstrate recognition of 
alternative RNA structures.  Gu and coworkers have shown that, in vitro, the 
modification enzyme tRNA (m5U54)-methyltransferase will methylate 16S 
ribosomal RNA from E. coli in addition to its physiological tRNA substrate [5], 
although they found no evidence for this occurring in vivo.  The enzyme 
pseudouridine synthase catalyzes the isomerization of specific uridines to the 
modified nucleoside %.  A single pseudouridine synthase has been shown to 
have “dual specificity”, recognizing and modifying both tRNA and snRNA [28-30].  
Ofengand and colleagues have also characterized a critical pseudouridine 
synthase responsible for site-specific modification with pseudouridine in vivo for 
both tRNA and 23S rRNA in E. coli [31, 32].  Such precedence for tRNA 
modification enzymes to recognize and modify other RNA species in vitro and in 
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vivo, suggests that virF mRNA modification mediated by TGT may also occur.  
As a first step to probe for this possibility, we examined the virF mRNA sequence 
for the presence of a U-G-U sequence in a TGT recognition motif.  Of the six U-
G-U sequences in the virF mRNA, the one involving bases 410-433 (Figure III-2 
and 4B) was predicted by Mfold analysis to be able to fold into a hairpin structure 
possibly suitable for recognition by TGT. 
Incubation of virF mRNA with E. coli TGT and radiolabeled preQ1 revealed 
that the virF mRNA is indeed a substrate for TGT in vitro.  The kinetic parameters 
(KM, kcat, Table III-2) for virF mRNA were determined from a nonlinear fit of the 
data to the Michaelis-Menten equation (Figure III-4A).  The virF mRNA 
substrates exhibit the same trend in kinetic parameters as the ECY substrates, 
where the minihelix substrates (dG34ECYMH and virF MH) have slightly higher 
values for both KM and kcat/KM with respect to the corresponding full-length RNA 
substrates (Table III-2).  The values of KM for both ECY and virF mRNA are very 
similar, both in the low micromolar range.  This is encouraging considering the 
size and structural difference between the two substrates, where ECY is 
approximately 80 nucleotides in length with a very well-defined tertiary structure 
common to tRNA and the virF mRNA is ca. 800 nucleotides in length and 
presumably does not have a compact tertiary structure.  The kinetic data for the 
virF mRNA (Figure III-4A) fits to a single KM, consistent with a single site of 
modification within the virF mRNA.  The kcat for the virF mRNA is ca. 40-fold 
lower than that for tRNA.  It has previously been shown that altering the position 
of the U-G-U sequence within the minihelix loop of cognate tRNAs is correlated 
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with a reduction in activity [33].  All of the biochemical and structural data 
previously reported is consistent with a covalent intermediate, via Asp264, in the 
TGT reaction [18, 34-36].  The hairpin loop of the ECY substrate contains 7 
nucleotides, whereas the hairpin in the virF mRNA substrate contains only 6 
nucleotides in the loop.  This difference in loop length may result in a suboptimal 
orientation of the guanosine ribose in the U420-G421-U422 loop in the virF mRNA, 
making nucleophilic attack by Asp264 somewhat less likely.  This difference in 
loop length and orientation could account for the reduced kcat that we have 
observed for the virF mRNA substrates. 
Our analysis of the virF mRNA sequence predicts that there should be a 
single site of modification, guanine 421.  We have taken two approaches to 
investigate this.  In our first approach, an RNA minihelix (virF MH) corresponding 
to the predicted hairpin structure within the native virF mRNA sequence (bases 
410-433) was chemically synthesized (Figure III-4B).  The stem consists of nine 
base pairs, where the first four nucleotides in the stem are uridine residues 
forming wobble pair interactions with three guanines and one Watson-Crick pair 
with an adenosine.  At first glance, the stability of a minihelix with three G-U 
wobble pairs might be questionable; however, in the context of the virF mRNA, 
the ends of the helix may be held in close proximity by other intramolecular 
interactions.  Additionally, the virF MH by itself has a predicted melting 
temperature of 71ºC, indicating the structure should be stable at physiological 
and assay temperatures.  The virF MH is a substrate for TGT in vitro.  The KM 
values for both the full-length virF mRNA and virF MH (1.8 #M and 0.87 #M, 
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respectively; Table III-2) are very similar, suggesting that the minihelix structure 
is likely a predominant conformation in the virF mRNA. 
Although the recognition of the virF minihelix by TGT is consistent with the 
virF mRNA serving as a substrate for TGT, it does not provide conclusive 
evidence that guanine 421 is the site of modification in the virF mRNA.  There 
are six UGU sequences within the virF mRNA that are possible recognition sites 
for TGT.  Therefore, our second approach was to construct the point mutation, 
G421A, in the full-length virF mRNA to demonstrate the importance of guanine 
421.  The virF mRNA(G421A) mutant resulted in a complete loss of activity at two 
different concentrations of RNA (Figure III-4C), indicating that G421 is indeed 
essential for recognition by TGT.  Had a second exchangeable guanine existed 
in the sequence, we would have expected to see a decreased or possibly even 
unchanged activity of the mRNA.  The relationship between the “no RNA” 
negative control and the virF mRNA(G421A) indicates that guanine 421 is the only 
exchangeable nucleotide in the virF mRNA sequence (at least within the 
concentration ranges tested), and that the kinetic parameters observed for virF 
mRNA(wt) are due to specific recognition by TGT and could not be attributed to 
non-specific interactions with this large nucleic acid molecule.  It should be noted 
that, under the conditions of the assay (Figure III-4C), it appears that the enzyme 
is undergoing a limited number of turnovers.  Two factors may be contributing to 
this.  The first is that our calculations of kinetic parameters assume 100% active 
enzyme, which is almost certainly an over-estimate.  The active enzyme 
concentration may be as much as two-fold lower as recent studies suggest that 
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the eubacterial TGT may exist as a homodimer with “half-of-sites” reactivity [37].  
This would effectively double the turnovers per active site.  Second, the off-rate 
for the modified mRNA may be sufficiently slower (relative to that for tRNA) such 
that the turnover rate may indeed be significantly slowed under these conditions.  
It remains to be seen if these observations hold under in vivo conditions. 
Conclusions 
The E. coli TGT, which has 99% sequence identity to the S. flexneri TGT, 
does indeed recognize the virF mRNA as a substrate in vitro.  Further, we show 
that this recognition results in the site-specific modification of a single base in the 
virF mRNA (G421) with mutagenesis and virF mRNA minihelix studies.  With a KM 
value in the low micromolar range, it is very possible that the modification of virF 
mRNA may be biologically relevant (e.g., may occur in vivo).  These results 
provide the first “proof of principle” evidence that post-transcriptional RNA 
modification may regulate mRNA function, as it has long been recognized to do 
for tRNA.  The recent work characterizing the preQ1 riboswitch revealed that it is 
a fairly simple hairpin structure (the simplest riboswitch structure characterized to 
date) [11].  Such a simple structure could feasibly occur in the coding region of 
an mRNA species.  In fact, the TGT modification site that we have discovered in 
the virF mRNA is predicted to occur in a simple hairpin structural motif.  Base 
modification in a hairpin structure in the coding sequence of virF mRNA could 
induce a similar structural switch as seen in the preQ1 riboswitch and thereby 
influence translation of VirF. 
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Notes to Chapter III 
This chapter has been published in Hurt, J. K., Olgen, S., Garcia, G. A. 
(2007).  Site-specific modification of Shigella flexneri virF mRNA by tRNA-
guanine transglycosylase in vitro, Nucleic Acids Research, 35(14): 4905-13.  We 
gratefully acknowledge Professor Glenn Björk for the plasmid pBDG302 
containing the virf gene.  It is worth noting that ongoing research in the Garcia lab 
suggests the active human TGT functions as a heterodimer.  We are currently 
working to characterize the activity of this eukaryl enzyme.  It may be worth 
revisiting the queuine modification with virF mRNA and in vitro translation 




Abbreviations used: TGT, tRNA-guanine transglycosylase; UTR, untranslated 
region; preQ1, 7-aminomethyl 7-deazaguanine; DTT, dithiothreitol; NTP, 
ribonucleotide triphosphate; dNTP, deoxyribonucleotide triphosphate; RT-PCR, 
reverse transcription polymerase chain reaction; PCR, polymerase chain 
reaction; Tm, melting temperature; ECY, E. coli tRNATyr ; ECYMH, E. coli tRNATyr 
minihelix; MH, minihelix; HEPES, 4-(2-hydroxyethyl-1-piperazineethanesulfonic 
acid); TCA, trichloroacetic acid; DPM, disintegrations per minute; SDS-PAGE, 
sodium dodecyl sulfate polyacrylamide gel electrophoresis; NMR, nuclear 
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CHAPTER IV  
Troubleshooting Expression and Purification of Recombinant VirF  
 
VirF (30 kDa, 263 residues) is the master transcriptional activator of the 
virulence cascade in Shigella spp.  Due to the importance of this virulence factor 
in the infection cycle of the bacterium, biochemical characterization of VirF has 
been of interest in many research groups.  The importance of VirF was first 
determined by genetic knockout experiments in Shigella flexneri [1].  Further 
analyses performed in vivo in S. flexneri allowed for identification of primary 
downstream targets, namely VirB and VirG(IcsA) [2-4].  The mechanisms that 
regulate VirF expression have also been extensively studied [5-10].  Of particular 
interest is the temperature-sensitive repression mechanism of the virf promoter 
by H-NS, which also represses many other virulence gene promoters.  Although 
much knowledge has been gained regarding the virulence cascade and 
mechanisms of S. flexneri infection, relatively little is known about the VirF 
protein itself. 
 In vitro characterization of VirF was first reported by Tobe et al. [11].  
Though expression of recombinant VirF in E. coli failed, the authors 
characterized the relevant DNA-binding sites in the virB promoter using a 
maltose-binding protein (MBP) fusion with VirF, MalE-VirF.  Transcriptional 
activation of virB by MalE-VirF was studied, in addition to repression by H-NS, to 
probe the molecular basis of the dual-regulation mechanism of S. flexneri 
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virulence.  Porter and Dorman also attempted expression of recombinant VirF in 
vivo [12].  The authors generated various point mutants of VirF that were 
expressed as soluble protein, by both site-directed mutagenesis and random 
mutagenesis with nitrosoguanidine.  While monitoring transcriptional activation in 
a mutant S. flexneri ($virf) strain, the authors monitored activity of the mutant 
VirF proteins by activation (through VirB) of a mxiC-lacZ fusion to identify 
residues important for structure and function.   
 Details about the structure of VirF have been inferred from the crystal 
structures of other AraC family members [13, 14].  With the many technological 
advances in molecular biology, there are a variety of protocols that aim to 
improve expression of “difficult” proteins (i.e., fusion tags, molecular 
chaperones).  Expression and purification of wildtype VirF would allow for further 
characterization of the virulence factor, especially the N-terminal dimerization 
domain, which remains poorly understood.  In this study, we aim to employ new 
techniques to express recombinant VirF. 
Materials and Methods 
Reagents 
 Unless otherwise specified, all reagents were from Sigma Aldrich.  
Gelase™ Agarose-Gel Digesting Preparation was from Epicentre.  The QIAprep 
Spin Miniprep Kit was from Qiagen.  Bactotryptone and yeast extract were from 
Fisher Scientific.  Chemically competent BL21(DE3) cells, Ni+2-NTA resin, 
Lysonase™ Bioprocessing Reagent, and Factor Xa Cleavage Capture kit were 
from Novagen.  Amicon Ultra-4 Centrifugal Filter Units were from Millipore.  
 
105 
Ultracompetent XL-2 Blue cells were from Stratagene.  Plasmids harboring 
molecular chaperones (GroEL, GroES, DnaK, DnaJ, GrpE) were from Takara.  
All restriction enzymes, Vent® DNA polymerase, calf-intestinal alkaline 
phosphatase (CIP), amylose resin, and pMAL-c2x were from New England 
Biolabs.  SeaPlaque agarose was from Cambrex.  Isopropyl !-D-thiogalactoside 
(IPTG), T4 DNA Ligase, V5-HRP antibody, Positope™ Control Protein, 
pBAD202-D/TOPO, LMG194 chemically competent cells, Expressway™ Cell-
free Expression System and all synthetic oligonucleotides were from Invitrogen.  
The ActivePro Kit was from Ambion.  HisProbe-HRP and CN/DAB substrate kit 
was from Pierce.  L-[35S]-methionine was  purchased from Perkin-Elmer.  GF-C 
glass fiber filters were from Whatman.  The deoxynucleotide triphosphates 
(dNTPs, monosodium salts) were from Promega.  Polyacrylamide gels, SDS-
PAGE buffer strips, low molecular weight protein standard, and all FPLC columns 
were from GE Healthcare.  The nitrocellulose membranes and blot paper were 
from BioRad. 
Bacterial Stains and Plasmids 
 All E. coli strains (with the exception of XL-2 Blue Ultracompetent cells) 
were purchased as glycerol stocks, and chemically competent cells were 
prepared according to vendor protocol.  The virf gene in the housekeeping vector 
pTZ19R (pTZvirF) was used for all subsequent subcloning reactions (See 
Chapter III for details). 
Constructs for Expression of Full-length Wildtype VirF 
 Lactose-inducible Expression Plasmids 
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 Using pTZvirF as a template (see Chapter III for details), the virf gene was 
subcloned into the dual promoter vector, pLacT7 [15].  In a total volume of 50 #L, 
samples containing 1 #g pTZvirF, PCR primers (10 pmol each, see pLacT7-virF 
in Table IV-1), dNTP mix (2.5 mM each NTP), 2 mM MgSO4, and Vent® DNA 
polymerase (2 U) were incubated according to the following temperature 
sequence: 30 cycles – 94°C for 1 min., 65°C for 1 min., and 72°C for 2 min.  The 
vector pLacT7 and the virf PCR product (20 #L DNA) were treated with NdeI and 
BamHI in a double restriction enzyme digestion (40 U each, 30 #L volume) at 
37°C for 90 min.  The vector and PCR product were gel-purified from Seaplaque 
agarose gel with Gelase™ according to the vendor’s protocol.  In a total volume 
of 20 #L, the virf PCR product and digested pLacT7 (5:1 volume ratio) were 
incubated overnight at 17°C with T4 DNA ligase (2 U).  The ligated sample 
(pLacT7-virF, 10 #L) was transformed into 100 #L Ultracompetent XL-2 Blue 
cells according to the vendor’s protocol and plated on L-Amp plates (50 #g/mL 
ampicillin).   Individual colonies were isolated, and grown in either 3 mL 2xTY or 
M9 cultures with 50 #g/mL ampicillin at 37°C with shaking (M9 Media, per 1L 
dH2O: 1 mM MgSO4, 0.2% glycerol, 0.00005% thiamine, 0.1% casamino acids 
and M9 salts (6 g Na2HPO4, 3 g KH2PO4, 1 g NH4Cl, 500 mg NaCl, 3 mg CaCl2).  
Plasmid was isolated via miniprep, and the correct sequence was confirmed by 
DNA sequencing (University of Michigan DNA Sequencing Core Facilities).   
To monitor VirF expression from pTZvirF directly, a dsDNA cassette was 
designed for insertion of the E. coli consensus ribosome-binding site (RBS, 
AGGAGG) between the T7 promoter and the virf gene (see pTZvirF+RBS in 
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Table IV-1).  The palindromic DNA sequence was designed with the restriction 
enzyme site PstI at both the 5’ and 3’ ends.  The vector pTZvirF and dsDNA 
cassette (10 #L DNA) were treated with PstI in a double restriction enzyme 
digestion (20 U, 20 #L volume) at 37°C for 1h.  The vector and insert were gel-
purified from Seaplaque agarose gel with Gelase™ according to vendor protocol.  
The purified pTZvirF sample (100 #L) was treated with alkaline phosphatase 
(CIP, 30 U) in NEBuffer 3 (50 mM Tris-HCl (pH 7.9), 100 mM NaCL, 10 mM 
MgCl2, 1 mM DTT) at 37°C for 1h.  The reaction was quenched by phenol-
chloroform extraction (1:1 ratio, buffered phenol (pH 8.0) and 24:1 
chloroform:isoamyl alcohol).  The aqueous layer was removed to a new 
microcentrifuge tube and precipitated for 1h at -20°C with 0.1 volume 3 M NaOAc 
(pH 5.3) and 2.5 volumes 100% EtOH.  In a total volume of 20 #L, the RBS 
cassette and digested pTZvirF (5:1 volume ratio) were incubated overnight at 
17°C with T4 DNA ligase (2 U).  The ligated sample (pTZvirF+RBS, 10 #L) was 
transformed into 100 #L Ultracompetent XL-2 Blue cells according to the 
vendor’s protocol and grown on L-Amp plates (50 #g/mL ampicillin) at 37°C.   
Individual colonies were isolated and sequenced as previously described. 
Arabinose-inducible Expression Plasmid 
pBADvirF was constructed following amplification of the virf gene for 
insertion into the directional pBAD202 vector via TOPO cloning.  In a total 
volume of 50 #L (performed in triplicate), samples containing 1 #g pTZvirF, PCR 
primers (10 pmol each, see pBADvirF in Table IV-1), dNTP mix (2.5 mM each 
NTP), and Vent® DNA polymerase (2 U) were incubated according to the  
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Table IV-1: Oligonucleotide Sequences for VirF Expression Plasmid 
Construction.  Key restriction enzyme sites or nucleotides of interest are 
underlined.  
Sample Name Primer Name Primer Sequence (5’ – 3’) 
pTZvirF+RBS VirF Insert RBS CTGCAGGAGGTACCTCCTGCAG 









pET FL FWD GAGCCATGGATGATGGATATG 
pET20b-virF 
BamHI REV *See pLacT7-virF BamHI REV 
pET M29 FWD GACCATGGATGACGGTTAGCTC pET20b-
virF(29-263) BamHI REV *See pLacT7-virF BamHI REV 
NdeI FWD GCATGCCTGCATATGATGGATATGGAC 
pLacT7-virF 
BamHI REV CGACGGCCAGTGGATCCTTAAAATTTTTTATG 
pBAD FWD CACCATGGCTTAATACGACTCACTATAGGG 
pBADvirF 
BamHI REV *See pLacT7-virF BamHI REV 
pBAD FWD *See pBADvirF pBAD FWD pBADvirF 
+His Add His REV GAGGGATCCGTAAAATTTTTTATGATATAAG 
XmnI FWD CTGAAATCGTTCGGGACATAAAAAC 
pMALvirF 
EcoRI REV GAGAATTCTTAAAATTTTTTATG 
QC (-G) FWD CTCGGGATCGAGGGAAGGCTGAAATCTTC- 
GGGACATAAAAACAAAATAG pMALvirF 
Quik-Change QC (-G) REV CTATTTTGTTTTTATGTCCCGAAGATTTCAG- 
CCTTCCCTCGATCCCGAG 
 
following temperature sequence: 30 cycles – 94°C for 1 min., 55°C for 1 min., 
and 72°C for 2 min. All replicate reactions were combined and ethanol 
precipitated at -20°C overnight.  The precipitate was collected by centrifugation, 
and the DNA pellet was resuspended in water (15 #L).  In a total volume of 6 #L, 
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2.5 ng virf PCR product and pBAD202-D/TOPO were ligated and transformed 
into chemically competent OneShot® TOP10 cells according to the vendor’s 
protocol.  Samples were grown on L-Kan plates (50 #g/mL kanamycin) at 37°C, 
and colonies were isolated as previously described. 
In a 200 #L total volume, purified pBADvirF (100 #L DNA) was treated 
with NcoI (70 U) at 37°C for 1h to remove upstream affinity tags (~376 bp).  
Samples were incubated at 65°C for 20 min. to inactivate the restriction enzyme, 
and the pBADvirF sample (50 #L digested DNA) was incubated overnight with T4 
DNA ligase (2 U, 57 #L total volume) at 17°C.  The re-ligated plasmid (10 #L) 
was transformed into 100 #L Ultracompetent XL-2 Blue cells according to vendor 
protocol and grown at 37°C on L-Kan plates.  The new vector is termed the 
corrected pBADvirF. 
Constructs for Expression of Full-length VirF with Fusion Tags 
Histidine (His) Tag 
Constructs for lactose-inducible expression of full-length VirF were 
prepared in pET vectors from Novagen.  The same virf PCR product prepared for 
insertion into pLacT7 above was subcloned into pET28a (yielding pET28a-virF 
with an N-terminal 6x His-tag) following the same protocol.  In collaboration with 
Prof. Oleg Tsodikov and Dr. Tappan Biswas, the virf gene was also subcloned 
into the expression vector pET19b (with N-terminal 10x His-tag) between the 
NdeI and XhoI sites.  The vector (pET19bpps) was manipulated to incorporate 
the PreScission protease cleavage site (LEVLFQGP) for removal of the fusion 
tag following purification.  For the arabinose-inducble pBADvirF, the virf gene 
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was amplified from pTZvirF+RBS with a single base change (stop codon 
converted to a tyrosine codon) incorporated into the reverse oligonucleotide to 
allow read-through of a C-terminal 6x His-tag (see pBADvirF+His in Table IV-1).  
Reactions were set up as described above for pBADvirF with the following 
exception: the annealing temperature was adjusted to 50°C in the PCR cycles. 
V5 Epitope 
For insertion of an N-terminal V5 epitope (GKPIPNPLLGLDST) into VirF, a 
70 bp dsDNA cassette was synthesized (see pTZvirF+RBS+V5 in Table IV-1).  In 
a 40 #L total volume, the complimentary oligonucleotides (10 #L each) were pre-
incubated at 37°C for 5 min.  The dsDNA cassette and pTZvirF (10 #L DNA, 20 
#L total volume) were treated with PstI (40 U) at 37°C for 1 h.  The insert and 
plasmid were gel-purified and subsequently treated as described for 
pTZvirF+RBS. 
pelB Leader Sequence 
The virf gene was subcloned into pET20b (Novagen) carrying the N-
terminal pelB leader sequence (MKYLLPTAAAGLLLLAAQPAMA) for co-
translational transport to the periplasm.  In a total volume of 50 #L, samples 
containing 1 #g pTZvirF, PCR primers (10 pmol each, see pET20b-virF in Table 
IV-1), dNTP mix (1.5 mM each NTP), 2 mM MgSO4, and Vent® DNA polymerase 
(2 U) were incubated according to the following temperature sequence: 30 cycles 
– 94°C for 1 min., 50°C for 1 min., and 72°C for 2 min.  The vector pET20b (5 #L 
DNA) and the virf PCR product (10 #L DNA) were treated with NcoI and BamHI 
via double restriction digestion (20 U each, 20 #L volume) at 37°C for 2 h.  The 
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vector and PCR product were gel-purified from a Seaplaque agarose gel with 
Gelase™ according to vendor protocol.  In a total volume of 20 #L, the virf PCR 
product and digested pET20b (5:1 volume ratio) were incubated overnight at 
17°C with T4 DNA ligase (2 U).  The ligated sample (pET20b-virF, 10 #L) was 
transformed into 100 #L Ultracompetent XL-2 Blue cells according to the 
vendor’s protocol and plated on L-Amp plates (50 #g/mL ampicillin).   Individual 
colonies were isolated as previously described. 
malE, Maltose-binding Protein (MBP) 
Construction of a MalE-VirF fusion protein has been previously described 
[11].  In a total volume of 50 #L, samples containing 1 #g pTZvirF, PCR primers 
(10 pmol each, see pMALvirF in Table IV-1), dNTP mix (0.25 mM each NTP), 2 
mM MgSO4, and Vent® DNA polymerase (2 U) were incubated according to the 
following temperature sequence: 30 cycles – 94°C for 1 min., 50°C for 1 min., 
and 72°C for 2 min.  The vector pMAL-c2x and the virf PCR product (3 #L DNA) 
were treated with XmnI (40 U, 30 #L volume) at 37°C for 1 h.  The samples were 
ethanol precipitated at -20°C overnight as previously described.  The DNA pellet 
was collected by centrifugation and resuspended in water (25 #L).  Both samples 
were treated with EcoRI (40 U, 30 #L volume) in a subsequent restriction enzyme 
digestion at 37°C for 1 h.  The vector and PCR product were gel-purified from 
Seaplaque agarose gel with Gelase™ according to vendor protocol.  In a total 
volume of 20 #L, the virf PCR product and digested pMAL-c2x (3:1 volume ratio) 
were incubated overnight at 17°C with T4 DNA ligase (2 U).  The ligated sample 
(pMALvirF, 10 #L) was transformed into 100 #L Ultracompetent XL-2 Blue cells 
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according to the vendor’s protocol and plated on L-Amp plates (50 #g/mL 
ampicillin).   Individual colonies were isolated as previously described. 
The XmnI site was ligated in a blunt-end manner, adding seven base pairs 
to the start of the virf gene.  One base was removed (G2697) by site directed 
mutagenesis according to vendor protocol to restore the proper reading frame 
(Stratagene).  In a total volume of 30 #L, samples containing 500 ng pMALvirF, 
Quik-Change PCR primers (10 pmol each, see pMALvirF Quik-Change in Table 
IV-1), dNTP mix (0.25 mM each NTP), 2 mM MgSO4, and Vent® DNA 
polymerase (2 U) were incubated according to the following temperature 
sequence: 20 cycles – 94°C for 1 min., 50°C for 1 min., and 72°C for 6.5 min.  
The amplified samples were treated with DpnI (40 U) in 1x NEBuffer 4 (20 mM 
Tris-Acetate (pH 7.9), 50 mM K(CH3COO), 10 mM Mg(CH3COO)2, 1 mM DTT) at 
37°C for 2 h to digest wildtype DNA.  The digested sample (10 #L) was 
transformed into 250 #L chemically competent TG2 cells and grown overnight on 
L-Amp plates (50 #g/mL ampicillin).  Plasmid DNA was isolated, and the 
sequence was confirmed as previously described. 
Constructs for Expression of VirF Fragments 
 VirF (29-263) 
 A fragment of the virf gene (705 bp) corresponding to a truncation in the 
first 84 bp was amplified from pTZvirF.  The resultant protein product would have 
an N-terminal deletion of 28 amino acids, but retain a portion of the dimerization 
domain and the full linker region and DNA-binding domain.  This virf fragment 
was subcloned into pET20b according to the protocol described for the full-length 
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virf gene (see pET20b-virF(29-263) in Table IV-1 for oligonucleotide sequences).  
In collaboration with Prof. Tsodikov and Dr. Biswas, this fragment was also 
subcloned into pET19bpps as described previously.  The virf (G421A) mutant of 
pET19b-virF(29-263) was prepared according to the protocol discussed in 
Chapter III. 
 VirF (154-263) 
 The virf fragment (297 bp) corresponding to the 99-amino acid DNA-
binding domain was amplified and subcloned into pET19bpps as previously 
described. 
Cell-based Expression Trials 
SDS-PAGE Analysis 
 Denaturing polyacrylamide gels were run with samples diluted 1:1 with 
SDS-PAGE buffer (50 #L, 60 mM Tris!HCl (pH 6.8), 2% SDS, 10% glycerol, 5% 
!-mercaptoethanol, 0.01% bromophenol blue).  The low molecular weight 
standard is run as a molecular weight marker (6 major protein markers (kDa): 97, 
66, 45, 30, 20, 14).  All samples (4 #L) were boiled for 5 min., and loaded on a 8-
25% gradient polyacrylamide gel (SDS buffer strips: 8.9 mM Tris base, 8.9 mM 
boric acid, 0.2 mM EDTA, 2% agarose) run under denaturing conditions 
according to the PhastGel™ protocol (GE Healthcare).  Polyacrylamide gels 
were visualized by Coomassie Blue staining according to the vendor’s protocol 





Western Blot Protocol 
Samples were run on polyacrylamide gels under denaturing conditions 
and transferred to a nitrocellulose membrane in ice-cold Towbin buffer (3.03 g 
Tris base, 14.4 g glycine, 200 mL methanol per 1L dH2O) at 60 V for 30 min.  
The membrane was washed with phosphate-buffered saline with Tween (PBST, 
0.1 M NaPO4 (pH 7.2), 0.15 M NaCl, 0.05% Tween-20) for 10 min. at room 
temperature.  The horseradish peroxidase (HRP) conjugated primary antibody 
(HisProbe-HRP or V5-HRP) was added (1:5000) in PBST in a total volume of 10 
mL.  The membrane was incubated at room temperature for 1 h with shaking.  
The membrane was washed with a second volume of PBST before addition of 
the CN/DAB substrate (4-chloro-1-naphthol/3,3-diaminobenzidine, 
tetrahydrochloride) in Stable Peroxide Substrate Buffer according to the vendor’s 
protocol (Pierce).  The Positope™ Control Protein was run in parallel as the 
positive control for His-tag or V5 epitope expression. 
Lactose-inducible Expression Vectors 
 For expression of full-length untagged VirF, several T7-based vectors 
(pTZvirF+RBS, pLacT7-virF) were prepared and transformed into BL21(DE3) and 
K12 ($tgt, DE3).  Individual colonies were isolated and grown at 37°C in 3 mL 
2xTY cultures (with appropriate antibiotics).  Several fusion-tagged constructs 
were also prepared to monitor VirF expression in cells.  For pTZvirF+RBS+V5, 
pET28a-virF, pET20b-virF, and pET19b-virF, expression was monitored in both 
BL21(DE3) and K12 ($tgt, DE3) cells.  Individual colonies were isolated for 
growth in 3 mL 2xTY media (with appropriate antibiotic) at 37°C overnight.  Fresh 
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media was inoculated with the starter culture (1:100), and samples were tested in 
parallel with varying concentrations IPTG (0.5-5.0 mM) in 3 mL 2xTY media or 
with Studier’s ZYP-5052 autoinduction media (both supplemented with the 
appropriate antibiotic) [16].  Following an appropriate induction period (4 hours 
for IPTG samples and overnight for auto-induction cultures), a small aliquot (100 
#L) was removed from each culture along with an uninduced control, and the 
cells were harvested by centrifugation.  The media was discarded, and the cell 
pellet was resuspended in SDS-PAGE buffer and analyzed by denaturing 
polyacrylamide gel. 
L-arabinose-inducible Expression Vectors 
 pBADvirF+His was transformed into E. coli TG2, LMG194($ara) and 
K12($tgt) cells for expression trials.  Individual colonies were isolated and grown 
in 3 mL minimal M9 media (supplemented with 50 #g/mL kanamycin) at 37°C 
overnight.  Fresh M9 minimal media (5 mL, supplemented with 2% L-arabinose 
and 50 #g/mL kanamycin) was inoculated with the starter culture (1:100) and 
grown at 37°C with shaking for 4 h.  Aliquots (1 mL) were removed from each 
sample, and the cells were harvested by centrifugation.  The supernatant was 
removed, and each pellet was resuspended in lysis buffer (250 #L, 10 mM 
Tris!HCl (pH 8.0), 1 mM EDTA, 0.5 mg/mL lysozyme, 0.1 mg/mL DNase I, 10 
mM CaCl2).  The samples were subjected to three rapid freeze/thaw cycles, 
frozen on dry ice then placed in a 42°C water bath for 1 min. each.  The samples 
were pelleted at 4°C, and the soluble portion was transferred to a fresh 
microcentrifuge tube.  The soluble fraction was analyzed by SDS-PAGE as a 1:1 
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mixture of supernatant and SDS-PAGE buffer described previously (50 #L total 
volume).  The insoluble pellet was resuspended in 250 #L SDS-PAGE buffer.  
Protein species of interest were excised from the polyacrylamide gel and placed 
in dH2O for trypsin digestion and subsequent mass spectrometry analysis 
(University of Michigan Proteome Consortium) 
Expression Trials with MalE-VirF 
MalE-VirF expression from the tac-promoter based vector, pMALvirF, was 
monitored in BL21 cells.  A 500 mL 2xTY culture with 50 #g/mL ampicillin was 
inoculated with a pMALvirF starter culture (1:100).  The culture was incubated at 
37°C with shaking to mid-log phase (OD600  0.6), and MalE-VirF expression was 
induced upon addition of 5 mM IPTG.  Following a 4 h incubation at 37°C, the 
cells were harvested by centrifugation, and the cell pellet was stored overnight at 
-20°C.  The cells were resuspended in VirF storage buffer (10 mL, 20 mM 
Tris!HCl (pH 7.4), 0.2 M NaCl, 1 mM EDTA, 10 mM !-mercaptoethanol) 
supplemented with PMSF in isopropanol (phenylmethylsulfonyl fluoride, 100 mM) 
and 10 #L Lysonase™ Bioprocessing Reagent (Novagen).  The lysis reaction 
proceeded at room temperature for 15 min., followed by sonication on ice (6 
rounds, 10 sec. at maximum setting).  The crude extract was purified by amylose 
affinity chromatography according to the vendor’s protocol (New England 
Biolabs).  Column fractions were analyzed by polyacrylamide gel and Coomassie 
Blue staining as previously described.  Samples containing MalE-VirF (70 kDa) 




Cleavage of the MalE fusion was performed with Factor Xa (recognition 
site: I(E/D)GR) according to the vendor’s protocol (Novagen).  In a total volume 
of 50 #L, samples containing MalE-VirF (10 #g), and various concentrations of 
Factor Xa (0.1-0.5 U) were incubated at varying temperatures (4-37°C).  Aliquots 
(10 #L) were removed over a 24 hour incubation period to monitor cleavage of 
the MBP fusion by polyacrylamide gel with Coomassie Blue staining as 
previously described.  Reactions were performed in the presence and absence of 
a linear DNA fragment of the virB operator or supercoiled pTB601 (1-5 #L DNA) 
(see Chapter V for details). 
Expression Trials with VirF Fragments 
Expression of VirF (29-263) 
pET19b-virF(29-263) was transformed into chemically competent 
BL21(DE3) cells according to vendor protocol.  A 500 mL ZYP-5052 culture with 
50 #g/mL ampicillin was inoculated with starter culture (10 mL), and expression 
of VirF(29-263) was induced by autoinduction as previously described for the full-
length VirF protein.  Soluble and insoluble fractions were isolated, and the 
insoluble pellet was resuspended in 8 M urea.  Samples (4 #L) were analyzed by 
SDS-PAGE and stained with Coomassie Blue or transferred to a nitrocellulose 
membrane for treatment with HisProbe-HRP in a Western blot procedure 
according to vendor protocol (Pierce).  The denatured His-tagged VirF(29-263) 
sample was applied to Ni-NTA resin and purified from contaminants by addition 
of 8 M urea supplemented with 250 mM imidazole.  The protein was refolded with 
step-wise buffer exchange in VirF storage buffer and decreasing concentrations 
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of urea (8 M, 4 M, 2 M, 0 M) in Amicon Ultra-4 centrifugal filter units at 7,000 x g 
for 10 min. at 4°C. 
Expression of VirF(29-263) was monitored in the presence of various 
molecular chaperones from Takara.  pET19b-virF(29-263) and pET19b-virF(29-
263, V141I) were transformed into BL21(DE3) cells containing either pGro7 or 
pKJE7 (expressing GroEL/ES or DnaK, DnaJ, and GrpE, respectively).  Induction 
of the VirF(29-263) protein was performed according to the same protocol 
regardless of chaperone identity.  A 500 mL 2xTY culture (100 #g/mL 
carbenicillin, 30 #g/mL chloramphenicol) supplemented with 0.5 mg/mL L-
arabinose and inoculated with starter culture (10 mL) was incubated at 37°C with 
shaking.  IPTG (1 mM) was added at mid-log phase, and the culture was 
incubated at 16°C with shaking overnight.  Soluble and insoluble fractions were 
isolated as previously described.  Protein samples were analyzed by SDS-PAGE 
and Coomassie Blue staining. 
Expression of VirF(154-263) 
 Purification and analysis of the VirF(154-263) protein was performed in 
collaboration with Prof. Tsodikov and Dr. Biswas.  BL21(DE3) cells harboring 
pET19b-virF(154-263) were induced at OD600 = 0.5 with 0.5 mM IPTG at 16 oC 
overnight.  The protein was purified from the soluble fraction on Ni-IMAC (GE 
LifeSciences) column followed by heparin chromatography and gel filtration 
chromatography on an S-200 column (GE LifeSciences).  Purified VirF(154-263) 
protein was incubated with a series of overlapping double-stranded DNA 
oligomers covering the virB promoter region (-131 to -11 in the virB operator) 
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previously shown to be important for regulation by VirF [11].  The gel mobility 
shift assay was conducted in VirF reaction buffer (50 mM Tris base (pH 7.0), 100 
mM NaCl, 0.05 mM EDTA, 10% glycerol). 
In vitro Translation Trials with Full-length VirF 
 A variety of cell-free in vitro translation kits were utilized to monitor 
expression of the VirF protein.  virF+RBS+V5 mRNA was generated by in vitro 
transcription as previously described [17].  VirF expression was first studied in 
the Expressway™ cell-free extract ($slyD) according to vendor protocol 
(Invitrogen).  Various concentrations of virF+RBS+V5 mRNA (0.3-2.5 #M) were 
tested.  Samples (100 #L) were incubated at 30°C and 37°C for 5 h in parallel.  
The soluble and insoluble fractions were separated according to the protocol 
described for pBADvirF induction trials.  Samples were loaded on 8-25% gradient 
polyacrylamide gels and analyzed by Coomassie Blue stain as well as anti-V5 
Western blot according to the vendor protocol (BioRad).   
 Expression of VirF in vitro was also monitored in the ActivePro™ Kit E. 
coli S30 extract according to vendor protocol (Ambion).  Samples (50 #L) 
containing either pTZvirF+RBS+V5 or virF+RBS+V5 mRNA were incubated at 
37°C for 2 h, and reactions were quenched with ice-cold acetone (50 #L).  
Soluble and insoluble fractions were prepared as previously described.  All 
samples (4 #L) were loaded on 8-25% gradient polyacrylamide gels and 
analyzed by Coomassie Blue staining.  T7-based plasmids expressing the 
human calmodulin-like 3 protein (CALML-3, 19.5 kDa) and chlorampenicol 
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acetyltransferase (CAT, 25 kDa) were run in parallel as positive controls for in 
vitro translation. 
An E. coli BL21(DE3) cell-free S12 extract was prepared according to the 
protocols of Kim et al. [18, 19].  A starter culture of BL21(DE3) was used to 
inoculate 500 mL 2xTY (1:100).  The sample was grown at 37°C with shaking to 
mid-log phase (OD600 = ~0.7).  IPTG was added to a final concentration of 1 mM, 
and the culture was induced at 37°C with shaking for 5 h to enhance expression 
of the T7 RNA polymerase.  The cells were harvested by centrifugation (6,000 x 
g) for 15 min. at 4°C.  The supernatant was removed, and the pellet was washed 
three times with Buffer A (20 mL/g cells, 10 mM Tris-acetate buffer (pH 8.2), 1 
mM DTT, 14 mM Mg(CH3COO)2, 60 mM potassium glutamate, 0.05% !-
mercaptoethanol).  The pellets were stored at -80°C overnight.  The BL21(DE3) 
cells were resuspended in 10 mL Buffer B (1.3 mL/g cells, 10 mM Tris-acetate 
buffer (pH 8.2), 1 mM DTT, 14 mM Mg(CH3COO)2, 60 mM potassium glutamate).  
Cell lysis was performed by French press (two rounds at 20,000 psi.), and the 
lysate was collected by centrifugation at 12,000 x g for 10 min. at 4°C.  The 
lysate (8 mL) was incubated at 37°C with shaking for 30 min. in the presence of 
preincubation solution (2.5 mL, 293 mM Tris-acetate buffer (pH 8.2), 4.4 mM 
DTT, 2 mM Mg(CH3COO)2, 10.4 mM ATP (adenosine triphosphate), 100 mM 
FBP (fructose-1,6-bisphosphate), amino acid mix (0.04 mM each), 23.4 #g/mL 
pyruvate kinase).  The E. coli BL21(DE3) S12 extract was stored in individual 
aliquots (27 #L) at -80°C. 
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In a total volume of 100 #L, reactions containing test plasmid DNA (0.67 
#g/mL), BL21(DE3) S12 extract (27 #L), 57 mM HEPES-KOH buffer (pH 8.2), 
NTP mix (1.2 mM ATP, 0.85 mM CTP, GTP, and UTP), 2 mM DTT, 90 mM 
potassium glutamate, 80 mM NH4(CH3COO), 12 mM Mg(CH3COO)2, folinic acid 
(34 #g/mL), amino acid mix (2 mM each, -Met), 2% PEG-8000 (polyethylene 
glycol), 33 mM FBP, pyruvate kinase (5 #g/mL), RNase inhibitor (2 U), and L-
[35S]-methionine (0.33 mCi/mL) were incubated at 37°C.  Aliquots (10 #L) were 
removed every 2 h over the 6 h incubation period.  Samples treated 37°C 1 M 
NaOH (300 #L) for 10 min. to deacylate any charged tRNAs.  The reactions were 
quenched with 2.5 mL ice-cold 5% TCA (trichloroacetic acid), vortexed briefly, 
and incubated on ice for 5 min.  Samples were filtered on GF-C glass fiber filters 
and the radioactivity was measured by scintillation counting as previously 
described [17].  The negative control for radioactivity incorporation was 
monitored from samples without DNA, and the positive control for protein 
synthesis was measured in samples containing the CAT expression plasmid.  
Various VirF expression plasmids were tested (i.e., pTZvirF+RBS+V5, pET19b-
virF (full-length, 29-263, and 154-263), pMALvirF).  Reactions were performed in 
the presence and absence of a linear DNA fragment of the virB operator or 
supercoiled pTB601 (1 #L DNA) (see Chapter V for details). 
Results 
Expression Trials with Full-length VirF 
The original virf vectors used for cloning and in vitro transcription (pTZvirF 
and pTZvirF(G421A), see Chapter III for details) were not designed for protein 
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expression due to the absence of a ribosome-binding site.  To monitor VirF 
expression in cells, a variety of plasmids were constructed to express untagged 
and fusion-tagged forms of the transcriptional activator.  Cell growth in the 
presence of untagged VirF expression (pTZvirF+RBS, pLacT7, pBADvirF) on 
solid media resulted in mucoidy colonies.  In the case of pTZvirF+RBS 
(BL21(DE3)) and pBADvirF (LMG194), the mucoid growth was diffuse over the 
agar plate, with satellite colonies protruding into the solid media.  With pLacT7 
(BL21(DE3)), cell growth was displayed as “burst colonies,” with a single, large 
colony surrounded by very small, salt-like colonies.  When isolated for growth at 
37°C in liquid culture, all samples exhibited dense, mucoidy growth attached to 
the sterile toothpick used for colony selection, while the surrounding media was 
essentially clear.  Due to growth issues, these constructs were not carried 
forward in cell-based expression trials. 
Various solubility (fusion) tags were employed with the hopes of 
increasing the concentration of soluble VirF in cells.  E. coli harboring the 6x His-
tagged construct, pET28a, exhibited the same mucoidy phenotype in solid and 
liquid media described previously.  While there was some mucoidy nature in 
minimal M9 media, LMG194 cells transformed with pBADvirF+His exhibited more 
uniform growth than was previously observed.  In induction trials with L-
arabinose (2% weight to volume), a band was observed by SDS-PAGE with 
Coomassie staining at approximately 30 kDa in both the soluble and insoluble 





Figure IV-1: Expression of Full-length VirF.  Expression of VirF in E. coli TG2 and 
K12 ($tgt) from pBADvirF monitored by SDS-PAGE and Coomassie 
Blue staining.  Lane 1, low molecular weight standard; lane 2, TG2 
insoluble fraction; lane 3, TG2 soluble fraction; lane 4, K12 ($tgt) 
insoluble fraction; lane 5, K12 ($tgt) soluble fraction. 
 
Both samples were excised from the polyacrylamide gel and submitted to the 
University of Michigan Proteome Consortium for MS/MS analysis following 
trypsin digestion.  Sequence analysis of the resulting peptide fragments 
confirmed the major identity of the protein sample was the kanamycin resistance 
protein.  It was observed that a low concentration of VirF was also present.  
Expression of 10x His-tagged VirF (pET19bpps-virF in BL21(DE3)) resulted in 
normal cell growth in liquid media, yet no protein was expressed as measured by 
Coomassie staining.  Since cytosolic over-expression of full-length VirF may be 
resulting in misfolding/aggregation, the virf gene was subcloned into pET20b with 
an N-terminal pelB fusion.  The leader sequence directs the protein to the 
periplasm, and has been shown to assist in protein folding [20].  BL21(DE3) cells 
harboring pET20b-virF demonstrated normal cell growth in 2xTY, but again, no 





Figure IV-2: Expression and Purification of MalE-VirF.  A) MalE-VirF was 
expressed in BL21 cells and purified by amylose affinity resin and 
size-exclusion chromatography.  Protein was analyzed by SDS-
PAGE and Coomassie Blue staining.  Lane 1, low molecular 
weight standard; lane 2, uninduced culture; lane 3, induced with 5 
mM IPTG; lane 4, crude extract; lane 5, eluate following amylose 
resin purification; lane 6, purified MalE-VirF; lane 7, major 
contaminating protein.  B) Representative Factor Xa cleavage 
reaction at room temperature with 0.5 U Factor Xa (lanes 2-5) or 
0.2 U Factor Xa (lane 6).  Lane 1, low molecular weight standard; 
lane 2, 3 h reaction time; lane 3, 5 h reaction time; lane 4, 7 h 
reaction time; lane 5, 24 h reaction time; lane 6, 24 h reaction time. 
 
Expression of soluble VirF in the form of a maltose-binding protein (MBP) 
fusion was previously reported [11].  pMALvirF was constructed according to the 
same protocol, using pMAL-c2x for cytosolic expression of the fusion protein.  
The vector was also designed with a Factor Xa recognition site between the 
malE and virf genes, allowing for cleavage of the fusion protein.  Expression in E. 
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coli BL21(DE3) cells induced with 5 mM IPTG yielded soluble protein (Figure IV-
2A).  This 70 kDa fusion protein, MalE-VirF, was purified by amylose resin and 
eluted with 10 mM maltose, which competitively binds the maltose-binding 
protein and displaces the polypeptide from the resin.  The major contaminating 
protein (likely endogenous MBP, 43 kDa) was separated by size-exclusion 
chromatography. 
Due to presumed increased difficulty in X-ray structural characterization of 
the fusion protein, MalE-VirF was treated with Factor Xa to obtain native VirF.  
Several different reaction conditions to enhance the stability of VirF in the Factor 
Xa cleavage reaction were tested (i.e., varying the enzyme to protein ratio, length 
of reaction time, temperature, available DNA binding site).  Analysis by SDS-
PAGE at various time points in the reaction followed a disappearance of the 70 
kDa fusion protein and the appearance of the 43 kDa MalE.  At lower reaction 
temperatures, a small concentration of the 30 kDa VirF protein was detected 
after a 24 h incubation period (Figure IV-2B), but this species could not be 
isolated.  In an attempt to improve the stability of VirF, purified pTB601, which 
contains the virB promoter sequence, or a PCR-amplified dsDNA fragment 
corresponding to the virB promoter were added to the reactions.  None of the 
above trials were successful in isolating native VirF.  This phenomenon of VirF 
instability in the Factor Xa reaction was previously observed [11]. 
Expression Trials of Truncated Forms of VirF 
In a collaborative effort with Prof. Oleg Tsodikov and Dr. Tappan Biswas, 
a truncated form of the VirF protein (beginning with methionine 29) was 
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expressed.  The protein product (~ 31 kDa with 10x His-tag) was initially 
expressed in BL21(DE3) cells and monitored by Coomassie staining and 
Western blot analysis.  The total protein sample illustrated a marked level of 
VirF(29-263) overexpression (Figure IV-3A).  Isolation of the soluble and 
insoluble fractions confirmed that the VirF(29-263) protein is insoluble. 
 
Figure IV-3: Expression of VirF(29-263).  A) Anti-His Western blot of total protein 
sample measuring VirF(29-263) expression in E. coli BL21 cells.  
Lane 1, low molecular weight standard; lane 2, E.coli TGT; lane 3, 
VirF(29-263).  B) Purification of denatured VirF(29-263) by Ni-NTA 
affinity chromatography analyzed by SDS-PAGE and Coomassie 
Blue staining.  Lane 1, low molecular weight standard; lane 2, flow-
through; lanes 3-4, elute fractions. 
 
Purification under native conditions was unsuccessful due to the low 
concentration of soluble VirF(29-263).  The insoluble protein was resuspended in 
8 M urea to denature the inclusion bodies and attempt purification under 
denaturing conditions.  The denatured protein sample was applied to a nickel 
column at room temperature, and was purified almost to homogeneity after 
several rounds of application and elution with 8M urea + 250 mM imidazole 
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(Figure IV-3B).  Protein refolding was initiated with  step-wise buffer exchange in 
the high-speed centrifuge using VirF storage buffer and decreasing 
concentrations of urea.  Typically, the protein began to precipitate in the filtration 
unit at concentrations of urea less than 2 M. 
 
Figure IV-4: Co-expression of VirF(29-263) with Molecular Chaperones. A) 
Expression of wildtype VirF(29-263) with GroEL/ES complex at 
37°C analyzed by SDS-PAGE and Coomassie Blue staining.  Lane 
1, low molecular weight standard; lane 2, uninduced control; lane 
3, total protein (4h); lane 4, soluble fraction; lane 5, insoluble 
fraction.  B)  Expression of VirF(29-263, V141I) with DnaK/J and 
GrpE at 16°C and purification by Ni-NTA affinity chromatography 
analyzed by SDS- PAGE and Coomassie Blue staining.  Lane 1, 
low molecular weight standard; lane 2, uninduced sample; lane 3, 
total protein (24 h); lane 4, flow-through; lanes 5-8, elute fractions. 
 
As the solubility issue may be linked to protein mis-folding or aggregation, 
the VirF(29-263) protein was expressed in the presence of various molecular 
chaperones from Takara.  Expression of the chaperone complex GroEL-GroES 
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(from pGro7), which functions at a later stage of protein folding, was first 
monitored with the truncated VirF protein.  Following induction, the VirF(29-263) 
protein was still observed in the insoluble fraction, and the major protein in the 
soluble fraction was the molecular chaperone (Figure IV-4A).  Co-expression of 
the DnaK-DnaJ complex with GrpE (from pKJE7) was also monitored, all of 
which are believed to function very early in protein folding.  Although a small 
amount of soluble VirF(29-263) was isolated following Ni-NTA affinity 
chromatography, the protein could not be separated from the molecular 
chaperones, which co-elute with the target protein (Figure IV-4B). 
 
Figure IV-5: Expression of VirF(V141I) and VirF(29-263, V141I) with Molecular 
Chaperones.  Co-expression of the (V141I) mutant full-length VirF 
and truncated VirF with DnaK/J and GrpE was monitored by anti-His 
Western blot.  The soluble fraction from each was purified by Ni-
NTA resin, and the elute fractions were analyzed by SDS-PAGE.  
Wildtype VirF(29-263) was run as a control.  Lane 1, low molecular 
weight standard; lane 2, VirF(V141I); lanes 3-4, VirF(29-263); lanes 
5-6, VirF(29-263, V141I). 
 
Expression of the VirF(29-263, V141I) protein fragment and full-length 
VirF(V141I) were also monitored in the presence of the pKJE7 chaperones 
(DnaK, DnaJ, and GrpE).  Both proteins (with 10x His-tag) were purified by Ni-
NTA affinity chromatography and visualized by anti-His Western blot (Figure IV-
5).  There was a slight increase in soluble VirF(V141I) concentration, but a more 
pronounced effect was seen with soluble VirF(29-263, V141I).  Though the 
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concentration of soluble protein improved in the mutant, isolation of purified 
protein was not achieved. 
Purification of soluble VirF(154-263) was more successful (Figure IV-6A).  
Though the dimerization domain has been deleted, a gel-mobility shift assay was 
performed with the VirF(154-263) protein and a series of overlapping double-
stranded DNA oligomers covering the key binding region in the virB promoter 
(Figure IV-6B) [11]. Purified dsDNA fragments of the virB promoter were 
incubated with varying concentrations of the VirF C-terminal DNA-bindingdomain, 
and the formation of a protein-DNA complex was monitored by gel-mobility shift 
assay and ethidium bromide staining (Figure IV-6C).  At the highest protein 
concentration tested, the most pronounced VirF(154-263)-DNA complexes were 
formed with fragments corresponding to the -130 to -61, -80 to -11, and -70 to -
31 regions of the virB promoter. 
In vitro Translation Trials with VirF 
 Expression of VirF was monitored in vitro using a variety of plasmid 
constructs and purified virF mRNA.  The commercially-available and lab-
prepared extracts used provide coupled transcription/translation for genes under 
the control of the T7 promoter.  Though the kits recommended using supercoiled 
DNA as a starting material, experiments were also performed with mRNA 
generated by in vitro transcription in an attempt to increase VirF yield.  The VirF 
expression constructs tested were altered to include fusion tags amenable for 
Western blot analysis (i.e., V5 epitope and His-tag).  Experiments were 




Figure IV-6:  Purification and Analysis of VirF(154-263).  A) Purified VirF(154-
263) analyzed by SDS-PAGE and anti-His stain.  B) Synthetic 
dsDNA fragments corresponding to regions the virB promoter from 
Shigella.  C) In vitro gel-mobility shift assay with purified VirF(154-
263) and dsDNA fragments analyzed by agarose gel and ethidium 
bromide staining. 
 
detected by standard immunoblotting.  Expression of the control proteins CAT 
and CALML-3 was only approximately 2-3 fold higher in comparison to 
background protein levels visualized by Coomassie Blue staining (a 
representative gel is shown in Figure IV-7). 
 For increased sensitivity, protein synthesis was measured by incorporation 
of L-[35S]-methionine.  In addition, a cell-free S12 extract was prepared using 
BL21(DE3) cells following induction of T7 RNA polymerase previously reported to 
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improve expression in vitro [18, 19].  As a quality control, the incorporation of L-
[35S]-methionine was measured in both negative (no DNA) and positive 
(chloramphenicol acetyltransferase, CAT) control reactions.  Briefly, reactions 
were incubated for 4 hours at 37°C.  Aliquots (10 #L) were removed and spotted 
on a glass-fiber filter following precipitation with NaOH (an untreated control was 
used to determine the total radioactivity in the reaction), and the observed 
radioactivity (CPM) was compared to the values predicted for the Ambion extract 
(ActiveProTM) (Table IV-2).  Though the signal to background ratio in the 
prepared extract is less than that observed in the commercial extract (~5-fold 
increase over the no DNA control), the sensitivity is improved in comparison with 
the immunoblotting detection method. 
 
Figure IV-7:  In vitro Translation of VirF Derivatives Analyzed by SDS-PAGE and 
Coomassie Blue Staining.  Lane 1, low molecular weight standard; 
lane 2, CALML-3 control; lane 3, VirF+V5 at 30°C; lane 3, 
VirF+RBS+V5 at 37°C. 
 
Expression from a variety of virf-containing plasmids was monitored in the 
presence and absence of virB DNA.  With high background radioactivity in the in 
vitro translation reactions, only two of the samples tested demonstrated L-[35S]-
methionine incorporation over the no DNA  control, VirF(154-263) and MalE-VirF.  
The CPM incorporation determined after 4 h for each VirF construct was low in 
 
132 
comparison to the CAT positive control (about 3-fold and 6-fold, respectively) 
(Figure IV-8).  Precipitate routinely developed in the in vitro translation reactions 
and produced inconsistent data between replicates. 
Table IV-2. Predicted and Experimentally Determined Values for Incorporation of 
L-[35S]-methionine with in vitro Translation Assays.  Aliquots were 
tested after 4 hours. 
 




Total radioactivity 3.9 x 106 3.3 x 106 
No DNA control 5 x 103 4.1 x 103 




Figure IV-8: In vitro Translation of VirF Derivatives Monitored by L-[35S]-
methionine Incorporation.  Chloramphenicol acetyltransferase 
(CAT) was monitored as a positive control and the no DNA sample 
as the negative control.  Total protein samples were measured 
after a 4 h incubation period.  The total radioactivity observed in 
each sample was normalized to the background radioactivity in the 
no DNA control (4100 CPM) and the number of methionine 





 VirF is a critical virulence factor in Shigella spp.  As a member of the AraC 
family of transcriptional activators, VirF shares a conserved DNA-binding domain 
of 99 amino acids that are predicted to adopt two helix-turn-helix motifs (HTH) 
[12].  Some evidence suggests that the significant sequence homology in the 
second HTH indicates the importance of this domain in a conserved function of 
this diverse class of activators (i.e., recruitment of RNA polymerase) [21].  In 
addition, VirF has an N-terminal domain, connected to the DNA-binding domain 
by a short linker region, consisting of more than 100 amino acids responsible for 
homodimerization [12].  Protein insolubility when expressed in E. coli has made 
structural analysis of VirF difficult [11, 12].  Several key insights into VirF 
structure and function have come from analyses of a MalE-VirF fusion protein 
and point mutants that resulted in expression of soluble protein.  As always, the 
question remains as to whether or not the biologically relevant structure and 
function is maintained in these mutant forms. 
 With a wide variety of molecular biology tools available to manipulate 
protein expression, several fusion tags, inducible promoters, growth 
temperatures, and VirF protein fragments were considered in an attempt to 
optimize VirF expression.  Uninduced maintenance of virf plasmids in E. coli is 
less problematic, as normal cell growth is observed and the plasmid can be 
obtained in standard miniprep procedures (See Chapter III).  In the presence of 
inducer; however, VirF expressed from either the T7 or lac promoter or the tightly 
regulated araBAD promoter resulted in a mucoidy phenotype.  It is unclear what 
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incites the observed mucoid production.  One possibility is that VirF aggregation 
and/or improper folding triggers a stress response yielding the mucoidy 
phenotype.  Protein misfolding can lead to formation of inclusion bodies, which 
disrupt the cytosolic environment and in some cases lead to cell death [22-24].  
In some pathogenic species, mucoidy phenotype and biofilm formation is related 
to pathogenesis (i.e., Pseudomonas, S. aureus) [25, 26].  It is interesting to 
speculate that VirF could be activating a specific pathway linked to E. coli cell 
wall stability, although the successful expression of the active malE-VirF fusion 
suggests otherwise  Unfortunately, the mucoidy phenotype prohibited purification 
and further characterization of full-length VirF. 
 Fusion tags have been shown to increase the solubility of target proteins.  
Though there are a number of common protein fusions, one that has been linked 
to protein folding is the pelB leader sequence.  This peptide directs the target 
protein to the periplasm, where the signal sequence is cleaved by an 
endogenous peptidase, and the target protein is in some cases secreted from the 
periplasm into the culture medium [20].  There are many potential benefits with 
this tag.  One important factor is the endogenous mechanism for cleavage of the 
protein fusion tag.  Crystallography and other structural characterization 
techniques are performed following cleavage of all solubility or affinity tags, which 
in some cases can prove problematic.  In addition, direction of folding to the 
periplasm eliminates the risk of intracellular toxic effects and potential proteolytic 
cleavage of the target protein.  Other affinity tags were selected based on the 
ease of purification or detection in standard immunoblotting procedures.  The 
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histidine tag (His-tag) is widely used in molecular biology for purification of target 
proteins by nickel affinity chromatography.  However, in light of observed 
differential rates of protein expression based on queuine-cognate codon usage 
(see Chapter II), we also chose to express VirF as a fusion with the V5 epitope 
(GKPIPNPLLGLDST), which contains only two Q-cognate codons.  Although 
there was visual improvement in cell phenotype and growth, no appreciable 
concentration of soluble full-length VirF protein was detected in the presence of 
any of these fusion tags. 
 Based on increased solubility with other monomeric members of the AraC 
family, we hypothesized that expression of truncated forms of VirF may be more 
successful in vivo [14].  In collaboration with Prof. Oleg Tsodikov and Dr. Tappan 
Biswas, plasmid constructs were prepared for expression of VirF with a deletion 
of 28 amino acids from the N-terminal domain, VirF(29-263), and the conserved 
C-terminal domain involved in DNA-binding, VirF(154-263).  Overexpression of 
VirF(29-263) in E. coli produced a high concentration of insoluble protein (Figure 
IV-3).  Following many attempts to improve solubility (i.e., expression with 
molecular chaperones, denaturation/refolding procedures), purification of the VirF 
fragment proved difficult due to the very dilute nature of the soluble fraction.  The 
difference in protein expression between full-length VirF and the VirF(29-263) 
fragment provide potential clues to the amino acids linked to insolubility.  The 
abundance of insoluble VirF(29-263) protein detected and normal cell 
morphology indicates that one or more amino acids in this region of the N-
terminal domain (residues 1-28) partially contribute to the toxic (e.g., mucoidy) 
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effects of VirF expression in E. coli.  Though the N-terminal domain is largely 
uncharacterized, Porter and Dorman have demonstrated that Y23 is highly 
conserved among other AraC-type activators (i.e., Rns, AggR), and the 
VirF(Y23S) mutant was inactive in a transcriptional activation assay [12].  It is 
interesting to note that more soluble protein was recovered when the VirF(29-
263, V141I) protein was co-expressed with molecular chaperones than the 
wildtype protein (Figure IV-5). The mRNA contains a conservative purine to 
purine point mutation (G421A), with a very conservative corresponding amino acid 
substitution, which eliminates recognition of the virF mRNA by TGT (at least in 
vitro) (see Chapter III for details).  The observation that the soluble concentration 
of this conservative mutant is higher than the wildtype form may speak to the 
biological relevance of the guanine 421 modification site.  Further studies to 
characterize this mutant are pending. 
A dramatic improvement in solubility was achieved with truncation of the 
entire N-terminal domain of VirF, expressing just the DNA-binding domain of 
VirF(154-263).  Though the identity of DNA-binding sites in the virB promoter was 
characterized previously with the MalE-VirF fusion in vitro, similar fragments 
were reanalyzed with the untagged C-terminal domain [11].  In the original 
experiment, DNA foot-printing analysis and transcriptional activation was 
monitored with various deletion mutants of the virB promoter (-120 to +10 
region).  With the truncated VirF(154-263) protein, two 70 bp fragments and five 
40 bp fragments of the -130 to -11 region were analyzed to monitor overlapping 
regions of the virB promoter region (Biswas and Tsodikov, unpublished). 
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Incubation with varying concentrations of the DNA-binding domain of VirF and 
the linear DNA fragments demonstrated two binding sites: one in or upstream of 
the -35 region (between -70 and -31, relative to the transcription start site) and 
the other is further upstream, between -130 and -91 (Figure IV-7C).  The 
observation that VirF(154-263) does not bind to the -90 to -51 and the -50 to -11 
fragments is suggestive that the binding site most likely includes -50.  Likewise, 
for the -130 to -91 binding site, we can deduce that it must include or lie 
upstream of -110 owing to the fact that C-VirF does not bind to the -110 to -71 
fragment.  These observations are in line with the report by Tobe et al., where 
DNA fragments containing nucleotides -105 to -17 were required for full 
transcriptional activation by MalE-VirF.  One interesting result of these studies is 
the observation that VirF (at least this truncated form) can bind to linear dsDNA, 
in apparent conflict with the demonstrated requirement of supercoiled DNA for 
transcription activation.  However, it is possible that although VirF(154-263) can 
bind to linear DNA , supercoiled DNA is required to adopt an active conformation 
for dimerization and recruitment of RNA polymerase. 
Because formation of inclusion bodies is not an issue in vitro, we 
attempted expression of several VirF constructs in cell-free extracts.  Originally, 
we hoped to test the translation of VirF in vitro from unmodified and queuine-
modified virF mRNA.  We hoped to monitor any changes in protein translation 
between the two states of the virF mRNA (modified vs. unmodified), and thereby 
directly assess the biological relevance of the TGT modification in virF.  
Unfortunately, we were unable to generate modified virF mRNA due to a lack of 
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synthetic Q nucleoside at that time (see Chapter III for details).  VirF expression 
was initially monitored from both DNA and mRNA starting materials in optimized 
cell-free extracts for synthesis of T7-driven constructs.  Though the concentration 
of the target protein should be high in comparison to the total cellular protein 
mixture, the limit of detection is low with SDS-PAGE and Coomassie Blue 
staining.  Constructs were tagged with either the V5 epitope or His-tag in an 
attempt to improve solubility and provide a more sensitive method of detection by 
Western blot.  The appropriate sensitivity was ultimately achieved with detection 
of protein synthesis by L-[35S]-methionine incorporation.  Expression of the 
control protein, CAT, was readily identified by in vitro translation (~3,000 counts 
above background); however, syntheses of the various forms of VirF tested were 
quite low.  The two constructs that demonstrated incorporation of labeled 
methionine above background were the two proteins that were expressed in 
soluble form in E. coli: VirF(154-263) and the MalE-VirF fusion (Figure IV-8).  
These results suggest that there is an inherently insoluble or unstable nature in 
VirF, and there is strong evidence to suggest this characteristic is linked to the N-
terminal domain. 
Ultimately, the MalE-VirF fusion vector was constructed according to a 
previously described protocol [11].  Though isolation of native VirF from the 
maltose-binding protein fusion was unsuccessful, Tobe et al. reported 
transcriptional activation by the fusion protein in vitro.  Structural analysis of the 
VirF protein was not possible, but we were still interested in a functional 
characterization of the transcriptional activator.  The MalE-VirF fusion could be 
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used to screen for potential VirF inhibitors in vitro as a secondary confirmation 
protocol for compounds identified in vivo.  For a complete list of plasmids 
constructed for the purpose of VirF expression, see Table IV-A1 in Appendix IV-
1. 
Conclusions 
 Many attempts to express and purify VirF in E. coli and in vitro were 
unsuccessful.  Several common molecular biology techniques were employed, 
including expression of fusion tagged proteins, co-expression with chaperones, 
various culture media, and lowered growth temperatures.  In most cases where 
expression of the full-length protein was monitored (excluding pBADvirF+His), 
cell growth was challenged, and a mucoidy phenotype was observed.  Ultimately, 
our observations are in line with those of other researchers who have tried to 
purify recombinant VirF.  In collaboration with Prof. Oleg Tsodikov and Dr. 
Tappan Biswas, two truncated fragments of the VirF protein were prepared.  The 
DNA-binding domain of VirF, VirF(154-263), was expressed in soluble form and 
DNA binding was characterized.  Though structural characterization of native 
VirF has failed, we turn our attention to a functional analysis of VirF to better 
understand this critical virulence factor through small molecule inhibition. 
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Notes to Chapter IV 
 
 I gratefully acknowledge Prof. Oleg Tsodikov and Dr. Tappan Biswas for 
their work in cloning and expressing the VirF fragments, in addition to 
characterization of VirF(154-263). 
 
Abbreviations used: MBP, maltose-binding protein; Ni-NTA, nickel-nitrilotriacetic 
acid; CIP, calf-intestinal alkaline phosphatase; IPTG, isopropyl !-D-
thiogalactoside dNTP, deoxyribonucleotide triphosphate; HRP, horseradish 
peroxidase; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis; Amp, ampicillin; CN/DAB, 4-chloro-1-naphthol/3,3-
diaminobenzidine; PCR, polymerase chain reaction; RBS, ribosome-binding site; 
TOPO, topoisomerase; Kan, kanamycin; His, histidine; dsDNA, double-stranded 
DNA; bp, base pair; pps, PreCission protease site; EDTA, 
ethylenediaminetetraacetic acid; PBST, phosphate-buffered saline with Tween; 
DTT, dithiothreitol; PMSF, phenylmethylsulfonyl fluoride; Ni-IMAC, nickel-
immobilized metal affinity chromatography; CAT, chloramphenicol 
acetyltransferase; CALML-3, calmodulin-like protein 3; ATP, adenosine 
triphosphate; FBP, fructose-1,6-bisphosphate; HEPES-KOH, 4-(2-hydroxyethyl-
1-piperazineethanesulfonic acid); NTP, ribonucleotide triphosphate; PEG, 
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Identification of Small Molecule Inhibitors of VirF: 
Development of a VirF – !-galactosidase Reporter Assay 
 
 Transcriptional activators of the AraC family are widely used as regulators 
of bacterial virulence (i.e., Rns from E. coli, ExsA in P. aeruginosa, TcpN from V. 
cholerae, and VirF from S. flexneri).  Commonly found in enteropathogens, AraC-
type activators have also been identified in virulent bacteria that invade the 
respiratory and urinary tracts [1].  Separated into two classes, AraC family 
members that function as homodimers are regulated by either 1) small molecules 
or 2) physical stimuli [2, 3].  The third class of AraC transcriptional activators are 
monomeric and typically respond to cell stress [4].  Despite such differences in 
protein structure and regulation mechanisms, AraC family members share a high 
degree of sequence homology in approximately 100 amino acids that constitute 
the DNA-binding domain in the C-terminus.   
Due to issues with protein solubility and expression of recombinant 
proteins (See Chapter IV for discussion of VirF), AraC family members have 
historically been difficult to study in vitro [5].  In the case of VirF from Shigella 
flexeri, molecular manipulations of both the virf gene and the downstream DNA 
target sequences have aided in our understanding of this critical virulence 
regulator.  The binding sites within the virB promoter were identified for both VirF 
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and the negative regulator, H-NS, by DNA footprinting analysis [6].  In addition, 
key amino acids required for DNA-binding and protein oligomerization were 
identified by mutagenesis experiments [7].  However, it is still unclear how VirF 
activates transcription at the molecular level; understanding of this process is 
critical for development of potential small molecule inhibitors of VirF.   
Much of the structural evidence to probe the DNA-binding properties of the 
AraC family comes from the monomeric transcriptional activators (including Rob 
and MarA) [8].  Recently, Paratek Pharmaceuticals reported identification of a 
class of hydroxybenzimidazoles that inhibited DNA-binding of MarA and other 
monomeric AraC-type activators in vitro (Figure V-1) [9].  A computational model 
of the DNA-binding domain of MarA was used to pre-screen small molecules in 
silico, and commercially available compounds were evaluated in a DNA-binding 
assay in vitro.  With computational evidence and preliminary inhibition data, the 
authors took a directed synthetic approach to generate optimized inhibitors of this 
class of AraC proteins.  Although DNA binding is critical for functionality of these 
activators, small molecules that inhibit the oligomerization of AraC-type activators 
could also be widely applicable to many members of this protein family. 
 
Figure V-1: Hydroxybenzimidazole Scaffold.  Analogues were identified by 
Paratek Pharmaceuticals as inhibitors of MarA and other members 




Because expression of recombinant, dimeric AraC-type proteins has been 
problematic in vitro, we propose study of this class of transcriptional activators in 
a cell-based assay.  Using a !-galactosidase (i.e., LacZ) reporter assay in 
avirulent Shigella flexneri BS103, VirF-specific activation of the virB promoter 
(controlling transcription of the lacZ reporter gene) was monitored 
spectrophotometrically with the substrate CPRG (chlorophenol red !-D-
galactopyranoside).  Small molecules that demonstrated confirmed inhibition of 
the reporter assay were analyzed further in a dose response analysis. 
 
Materials and Methods 
Reagents 
Unless otherwise specified, all reagents were from Sigma Aldrich.  
Gelase™ Agarose-Gel Digesting Preparation was from Epicentre.  The QIAprep 
Spin Miniprep Kit was from Qiagen.  Carbenicillin (disodium salt), Corning 
microtiter plates, bactotryptone and yeast extract were from Fisher Scientific.  
Electrocompetent NovaXG Zappers and Induction Control E BL21(DE3) were 
from Novagen.  Chlorophenol red !-D-galactopyranoside (CPRG, monosodium 
salt) was from Roche.  All restriction enzymes, Vent® DNA polymerase, Calf-
intestinal alkaline phosphatase (CIP), and pACYC184 were from New England 
Biolabs.  SeaPlaque agarose was from Cambrex.  Isopropyl !-D-thiogalactoside 
(IPTG), 5-bromo-4-chloro-3-indolyl !-D-galactoside (X-gal), T4 DNA Ligase, 
pBAD202-D/TOPO and all synthetic oligonucleotides were from Invitrogen.  The 
deoxynucleotide triphosphates (dNTPs, monosodium salts) were from Promega.  
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The electroporation 0.2 cm cuvettes were from BioRad.  The permeable E. coli 
strain, EC2880, was a generous gift from Dr. Michael Hubband (Pfizer Scientific).  
The virulence plasmid-cured S. flexneri strain, BS103, was a generous gift from 
Prof. Anthony Maurelli (Uniformed Services University of the Health Sciences).  
The plasmid harboring virB was a generous gift from Prof. Chihiro Sasakawa 
(The University of Tokyo, Japan). 
VirF-LacZ Reporter Plasmid Construction 
Construction of Altered lacZ! ("MCS) 
The lacZ !-peptide (i.e., !-galactosidase "-compliment) from the cloning 
vector pTZ18UAmp was used as the template for subsequent plasmid 
construction.  For cloning purposes, the multiple cloning site (MCS) were 
replaced by a 15 b.p. DNA cassette (see pTZ18U($MCS) in Table V-I for oligo 
sequences).  The complimentary oligos were designed with the appropriate free 
3’ and 5’ ends as if following restriction digestion with EcoRI and HindIII.  In a 
reaction volume of 33 #L, 0.75 nmol of each oligo was incubated at 37°C for 1h 
in 1x T4 DNA Ligase buffer (50 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 1 mM ATP, 
1 mM DTT, 5% PEG-8000).  The dsDNA sample was precipitated overnight with 
0.1 volume 3M NaOAc (pH 5.3) and 2.5 volumes 100% EtOH at -20°C.  The 
vector pTZ18U was linearized via double restriction digestion with EcoRI and 
HindIII (20 U each, 20 #L volume) at 37°C for 1h.  The vector was gel-purified 
from Seaplaque agarose gel with Gelase™ according to vendor protocol.  In a 
total volume of 20 #L, 6 #g of the DNA cassette and 0.01 #g of digested pTZ18U 
were incubated overnight at 17°C with T4 DNA ligase (2 U).  The ligated sample 
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(pTZ18U($MCS), 10 #L) was transformed into 250 #L of chemically competent 
TG2 cells and plated on L-Carb plates (100 #g/mL carbenicillin).   Individual 
colonies were isolated, and 3 mL 2xTY cultures (with 100 #g/mL carbenicillin) 
were inoculated at 37°C with shaking.  Plasmid was isolated via miniprep, and 
the correct sequence was confirmed by DNA sequencing (University of Michigan 
DNA Sequencing Core Facilities).  TG2 cells harboring pTZ18U($MCS) exhibited 
!-galactosidase activity when grown at 37°C on L-Carb plates supplemented with 
X-gal and IPTG (40 #g and 3 #mol, respectively). 
pACYC184 Reporter Dervatives 
To generate the low-copy number counter screen, plac-LacZ!, the lac 
operator and lacZ! sequence were amplified by PCR from pTZ18U($MCS).  In a 
total volume of 54 #L, reactions containing 500 ng pTZ18U($MCS), PCR primers 
(20 pmol each, see plac-LacZ! in Table V-1), 1.85 mM MgSO4, dNTP mix (0.24 
mM each NTP) and Vent® DNA polymerase (2U) were incubated according to 
the following temperature sequence: 30 cycles – 94°C for 1 min., 45°C for 1 min., 
and 72°C for 2 min. The amplified lac-lacZ" sequence and pACYC184 were 
treated in double restriction digestions with AvaI and BamHI (40 U each enzyme, 
20 #L reaction) at 37°C for 1 h. Both the plasmid and PCR product were purified, 
ligated, and transformed into TG2 cells as previously described.  The resultant 
plasmid, plac-LacZ!, was isolated via miniprep from 3 mL 2xTY cultures (with 30 
#g/mL chloramphenicol), and samples were confirmed with DNA sequencing. 
For the VirF-driven LacZ !-peptide reporter, pvir-LacZ!, the virB operator 
was amplified from pTB601 [6] and ligated with lacZ("MCS) !-compliment in two  
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Table V-1: Oligonucleotide Sequences for Reporter Plasmid Construction.  Key 
restriction enzyme sites or nucleotides of interest are underlined.  
 
Sample Name Primer Name Primer Sequence (5’ – 3’) 
EcoRI $MCS FWD AATTCGACTGCGCGCGAGTCA pTZ18U 
($MCS) HindIII $MCS REV AGCTTGACTCGCGCGCAGTCG 
LacZ" AvaI FWD CTGTCCCGGGGAGCGCCCAATACG 
plac-LacZ" 
LacZ" BamHI REV GCTGGATCCCCATCACCCTAATC 
virB Op AvaI FWD AGCTCCCGGGCTCACATCAGAGCTCC 
virB Op 
virB Op AatII REV AGCTGACGTCATCACACCCTGTTTATTC 
LacZ" AatII FWD GAGACGTCATGACCATGATTAC 
lacZ! 
LacZ" BamHI REV *See sequence above 
Add RBS-His FWD CAGACGTCAAGGAGATATACCATATG- 
CATCATCATCATCATCACGACGTCAC pvir-LacZ" + 
RBS-6x His Add RBS-His REV GTGACGTCGTGATGATGATGATGATG- 
CATATGGTATATCTCCTTGACGTCTG 
LacZ" AatII QC FWD GATGAGCGGCATTTTCCGTGACGTAT- 
CGTTGCTGCATAAACCGACTACAC LacZ($AatII) 
Quik-Change LacZ" AatII QC REV GTGTAGTCGGTTTATGCAGCAACGAT- 
ACGTCACGGAAAATGCCGCTCATC 
virB Op PstI FWD GCTCTGCAGCTCACATCAGAGCTCC pMALvirF-
LacZ" LacZ" XbaI REV CTTCTAGACTAATCAAGTTTTTTGG 
LacZ AatII FWD GAGGACGTCATGGGCAGCAGCCATC pMALvirF 
-LacZ LacZ XbaI REV GAGTCTAGATTATTTTTGACACCAG 
MalE-VirF-LacZ FWD CACCATGAAAATCGAAGAAG pBADvirF 




forms: 1) separated by only the AatII restriction enzyme site or 2) with the E. coli 
ribosome-binding site (RBS) and 6x His-tag upstream of the lacZ ! start codon.  
Briefly, in a volume of 53 #L, samples were amplified in triplicate containing 500 
ng pTB601, PCR primers (20 pmol each, see virB Op in Table V-1), dNTP mix 
(0.24 mM each NTP), and Vent® DNA polymerase (2U) as previously described.  
The lacZ("MCS) fragment was amplified from pTZ18U($MCS) under the same 
conditions with the appropriate primers (see lacZ! in Table V-1).  All replicate 
reactions were combined and ethanol precipitated at -20°C overnight.  Each DNA 
precipitate was resuspended in water (40 #L).  Both PCR products (20 #L DNA, 
40 #L total volume) were treated with AatII (40 U) at 37°C for 1 h.  The digested 
samples were gel-purified as previously described.  The virB Op and lacZ("MCS) 
fragments were ligated overnight at 16°C (2:1 volume ratio, 20 #L total volume) 
with T4 DNA Ligase (2 U).  To increase the concentration, the ligated product 
was amplified by PCR under the following conditions in duplicate: virB Op-lacZ" 
(1 #L ligation sample), dNTP mix (0.25 mM each NTP), virB Op AvaI FWD primer 
(20 pmol), LacZ" BamHI REV primer (20 pmol), and Vent® DNA polymerase 
(2U) in a 52 #L volume as previously described.  The reactions were combined 
and ethanol precipitated at -20°C overnight.  The DNA pellet was resuspended in 
water (20 #L).  The amplified virB Op-lacZ" fragment was subcloned into 
pACYC184 following double restriction digestion with AvaI and BamHI according 






Figure V-2: Construction of the Dual-Plasmid Reporter with LacZ "-peptide. 
 
 Following construction of pvir-LacZ", a dsDNA cassette was engineered 
(see pvir- LacZ" + RBS-6x His in Table V-1) to incorporate the E. coli ribosome-
binding site concensus sequence (RBS, AGGAGA) and a 6x-Histidine tag for 
expression trials in E. coli.  Designed with AatII restriction sites on either end, the 
two complimentary oligos (0.1 #mol each) were annealed in water at 37°C for 1 h.  
The dsDNA insert and pvir-LacZ" (20 #L DNA) were treated with AatII (40 U, 26 
#L total volume) at 37°C for 1 h.  Alkaline phosphatase (CIP, 30 U) was added 
directly to the digested pvir-LacZ" sample to prevent religation, and the sample 
was incubated at 37°C for an additional 1 h.  Both digested fragments were gel-
purified as previously described.  In a total volume of 20 #L, the dsDNA insert and 
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digested pvir-LacZ" (5:1 volume ratio) were incubated overnight at 17°C with T4 
DNA ligase (2 U).  The ligated sample (pvir-LacZ"+RH, 10 #L) was transformed 
into 250 #L of chemically competent TG2 cells and plated on L-Carb plates (100 
#g/mL carbenicillin).   Individual colonies were isolated, and 3 mL 2xTY cultures 
(with 100 #g/mL carbenicillin) were inoculated at 37°C with shaking.  Plasmid was 
isolated via miniprep (Qiagen).   
 Electrocompetent TG2 cells (50 #L) were transformed with pvir-lacZ! (or 
pvir-lacZ!+RH) and pMALvirF (see Chapter IV) simultaneously, according to the 
BioRad electrotransformation protocol.  Cells were grown overnight on L-plates 
(with 100 #g/mL carbenicillin, 30 #g/mL chloramphenicol, 40 #g X-gal and 3 #mol 
IPTG) at 37°C.  Plasmid DNA was isolated from the positive (blue) transformants.  
A representative scheme for this dual VirF reporter subcloning strategy is 
illustrated in Figure V-2. 
High-copy Number Reporter Plasmids 
A collection of single, high-copy number vectors was also constructed. 
The virB Op-lacZ! fragment was initially amplified by PCR and subcloned into 
pMALvirF.  Briefly, in a total volume of 50 #L, samples containing 500 ng pvir-
LacZ", 2 mM MgSO4, dNTP mix (2.5 mM each NTP), PCR primers (20 pmol 
each, see pMALvirF-LacZ" in Table V-1), and Vent® DNA polymerase (4 U) 
were incubated according to the following temperature sequence: 30 cycles – 
94°C for 30 sec., 50°C for 1 min., and 72°C for 2 min. The amplified virB Op-
lacZ! sequence and pMALvirF (15 #L DNA) were treated in double restriction 
digestions with PstI and XbaI (40 U each enzyme, 30 #L reaction) at 37°C for 1 
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h. Both the plasmid and PCR product were purified, ligated (7:1 volume ratio, 
insert to plasmid), and transformed into TG2 cells as previously described.  The 
resultant plasmid, pMALvirF-LacZ", was isolated via miniprep from 3 mL 2xTY 
cultures with carbenicillin, and samples were confirmed with DNA sequencing. 
Full-length lacZ (3 kb) was amplified by PCR from the Novagen Induction 
Control E (pET28a derivative).  An internal AatII restriction site was altered with a 
silent mutation introduced by site-directed mutagenesis (according to Stratagene 
protocol).  In a 30 #L total volume, samples containing 500 ng pET28a-lacZ, 
Quik-change PCR primers (10 pmol each, see LacZ($AatII) Quik-Change in 
Table V-1), dNTP mix (0.25 mM each NTP), 2 mM MgSO4, and Vent® DNA 
polymerase (2 U) were incubated according to the following temperature 
sequence: 15 cycles – 94°C for 1 min., 50°C for 1 min., and 72°C for 6.5 min.  
The amplified samples were treated with DpnI (40 U) in 1x NEBuffer 4 (20 mM 
Tris-Acetate (pH 7.9), 50 mM K(CH3COO), 10 mM Mg(CH3COO)2, 1 mM DTT) at 
37°C for 2 h to digest wildtype DNA.  The digested sample (10 #L) was 
transformed into 250 #L chemically competent TG2 cells and grown overnight on 
L-Kan plates (50 #g/mL kanamycin).  Plasmid DNA was isolated, and the 
sequence was confirmed as previously described.   
The corresponding lacZ open reading frame was amplified in triplicate as 
follows (30 #L volume): 5 #g pET28a-LacZ($AatII), PCR primers (10 pmol each, 
see pMALvirF-LacZ in Table V-1), dNTP mix (0.25 mM each NTP), 2 mM 
MgSO4, and Vent® DNA polymerase (2 U) were incubated according to the 
following temperature sequence: 30 cycles – 94°C for 1 min., 55°C for 1 min., 
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and 72°C for 2 min.  The samples were combined and ethanol precipitated at -
20°C overnight.  The DNA pellet was resuspended in water (30 #L).  The lacZ 
gene was subcloned into pMALvirF-LacZ! via a double restriction digestion.  
Briefly, samples containing 5 #L DNA (10 #L total volume) were treated with AatII 
and XbaI (20 U each) at 37°C for 1.5 h.  Both the plasmid and PCR product were 
gel-purified, ligated (5:1 volume ratio, insert to plasmid), and transformed into 
TG2 cells as previously described.  The resultant plasmid, pMALvirF-LacZ, was 
isolated via miniprep from 3 mL 2xTY cultures with carbenicillin, and samples 
were confirmed with DNA sequencing.  The entire malE-virF+virB Op-lacZ 
fragment (~6 kb) was amplified for insertion by TOPO cloning into the araBAD-
controlled vector, pBAD202-D/TOPO, according to vendor protocol.  Briefly, 
samples containing 500 ng pMALvirF-LacZ, 2 mM MgSO4, dNTP mix (0.25 mM 
each NTP), PCR Primers (20 pmol each, see pBADvirF-LacZ in Table V-1), and 
Vent® DNA polymerase (2 U) in a total volume of 50 #L were incubated 
according to the following temperature sequence: 30 cycles – 94°C for 1 min., 
50°C for 1 min., and 72°C for 2 min.  TOPO cloning was conducted according to 
the electrocompetent E. coli transformation protocol (Invitrogen).   The pBAD202-
D/TOPO sample was incubated with 12 ng PCR product for 30 min. at room 
temperature, and the ligation product (pBADvirF-LacZ, 3 #L) was transformed 
into electrocompetent NovaXG Zapper™ cells according to vendor protocol.  






Figure V-3: Single Plasmid Reporter Constructs with LacZ. 
A positive control vector was created for both pMALvirF-LacZ and 
pBADvirF-LacZ as a measure of !-galactosidase activity in the absence of VirF.  
Each reporter plasmid (10 #L, 20 #L total volume) was treated with the restriction 
endonuclease BglII (20 U) at 37°C for 90 min.  The digested plasmids were gel-
purified as previously described to remove the resultant 1200 nucleotide 
fragment of the malE-virF open reading frame.  The purified samples were re-
ligated at 17°C overnight with T4 DNA ligase (2 U).  The ligation products (5 #L) 
were transformed into 250 #L chemically competent TG2 cells, and grown at 
37°C on L-Carb (pMAL reporter) or L-Kan plates (pBAD reporter).  
Representative plasmid diagrams with key restriction enzyme sites for pMALvirF-
LacZ and pMAL($virF)-LacZ are shown in Figure V-3.  
!-galactosidase Assay Protocols 
MUG Assay 
 This approach is a modified Miller method for cell-based assays in 
microtiter plate format described by F. Vidal-Aroca and coauthors [10, 11].  This 
method was analyzed with the pACYC184 derivatives plac-LacZ" and pvir-LacZ" 
(in the presence and absence of pMALvirF).  Cells were grown in batch culture 
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(rich 2xTY and minimal M9 media tested) containing 30 #g/mL chloramphenicol 
at 37°C with shaking to mid-log phase (OD600 0.6-0.7).  Varying concentrations 
of IPTG (0-5 mM) were added, and samples were incubated at 37°C with shaking 
for an additional 4 h.  Cultures were assayed in 96-well microtiter plates (both 
black/clear bottom and black/opaque were tested) for !-galactosidase activity 
following 2 h and 4 h of induction with IPTG.  Briefly, cells were diluted 5-fold in 
plates with Miller’s Z buffer without !-mercaptoethanol (60 mM Na2HPO4, 40 mM 
NaH2PO4, 10 mM KCl, 1 mM MgSO4).  The cell density was measured at A595 
(black/clear plates only).  The samples were incubated at room temperature for 
15 min. following addition of the methylumbelliferyl !-D-galactopyranoside 
substrate (MUG, 25 #g in DMSO).  The reactions (125 #L total volume) were 
quenched with 1M Na2CO3 (30 #L), and accumulation of the 4-MU reaction 
product was measured by fluorescence (%ex = 360 nm, %em = 460 nm) in a 
Molecular Dynamics microtiter plate reader.  Calculation of Miller “MUG” Units 
was performed with the following equation (black/clear plates only): Activity = 
F360/460/(t ! A595). 
CPRG Assay 
 The lab protocol for assaying !-galactosidase activity with the substrate 
CPRG (chlorophenol red !-D-galactopyranoside) was modified from a protocol 
developed by Thomas McQuade at Pfizer Inc.  Briefly, this assay was performed 
with "-complementation vectors (plac-LacZ", pTZ18U($MCS), and pTZ18U) and 
reporters expressing full-length LacZ (pET28a-LacZ, pMALvirF-LacZ, and 
pBADvirF-LacZ) in both E. coli (TG2 and EC2880) and S. flexneri (BS103).  A 
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wide variety of conditions were tested: the concentration of cells (OD600 = 1.5-
0.03), inducer ([IPTG] = 2-0.25 mM, [L-arabinose] = 0.02-0.00002%), substrate 
([CPRG] = 0.25-0.5 mg/mL), detergent ([Triton X-100] = 0.05-0.01%), and growth 
conditions (plated/batch culture, growth at 37°C vs. 30°C, etc.).  The optimized 
conditions for each construct is outlined below. 
 For alpha-complementation with the altered LacZ "-peptide, E. coli TG2 
cells harboring either plac-LacZ" or pTZ18U($MCS) were grown in 2xTY batch 
culture (supplemented with 30 #g/mL chloramphenicol or 100 #g/mL carbenicillin, 
respectively) to saturation (OD600  5).  Samples were diluted in 384-well 
microtiter plates with 2xTY containing the appropriate antibiotic to the following 
final concentrations (50 #L total volume): OD600 = 0.3, 0.6, and 1.2.  In addition to 
an uninduced control, each sample was plated with 2.5 mM IPTG at 37°C. !-
galactosidase activity was measured with the addition of 0.5 mg/mL CPRG and 
0.05% Triton X-100 (equal volume ratio, 50 #L total volume).  The plates were 
incubated at room temperature for 45-60 min.  All samples were assayed in 
replicate (n=6) after 4 h and 24 h post-induction.  Accumulation of the CPR 
reaction product was detected by measuring absorbance (%max = 575 nm). 
 Assays performed with constituitive expression of the unaltered LacZ "-
peptide (pTZ18U in TG2 cells) and full-length LacZ (pET28a-LacZ in TG2 and 
EC2880) were conducted as described previously with a few alterations based 
on observations from the previous assays.  Cells were grown in batch 2xTY 
culture with appropriate antibiotics at 37°C to OD600  1.5 and plated with low 
concentrations of IPTG (0, 0.25, 0.5 mM) for 24 h at 37°C.  CPRG was held 
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constant at 0.5 mg/mL and the concentration of Triton X-100 was varied (0.01-
0.05%).  Plates with TG2 cells were incubated at room temperature for 45-60 
min., and the EC2880 samples were incubated for 20 min. at room temperature 
prior to absorbance measurements. 
 The assay conditions for the VirF reporter plasmids (pMALvirF-LacZ and 
pBADvirF-LacZ) in EC2880 were as previously described with the following 
exceptions. Cells were grown in batch 2xTY culture with appropriate antibiotics at 
37°C to OD600  0.7-0.8 and plated in a 30 #L total volume with high 
concentrations of IPTG (2 mM) or L-arabinose (0.02%).  The pMAL samples 
were grown at 37°C for 18 h, and the pBAD samples were incubated for 4 h.  
Cells were diluted to a total volume of 50 #L with 2xTY prior to addition of the 
substrate/detergent mixture.  CPRG and Triton X-100 concentration were held 
constant at 0.25 mg/mL and 0.05%, respectively.  The CPR reaction product was 
measured following a 10 min. incubation at room temperature.  The same 
constructs (in addition to pMAL($virF)-LacZ) were assayed in avirulent S.flexneri 
BS103 using essentially the same protocol.  For each construct the concentration 
of inducer was varied (for pMAL reporters, [IPTG] = 0-2 mM; for the pBAD 
reporter, [L-arabinose] = 0-0.02%), and the induction period was shortened to 3 h 
at 37°C.  The CPRG/Triton X-100 mixture was added, and absorbance was 
measured following a 10 min. incubation at room temperature. 
CPRG Assay Conducted at the CCG 
 The protocol for measuring !-galactosidase activity from BS103 harboring 
pMALvirF-LacZ (or the positive control for inhibition of !-galactosidase activity, 
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pMAL($virF)-LacZ) was optimized at the Center for Chemical Genomics (CCG, 
University of Michigan).  Cells were grown to saturation in 2xTY at 37°C with 
shaking.  The pMALvirF-LacZ samples were diluted in 384-well microtiter plates 
with 2xTY supplemented with carbenicillin to a final OD600 = 0.004 (30 #L total 
volume).  Plates were incubated for 24 hours at 30°C.  Cell density (OD600) was 
monitored prior to addition of the CPRG/Triton X-100 mixture (0.5 mg/mL and 
0.05%, respectively).  The samples were incubated at room temperature for 10 
min. before measuring CPR absorbance (A570) in the PHERAStar plate reader 
with a narrow band pass filter.  Initially, assay consistency was monitored in the 
absence of compound (VirF reporter tested in replicate, n=352).  Subsequent 
trials with small molecule libraries (~42,000 compounds) were conducted with the 
positive and negative controls assayed in replicate (n=32), and diluted cells 
grown for 24 h at 30°C in the presence of test compounds (10 #M, n=1) added to 
20 #L 2xTY by pintool.  Potential hits were considered active by the following 
criteria: & 55% inhibition by plate of the VirF-LacZ assay in comparison to 
controls, and inhibition of cell growth (OD600) ' 20%.  This compound set (1273 
small molecules) was confirmed according to the above assay protocol (n=3).  In 
addition, the test set was pre-incubated with purified !-galactosidase in Z buffer 
(25 nM, 30 #L total volume) for 1 h at 30°C.  This preliminary in vitro 
counterscreen was conducted in triplicate with the same CPRG/Triton X-100 
mixture.  The absorbance measurements were made following a 2.5 min. 
incubation at room temperature. 
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 Following data triage, compounds with reactive or toxic functionalities, 
solubility or promiscuity issues were discarded.  Remaining test compounds (238 
small molecules) were assayed in a dose response study (n=4) according to the 
previous protocol with the following exception: the concentration of small 
molecule was varied in 2-fold serial dilutions, ranging from 100-1.5 #M.  The data 
were plotted as a function of the concentration of small molecule (#M) versus 
absorbance (570 nm).  The data were fit by non-linear regression to the following 
equation for sigmoidal kinetics:  
y = lower+((upper-lower)/(1+10(([I]-M1)*M2))) 
where lower is the lower limit of the assay, and upper is the upper limit of the 
assay, [I] is the inhibitor concentration, M1 is the IC50 and M2 is the Hill Slope.  
During the fitting process, the upper limit was manually entered (from the no 
inhibitor control) owing to the fact that the data generally do not go to low enough 
concentrations to sufficiently define the upper portion of the curve.  The lower 
limit was also manually entered as defined by the average absorbance of the 
positive control for each individual plate. 
  
Results 
Construction of !-galactosidase Reporter Plasmids 
  Several low-copy number pACYC184 derivatives were constructed for the 
purpose of controlled expression of the lacZ("MCS) "-peptide.  The VirF-specific 
reporter plasmid, pvir-LacZ! was constructed for cotransformation with the VirF 
expression vector, pMALvirF.  The counterscreen for this system (plac-LacZ") 
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measures constituitive expression of LacZ! from the lac promoter.  In parallel, 
another line of plasmids was constructed as a single expression/reporter system.  
The virB Op-lacZ! fragment was subcloned directly into pMALvirF, and the malE-
virF+virB Op-lacZ! fragment was inserted into pBAD202-D/TOPO.  A 
counterscreen was generated via deletion of a portion of the malE-virF open 
reading frame, eliminating expression of VirF from these samples.  Through "-
complementation or expression of the full-length reporter, !-galactosidase activity 
from all plasmids was assessed via cell growth on X-gal/IPTG supplemented 
agar plates.   
!-galactosidase "-complementation Assay Trials 
 The !-galactosidase assay conditions were first optimized with the vector 
plac-LacZ".  Independent cultures were grown in 2xTY with chloramphenicol at 
37°C with shaking.  Following induction with IPTG, aliquots were removed at 
various time points, and !-galactosidase activity was measured with MUG in a 
modified Miller assay.  The optimal assay conditions for enzymatic activity in 
plac-LacZ" were determined to be a 4-hour induction period with 2.5 mM IPTG 
(Figure V-4A).  Due to significant background fluorescence in the uninduced 
samples, a series of negative control samples were tested (Figure V-4B).  There 
was a slight increase in MUG hydrolysis in the absence of inducer and/or the 
transcription factor, VirF, in all of the reporter negative control samples with 
respect to the media control.  Interestingly, the background fluorescence of the 
2xTY media itself was quite high (approximately 1500 fluorescence units). !-




Figure V-4: !-galactosidase Assay Trials with MUG Substrate.  A) MUG assay 
performed with plac-LacZ " (termed plac here) in E. coli TG2 in 
duplicate.  Aliquots were removed from uninduced samples, 2 h (") 
and 4 h (") post-induction with IPTG (tested in triplicate).  Detection 
of the 4-MU reaction product (F360/460 nm) was measured, and plotted 
as the average and standard deviation.  B) Negative controls tested 
with the MUG substrate.  The background fluorescence was 
measured (in triplicate) in 2xTY media only ("), uninduced plac-LacZ 
" ("), uninduced reporter pMALvirF + pvir-LacZ " ("), and pvir-LacZ 
" induced in the absence of pMALvirF ("). 
 
164 
media.  Although the background fluorescence was reduced 3-fold, accumulation 
of the 4-methylumbelliferone (4-MU) reaction product also increased over time in 
the plasmid-free TG2 control samples (data not shown). 
 Due to issues with very high background signal with MUG, a more 
sensitive !-gal substrate was selected for further assay optimization.  CPRG is 
spectrophotometrically active (A575) and sensitive to low concentrations (nM 
range) of !-galactosidase.  Conditions were first optimized in the altered lacZ "-
peptide constructs, plac-LacZ" and pTZ18U($MCS), to compare enzymatic 
activity in relationship to plasmid copy number.  All samples were grown with 
shaking at 37°C in independent 2xTY cultures to late log-phase (OD600  5).  
Varying the concentration of cells, samples were induced with 2.5 mM IPTG in 
384-well clear microtiter plates and grown in the 37°C oven.  Aliquots removed 
after a 4 hr induction period revealed little change in !-galactosidase activity via 
alpha-complimentation from plac-LacZ" between uninduced cells and those 
supplemented with IPTG (Figure V-5).  As predicted, LacZ "-complementation 
with the high-copy number vector, pTZ18U($MCS), was higher than that 
observed in plac-LacZ".  After 4 hours of growth at 37°C, pTZ18U($MCS) 
demonstrated increased !-galactosidase activity in the absence of IPTG (2-4 fold 
higher than the induced cultures).  Enzyme "-complementation was 
approximately 3-fold higher in pTZ18U($MCS) in comparison to plac-LacZ".  For 
both constructs, overnight growth at 37°C in the presence of IPTG saturated the 
expression of LacZ.   
Expression Trials with Full-length LacZ 
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 Assays were also conducted to measure expression of LacZ via "-
complementation from the wildtype vector pTZ18U in comparison to expression 
of full-length LacZ (Figure V-6).  TG2 cells (lacZ"M15) were transformed with 
both pTZ18U and the pET28a derivative, pET-LacZ.  Cells were plated (OD600 = 
1.5) with varying concentrations of IPTG for 24 hours at 37°C in microtiter plates.  
The following day, the concentration of Triton X-100 detergent was also varied to  
 
Figure V-5: !-galactosidase "-Complementation Assay with CPRG Substrate.  
Both the low-copy and high-copy number counter screen vectors 
with altered lacZ! (plac-LacZ" and pTZ18U($MCS), respectively) 
were assayed in replicate (n=6).  Cells were plated (OD600 = 0.3 ("), 
0.6 ("), and 1.2 (")) prior to induction with IPTG in 384-well 
microtiter plates.  Aliquots were also removed from all samples prior 
to addition of IPTG as the uninduced control (").  Samples were 
treated with CPRG and Triton X-100 following 4 hrs and 20 hrs of 
growth at 37°C.  The chlorophenol red product was detected 
spectrophotometrically (A575).  The average of each trial is illustrated 
with the error represented as standard deviation. 
 
optimize the CPRG assay.  Maximal LacZ expression was observed in both 
constructs following induction with a relatively low concentration of IPTG (0.5 
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mM).  In addition, pET-LacZ expression was tested in the permeable E. coli 
strain, EC2880 ("tolC, imp-, "lac).  This cell line has a deletion in the entire lac 
operon, and is therefore unsuitable for "-complementation.  !-galactosidase 
activity in EC2880 was increased 20-50% in comparison to the corresponding 
conditions in TG2 cells (Figure V-6). 
 
 
Figure V-6: Comparison of !-galactosidase "-Complementation and Expression 
of Full-length Reporter Gene.  The high-copy number counter 
screen vectors with either wildtype lacZ! (pTZ18U)  or lacZ (pET-
LacZ) were assayed in triplicate.  The pET-LacZ construct was 
assayed in both E. coli TG2 and the permeable E. coli stain, 
EC2880.  Cells (OD600 = ~1.5) were incubated for 24 hours at 37°C 
in 384-well microtiter plates with no IPTG ("), 0.5 mM IPTG (") or 
0.25 mM IPTG (").  The !-galactosidase assay was performed with 
addition of CPRG and Triton X-100.  The chlorophenol red product 
was detected spectrophotometrically (A575). The average of each 





Further optimization of the VirF reporter assay was conducted with 
constructs expressing the full-length LacZ protein.  Two high-copy number 
vectors (the tac promoter-based vector, pMALvirF-LacZ and the L-arabinose-
inducible plasmid, pBADvirF-LacZ) expressing the MalE-VirF fusion protein and 
the virB promoter-driven lacZ gene were tested in EC2880.  !-galactosidase 
activity was high in the uninduced samples for each reporter following growth in 
microtiter plates at 37°C (Figure V-7).  Expression of LacZ in the IPTG-induced 
pMALvirF-LacZ samples was 3-4 fold lower than the uninduced cells following 18 
hours of growth.  !-galactosidase activity was observed following much shorter 
incubation times in the pBADvirF-LacZ samples (4 hr vs. 18 hr); interestingly, 
identical levels of !-galactosidase activity was observed in the presence and 
absence of L-arabinose.  
In an attempt to overcome the apparent “leaky” expression of !-
galactosidase observed in the previous trials, both VirF-LacZ reporter constructs 
were assayed in Shigella flexneri BS103 (virulence plasmid-cured derivative of S. 
flexneri 2a).  Cells were grown to mid-log phase and plated in varying 
concentrations of inducer for 3 hours at 37°C.  BS103 cells exhibited no 
endogenous !-galactosidase activity in the presence of either IPTG or L-
arabinose (Figure V-8A and B, respectively).  Uninduced pMALvirF-LacZ again 
produced the highest level of !-galactosidase activity, although at a faster rate 
than was observed in E. coli EC2880 (Figure V-8A). Again, increasing 
concentration of IPTG resulted in decreased expression of LacZ in the pMALvirF 




Figure V-7: VirF-!-galactosidase Reporter Assay in Permeable E. coli. The high-
copy number vectors pMALvirF-LacZ and pBADvirF-LacZ were 
assayed in duplicate in EC2880.  Cells (OD600 = ~0.7-0.8) were 
incubated without inducer (") and in the presence of the highest 
concentration of inducer tested (", 2.0 mM IPTG for pMAL and 
0.02% L-arabinose for pBAD).  The pMAL reporter was incubated for 
18 hours at 37°C in 384-well microtiter plates, and the pBAD reporter 
for 4 hours at 37°C.  The !-galactosidase assay was performed with 
additon of CPRG and Triton X-100, and the chlorophenol red product 
was detected by absorbance (A575). The average of each trial is 
illustrated, where the error is represented by the standard deviation. 
 
arabinose in the pBADvirF reporter construct, but maximal expression of !-
galactosidase was 2-fold lower than was observed for the pMALvirF-LacZ 
reporter (Figure V-8B).  To confirm that expression of LacZ was VirF-dependent 
in BS103, a mutant version ($virF) of each reporter was constructed.  Uninduced 
!-galactosidase activity was monitored from the pMALvirF-LacZ and 
pMAL($virF)-LacZ reporters in BS103, and VirF-driven expression of LacZ was 
4-fold higher than the positive control (Figure V-8C).  CPRG-mediated detection 
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of LacZ expression from the pMALvirF-LacZ reporter in BS103 were chosen as 
the optimal assay conditions for further trials. 
Optimization of High-throughput VirF-LacZ Assay 
 The microtiter plate-based assay was optimized at the Center for 
Chemical Genomics (CCG, University of Michigan).  Assays were performed in 
the absence of small molecules according to the desired protocol for the final 
assay.  Each set of conditions was performed in replicate (n=352) to determine 
the consistency of cell growth and !-galactosidase activity across each well in 
the plates.  Conditions such as growth temperature (30 vs. 37°C), total volume 
(60 vs. 80 #L), and concentrations of the CPRG substrate (0.25 vs. 0.50 mg/mL) 
and Triton X-100 detergent (0.01 vs. 0.05%) were considered in the initial 
troubleshooting measures.  The most reproducible !-galactosidase assay was 
observed when cells (OD600 = 0.004) were incubated at 30°C for approximately 
24 hours, and assayed with 0.50 mg/mL CPRG + 0.05% Triton X-100 in a 60 #L 
total volume (Figure V-9). Cell growth was measured (A600) to ensure equivalent 
cell density between replicate wells (data not shown).  The heat map 
representation illustrates the !-galactosidase activity in each well of the 384-well 
microtiter plate following treatment with CPRG and Triton X-100.  The negative 
control (pMALvirF-LacZ without compound) was plated in the first two columns 
(n=32), and the average absorbance was recorded (A570 = 2.5).  The positive 
control (pMAL($virF)-LacZ) was plated in the last two columns (n=32), with an 




Figure V-8: VirF-!-galactosidase Reporter Assay in Avirulent Shigella flexneri. A) 
pMALvirF-LacZ in BS103.  All samples were grown to OD600 = ~0.6-
0.7 and plated with varying concentrations of inducer in duplicate: 
uninduced ("), 0.25 mM ("), 0.50 mM ("), 1.0 mM ("), and 2.0 mM 
(") IPTG.  Samples were treated with CPRG and Triton X-100 
following a 3 h induction period, and the chlorophenol red product 
was detected by absorbance (A575).  B) pBADvirF-LacZ in BS103 
were assayed as above.  The concentration of L-arabinose was 
varied as follows: uninduced ("), 0.00002% ("), 0.0002% ("), 
0.002% ("), and 0.02% (") L-arabinose.  C) !-galactosidase activity 
in BS103 with pMALvirF-LacZ or pMAL($virF)-LacZ.  Samples were 
grown to a final OD600 = ~0.5 and plated in the absence of IPTG in 
replicate (n=4).  All samples were assayed as described above. 
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the internal 320 wells, and !-galactosidase activity was measured in comparison 
to the controls by % inhibition (100% inhibition set to the A570 reading for the 
positive control).  There was some variation in growth between individual wells, 
but the overall Z’ factor determined was reasonable (Z’ = 0.59).  In addition, a 
plot of the raw absorbance values indicated that most of the pMALvirF-LacZ 
replicates achieved & 3 SD (standard deviations) above the $virF positive control. 
 
 
Figure V-9: Optimization of VirF-!-galactosidase Reporter Assay in 384-well 
Microtiter Plate.  S. flexneri BS103 transformed with either 
pMALvirF-LacZ or pMAL($virF)-LacZ were plated in a 30 #L 
volume at a final OD600 = 0.004 (columns 1-22: pMALvirF-LacZ, 
columns 23-24: pMAL($virF)-LacZ).  The microtiter plate was 
incubated at 30°C overnight.  !-galactosidase activity was 
measured (A570) upon addition of CPRG and Triton X-100.  The 
calculated Z’ factor = 0.59.  The data is visualized both as a 
heatmap of assay consistency and by the measured absorbance 
value for each well. 
 
 
 The primary HTS screen of the VirF-LacZ cell-based assay was run with 
several small molecule libraries, including MicroSource Spectrum 2000, the 
Chemical Diversity set, Maybridge Hit-Finder, and the NCC BioFocus library.  
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Approximately 42,000 compounds were tested in total, and the raw absorbance 
data is shown in Figure V-10.  Cell growth was monitored (A600, Figure V-10A) 
prior to addition of the CPRG substrate/detergent mixture.  Each small molecule 
was tested in a single well (n=1) in a 384-well microtiter plate, and ~1270 
compounds were selected as potential hits based on the following selection 
criteria (normalized to the controls of each individual plate) (Figure V-10B): & 
55% VirF inhibition by plate (A570 < 1.4), with 100% inhibition defined as the 
mean A570 measurement for the positive control replicates for each plate (A570  
0.7-1.0).  Compounds with antibiotic activity of & 20% growth inhibition were also 
removed from consideration. The 1273 initial hits were re-assayed using the 
primary screen conditions in triplicate to confirm activity (Figure V-11A).  
In addition, these compounds were counter-screened in triplicate against 
purified !-galactosidase, in vitro, to filter out any false positives that directly 
inhibit the reporter (Figure V-11B).  Four compounds were found to inhibit !-
galactosidase in vitro (Table V-2), three with modest inhibition (~40%) and one 
that demonstrated significant inhibition of the purified enzyme (92%, CCG-
28697).  Three compounds (CCG-28697, 28450, and 28967) share a common 
tricyclic structure with a bridging piperdine-sulfonyl moiety, derivatized with 
various aromatic functionalities (Table V-2).  The structures are distinct from 




Figure V-10: VirF-!-galactosidase Reporter Assay Primary Screen.  S. flexneri 
BS103 harboring pMALvirF-LacZ or pMAL($virF)-LacZ were plated 
in replicate (n=32) to a final OD600 = 0.004 and grown at 30°C 
overnight.  Small molecules (10 #M) were added by pintool (320 
compounds/plate, n=1). Approximately 42,000 small molecules 
were tested in the primary screen.  A) Cell growth (OD600) was 
monitored prior to addition of CPRG/detergent mixture as a control 
for antibacterial activity.  B) !-galactosidase activity was measured 





Figure V-11: VirF-!-galactosidase Reporter Assay Confirmation Screen.  A) 
Compounds identified as potential hits in the primary screen (1273 
small molecules, 10 #M) were re-assayed to confirm activity in 
triplicate.  The assay was carried out as described in the text.  B) 
Identical plates were prepared to counterscreen with purified !-
galactosidase (25 nM) to monitor direct inhibition of the reporter in 
vitro.  The positive control (enzyme without compound) and 































Following further selection criteria for optimized hit-to-lead scaffolds (i.e., 
molecular weight < 600, no reactive or toxic functionalities) a test set of 238 
compounds was chosen for dose response studies.  Each compound was tested 
in replicate (n=4) in serial dilutions ranging in concentration from 100 - 1.5 #M.  
The data were plotted (concentration versus absorbance) fit by non-linear 
regression using an equation for sigmoidal kinetics, and the IC50 values were 
calculated using Kaleidagraph (Synergy Software).  From this assay, 7 
compounds were confirmed by dose response analysis, with typical IC50 values 
ranging between 1-90 #M (Table V-3).  Representative data for the dose 
response analysis is shown in Figure V-12. 
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Library IC50 ("M) Structure 
    
CCG-38543 MicroSource 1.0 
 
CCG-25354 ChemDiv 2.7 
 
CCG-24904 ChemDiv 4.5 
 
CCG-50009 Maybridge 10 
 
CCG-55215 Maybridge 12 
 
CCG-42010 Maybridge 43 
 






Figure V-12: VirF-!-galactosidase Reporter Assay Dose Response Analysis.  
Three compounds fit by non-linear regression for sigmoidal 
kinetics.  Each compound was confirmed in replicate (n=4). 
 
Discussion 
In considering a robust, cell-based assay to screen for inhibitors against 
VirF activity, !-galactosidase was initially chosen as a reporter for its history as a 
molecular biology tool and its enzymatic stability [10].  With a wide variety of 
substrates described in the literature, there are several potential options to suit a 
range of !-galactosidase assay protocols (Figure V-13). The most common 
substrate for measuring LacZ expression on solid media is X-gal (5-bromo-4-
chloro-3-indolyl !-D-galactopyranoside), however detection of the insoluble blue 
product is less amenable to liquid culture.  The classical substrate described by 
J. H. Miller for !-galactosidase enzyme kinetics is o-nitrophenyl !-D-
galactopyranoside (ONPG) [10].  The ONP product of hydrolysis is yellow in color 
and detected by absorbance (A420).  This spectrophotometrically active substrate 
is best suited to in vitro reactions because the signal to noise ratio is high in 




Figure V-13: !-galactosidase Substrates.  Chemical name and detection method 
for the reaction product is listed. 
 
masked by the inherent absorbance in the liquid media.  The fluorescent 
substrate MUG was previously described for use in a whole-cell assay for !- 
galactosidase activity [11].  Without significant dilution of the starting cell culture, 
there is a concern for background fluorescence from the media.  Finally, CPRG 
(chlorophenol red !-D-galactopyranoside) has also been described for cell-based 
applications, and this substrate is particularly sensitive to low concentrations of !-
galactosidase [12].   
In addition to choosing the optimal substrate, LacZ enzyme activity can be 
monitored from expression of the full-length protein or by "-complementation.  
Initially we considered use of the lacZ "-compliment because this short peptide 
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sequence is readily available in most plasmids as a tool for blue/white selection 
of positive transformants.  LacZ "-complementation is achieved through 
expression of the "-peptide in cells with the genotype lacZ"M15, which indicates 
that only the LacZ (-peptide is present.  Cell lines with a "lac genotype must be 
transformed with a plasmid carrying the entire lacZ gene sequence to exhibit !-
galactosidase activity.  For our purposes and ease in future subcloning steps, the 
multiple cloning site (MCS) of the lacZ "-peptide in pTZ18U was replaced by a 
short cassette that did not disrupt the reading frame.  The corresponding lacZ "-
peptide contains an altered N-terminus, with a deletion in 10 amino acids and 
several major amino acid substitutions (e.g. P19R, D21T, C27A, H29E).  When 
transformed into TG2 cells and plated with X-gal and IPTG, the colonies 
exhibited blue/white selection, indicating that although some pronounced 
sequence alterations were made, the resultant LacZ protein is still functional.   
The lacZ()MCS) fragment was amplified by PCR, and subcloned initially 
into the low/medium copy-number vector pACYC184.  Because VirF-mediated 
activation of the virB promoter is quantified by resultant !-galactosidase activity, 
we hypothesized that detection of LacZ might be more sensitive if the 
concentration of the lacZ! gene was lower in cells.  Assays were first conducted 
with the constituitive lac promoter-driven expression vectors in an attempt to 
optimize conditions for the ultimate VirF reporter assay (Figure V-4A).  !-
galactosidase activity was quantified in a modified Miller method using a cell-
based high-throughput assay with the LacZ substrate, MUG [11].  The Vidal-
Aroca method monitored !-galactosidase activity in black/clear-bottom microtiter 
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plates, however fluorescence measurements were more consistent in black 
opaque plates.  For this reason, the preliminary absorbance readings were 
omitted, and the data was reported in fluorescence units as opposed to Miller 
Units.  One difficulty with the MUG assay was the increased background due to 
inherent fluorescence in the media (Figure V-4B).  This increase is likely due to 
the presence of riboflavin in the rich media, which fluoresces at approximately 
the same wavelengths (%ex = 350 nm, %em = 450 nm).  Some success in reducing 
the signal to background ratio was achieved by conducting the assay with plac-
LacZ" in minimal media, but it seems unlikely that these conditions would 
translate well to the VirF reporter assay (see Chapter IV: Troubleshooting VirF 
Expression).   In addition, optimal !-galactosidase activity results were observed 
following induction in shaking, independent cultures.  This technique is suitable 
for a small volume of samples but would never be amenable to development of a 
high-throughput assay.  Ultimately, use of the MUG substrate was abandoned 
due also to the non-specific hydrolysis observed in plasmid-free TG2 cells (data 
not shown).  
CPRG was the next !-galactosidase substrate selected for assay 
optimization due to the sensitivity of CPRG to low LacZ concentrations.  In 
addition, the yellow substrate turns a deep red upon hydrolysis by !-
galactosidase, and accumulation of the chlorophenol red product is easily 
detected by absorbance.  One potential concern with use of CPRG was the 
optical density of the cells necessary for conducting the VirF assay.  The whole-
cell assay could require long growth periods to produce enough VirF protein that 
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could in turn activate expression of a reasonable amount of !-galactosidase.  
The optical density is typically measured at A600, and a high cell content could 
complicate the measurement of chlorophenol red at A575.  Because high 
background had also been an issue with MUG, it was important to develop this 
method further with the lac promoter-driven constructs. 
Trials with CPRG were conducted to monitor LacZ "-complementation in 
both pACYC184 and pTZ18U to address the issue of plasmid copy number 
(Figure V-5).  The "-complementation assay with pTZ18U($MCS) produced 
higher absorbance measurements in the CRPG assay than the low copy vector, 
plac-LacZ" (3-6 fold).  However, the variability between replicates was also 
increased in the high copy-number vector.  To determine whether this 
observation was a result of the alteration in lacZ!, wildtype pTZ18U was also 
assayed in TG2 cells.  The replicates were much more consistent in the 
unaltered "-complementation assay (Figure V-6).  Expression of the full-length 
lacZ gene from a high copy-number vector, pET-LacZ (pET28a derivative), was 
also monitored for comparison between "-complementation and expression of 
the native reporter sequence (Figure V-6).  The most successful expression of 
LacZ in a lac promoter-based vector was demonstrated in the permeable E. coli 
strain, EC2880.  This cell line was commonly used in high-throughput screening 
endeavors at Pfizer.  The "tolC mutation results in increased drug permeability 
and allows for study of molecules that might otherwise be removed by the drug 
efflux pump.  With these results taken together, we made several conclusions in 
moving forward with the VirF reporter assay: 1) measuring !-galactosidase 
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activity with "-complementation is not suitable for detailed assay measurements, 
2) expression of VirF and LacZ in a single, high-copy vector would be optimal, 
and 3) detection of !-galactosidase activity by CPRG is the most sensitive in 
liquid culture. 
Following construction of the all-encompassing VirF reporter plasmids, 
pMALvirF-LacZ and pBADvirF-LacZ, each construct was assayed in EC2880.  !-
galactosidase activity was very high in the uninduced samples, but activity was 
reduced in pMALvirF-LacZ supplemented with 2 mM IPTG (Figure V-7).  
Interestingly, inhibition of VirF in the presence of IPTG has been observed 
previously [13].  Standard induction with 1 mM IPTG resulted in growth inhibition 
in Shigella, and VirF expression was achieved only through induction with 
submillimolar concentrations (50-100 #M IPTG).  One potential explanation for 
this uninduced !-galactosidase activity is the result of leaky VirF expression.  
Another concern is the possibility that the virB promoter controlling expression of 
the lacZ gene is being activated by an E. coli transcription factor.  A report 
published by C. Dorman and colleagues detailed the cross-reactivity of the 
enterotoxigenic E. coli AraC-type transcriptional activator, Rns, which was shown 
to activate transcription of VirF-specific promoter sequences [14].  It is possible 
that we are detecting Rns-activated expression of !-galactosidase in our E. coli 
cell-based assay, as opposed to leaky expression of the VirF protein. 
Because there is no other known transcriptional activator in Shigella that 
can activate VirF promoters, the VirF reporter assay was optimized in an 
avirulent strain of Shigella flexneri, BS103 [15].  BS103 is a derivative of S. 
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flexneri 2a that has been cured of the 220 kb virulence plasmid, and hence lacks 
endogenous virulence gene expression (including virF, virB, and virR (hns)).  As 
with E. coli, uninduced !-galactosidase activity was observed in both pMALvirF-
LacZ and pBADvirF-LacZ (Figure V-8A and B, respectively).  With no other 
activator capable of initiating transcription of the virB-lacZ open reading frame, 
the resultant activity was hypothesized to be the result of leaky VirF expression.  
With no known small molecule inhibitor of VirF, a deletion in the malE-virF open 
reading frame was constructed in each reporter plasmid to monitor any 
background LacZ expression not related to VirF-specific activation.  This 
construct was in every other aspect identical to the reporters discussed 
previously.  Assays were conducted with the pMAL($virF)-LacZ reporter due to 
the increased !-galactosidase activity observed in the tac promoter-based 
system.  We confirmed that LacZ expression in BS103 is the direct result of VirF 
activation of the virB promoter, with the "virF reporter responding similarly to the 
"lac BS103 cell control (Figure V-8C). 
With optimized conditions for the reporter construct and positive control, !-
galactosidase substrate for the cell-based assay, and Shigella cell line in place, 
the high-throughput assay methods were defined in conjunction with the Center 
for Chemical Genomics (University of Michigan).  One primary difference in HTS 
assay setup in comparison to the lab protocol described previously is the initial 
growth phase.  Cells had previously been grown in batch culture with shaking to 
the optimal induction OD600, then cells were plated from this common stock for 
induction in microtiter plates.  Reproducibility in the new assay setup was critical 
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to establish that cell growth and corresponding !-galactosidase activity would be 
uniform.  Another benefit to monitoring assay conditions at the CCG is the narrow 
band pass filter used in the PHERAstar plate reader, which has an increased 
sensitivity in absorbance measurements in comparison to the monochromator 
detection of the Molecular Devices plate reader.  Conditions for optimal cell 
growth and !-galactosidase activity were identified in 384-well microtiter plate 
format, and a reasonable Z’ factor = 0.59 was achieved (Figure V-9). 
Although enzymatic activity was relatively consistent across the plate, 
there was an issue of evaporation around the perimeter of each microtiter plate.  
These so called “edge effects” were also observed in other cell-based assays 
performed at the CCG.  In these wells, although the OD600 reading was not 
altered significantly, the total volume was reduced by 5-10 #L.  This phenomenon 
was more pronounced following overnight growth at 37°C.  Because the 
virulence plasmid has been removed from the BS103 cells, there was no concern 
of temperature-regulated VirF inhibition with growth at lower temperatures, so 
HTS was performed at 30°C.  Another issue of consistency observed in the cell-
based reporter assay was the length of incubation time.  Typically cells were 
plated in the presence of compound for approximately 24 hours prior to addition 
of the substrate/detergent mixture, and the relatively consistent OD600 readings 
indicate that cell growth was uniform across the primary assay (Figure V-10A).  
However, one set of plates was measured following ~30 hours of incubation 
(Cmpds. 40,000-50,000), and both the OD600 measurement and A570 values for 
these plates have a skewed background for !-galactosidase activity (Figures V-
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10A and B, respectively).  Although there was discrepancy in some cases 
between wells and plates, the internal controls for each plate were used to 
normalize the data.  Overall the “noisy” data is reflected in a lower Z’ factor  0.4, 
but we felt keeping all the data was most beneficial to our understanding of small 
molecule inhibition of VirF in the reporter assay. 
Approximately 3% of the compounds tested in the primary screen 
demonstrated modest to significant inhibition of the VirF-LacZ assay.  These 
compounds were confirmed in triplicate according to the primary assay protocol.  
The confirmation screen was more consistent, although there were a few new 
compounds that exhibited antibacterial activity previously undetected (Figure V-
11A).  As a preliminary counter screen, purified !-galactosidase was pre-
incubated with the same small molecules in vitro.  Most compounds tested in the 
confirmation screen did not inhibit the reporter directly (Figure V-11B, Table V-2).  
One concern is this counter screen does not address the issue of non VirF-
specific activity.  The best counter screen to address off-target activity would be 
another cell-based system where LacZ expression was activated by the 
endogenous Shigella transcription complex.  We had initially considered this with 
the lac promoter-driven reporter plasmid (plac-LacZ").  However, Shigella is a 
"lac strain, and thus transformation with a lac-driven reporter would be 
ineffective.  One potential candidate is the endogenous trp promoter. 
The confirmation hits were triaged further, taking into account the 
“drugability” of the potential lead molecules.  Ultimately a set of 238 compounds 
were selected for dose response analysis.  Although most compounds did not 
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demonstrate dose-dependent inhibition of the VirF-LacZ assay, 7 small 
molecules were identified, with IC50 values in the low-mid micromolar range 
(Table V-3).  The data were fit by non-linear regression for sigmoidal kinetics, 
and the reported pIC50 values were converted to IC50 values.  Interestingly, 
several compounds identified were also characterized as “active” in other 
bacterial cell-based assays targeting transcription factors. The 7 confirmed 
compounds identified in the VirF-!-galactosidase assay have each been tested in 
& 35 individual assays, including screens against prokaryotic and eukaryotic 
targets in vitro and in vivo.  In general, the compounds have demonstrated little 
activity against eukaryotic targets.  The similarity in effects against assays with 
structurally distinct proteins performing similar functions (i.e., DNA-binding, 
transcriptional activation) could suggest that these small molecules target a 
conserved function of bacterial transcription factors.  Further studies are needed 
to confirm the specificity of these small molecules. 
Conclusions 
In collaboration with the University of Michigan, Center for Chemical 
Genomics (CCG), we have developed a cell-based bacterial transcription assay 
amenable for high throughput screening (HTS) of large compound libraries 
against VirF from Shigella flexneri.  Initial HTS results screening ~42,000 small 
molecules in the VirF-LacZ reporter assay identified 238 potential hits with 
favorable medicinal chemistry properties (i.e., molecular weight < 600, no 
reactive or toxic functionalities, logP < 7).  Dose response data for 7 compounds 
revealed IC50 values in the micromolar range (1-90 #M).  Future work will be 
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conducted with several secondary assays (i.e., in vitro DNA-binding assay and in 
vitro transcription assay) to probe the mechanism of inhibition for these “hits”.  
Work will also be conducted with other AraC-type proteins to identify scaffolds 
with broad-spectrum activity in this family of bacterial transcriptional activators. 
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Shigella flexneri, a causative agent of bacillary dysentery, is an 
enteropathogen that invades the intestinal mucosa.  A food- and water-borne 
pathogen, Shigella infections are most commonly found in third-world countries 
where sanitation standards are lower than in the more developed nations [1].  
Increasing emergence of antibiotic-resistant strains of Shigella heightens the 
need for identification of novel antibacterial targets for a directed drug discovery 
approach in the treatment of shigellosis.  One facet of Shigella infection is the 
expression of key virulence factors (i.e., VirF, VirB, TTSS), found on a large 
molecular-weight virulence plasmid, that promote cell contact and expression of 
all downstream virulence genes [2].  The master positive regulator of the 
virulence plasmid is VirF, an AraC-type transcriptional activator, which functions 
primarily to activate the secondary virulence regulator, VirB.  Mutant Shigella 
flexneri ($virF) strains have been characterized as avirulent, demonstrating the 
importance of this key virulence factor in the pathogenicity cascade. 
Many cellular factors have been implicated in the transcription of virF 
mRNA (i.e., DNA superhelicity, pH, temperature) and translation of the VirF 
protein (i.e., concentration of oxygen, iron, amino acids) [3-5].  Interestingly, VirF 
protein levels in an S. flexneri ($vacC) strain were reduced to ~40% in 
comparison to the concentration of VirF in wild-type Shigella [6].  VacC is the 
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Shigella homologue of tRNA-guanine transglycosylase (TGT), which catalyzes 
the incorporation of the non-canonical nucleoside queuosine (Q) into four 
substrate tRNAs (tRNAAsn, Asp, His, Tyr).  This relatively subtle decrease in VirF 
protein expression resulted in a decreased ability for the bacteria to invade host 
cells in a hemolytic assay.  It is conceivable that a modest VirF inhibitor could 
ultimately become a potent antibiotic against Shigella.  We proposed targeting 
the VirF protein as a novel antibacterial target in Shigella flexneri.  The purpose 
of this dissertation is to address both the role of TGT and the queuine 
modification in expression of the VirF protein and identify potential inhibitors of 
VirF through development of a high-throughput reporter assay. 
We hypothesize that TGT modulates VirF expression with queuine 
modification at both the level of tRNA and the virF mRNA.  We report that the 
modification state of tRNA with queuine and the Q-cognate codon usage (NAU 
versus NAC codons) in the target mRNA alters the rate of protein expression.  
Using GFP (green-fluorescent protein) as a model protein, we observe that 
expression of gfp mRNA with relatively equivalent queuine-cognate codon usage 
results in similar rates of translation with either tRNA-G34 or -Q34.  In every case, 
the rate of translation was slower in the mutant E. coli K12($tgt) in comparison to 
wild-type K12.  In addition, the rate of GFP translation was slower for every 
codon-biased construct in comparison to GFP(wt), with the exception of GFP(U) 
in K12.  The rate of translation from gfp mRNA with a significant NAU-bias is 
increased in wild-type E. coli expressing tRNA-Q34, while the rate of translation 
from gfp mRNA with pronounced NAC-bias is decreased in E. coli ($tgt) with 
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tRNA-G34.  VirF mRNA contains an overall bias of 80% for the NAU Q-cognate 
codons, and it is conceivable that the subtle decrease in VirF protein expression 
in the S. flexneri ($vacC) mutant could result from the absence of queuine-
modified tRNA.   
In addition, we report that the virF mRNA is itself a substrate for E. coli 
TGT in vitro [7].  TGT has a rather minimal recognition element: a U-G-U 
sequence in a hairpin loop structure.  In addition to tRNA, the enzyme can 
recognize and modify other substrates with this motif, including a minihelical 
hairpin and a dimeric form of tRNATyr [8].  We observe that TGT catalyzes the 
incorporation of queuine into virF mRNA with KM = 1.8 #M [7].  A minihelical virF 
substrate (corresponding to nucleotides 410-433) was modified by TGT with KM = 
0.87, but a virF mRNA(G421A) point mutant was not recognized as a substrate by 
TGT.  Taken together, these results suggest that the virF mRNA is site-
specifically modified by TGT in vitro, exchanging guanosine 421 (G421) with 
queuine.  Direct recognition of virF mRNA could help explain the observation that 
the VirF protein concentration was specifically decreased in the Shigella flexneri 
($vacC) mutant.  Interestingly, this is the first observation of a modified 
nucleoside incorporated within the open reading frame of an mRNA. 
A wide variety of techniques were employed to express recombinant VirF, 
including expression of several fusion tags, co-expression with molecular 
chaperones, decreased expression temperatures, and in vitro translation from 
both mRNA and DNA starting materials.  The isolation of soluble, full-length VirF 
was ultimately successful only when expressed as a MalE-fusion, as described 
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previously [3].  Two fragments of the VirF protein were also expressed in E. coli, 
the VirF(29-263) protein with a truncation in the first 28 amino acids and 
VirF(154-263) containing only the DNA-binding domain.  The expression and 
purification of soluble VirF(154-263) was successful in E. coli, and the truncated 
protein was shown to bind linear fragments of the virB promoter in vitro (Biswas 
and Tsodikov, unpublished).  The level of VirF(29-263) expression was high in 
cells, but the product was predominantly insoluble.  Ultimately, soluble protein 
was recovered from a mutant VirF(29-263, V141I) construct when co-expressed 
with the molecular chaperones DnaK, DnaJ, and GrpE.  This point mutant 
(translated from the G421A mutant virF mRNA) helps to illustrate two key factors 
regarding the VirF protein: 1) the first 28 amino acids partially contribute to VirF 
insolubility, and 2) the increased solubility of this conservative mutant fragment 
could suggest a potential relevance to the TGT/queuine modification in the virF 
mRNA. 
Because expression of purified, un-tagged VirF was unsuccessful, we 
were unable to gain structural information by x-ray crystallography or other 
biophysical methods.  Instead, we focused on development of a functional assay 
to monitor VirF activity in the presence of potential small molecule inhibitors.    A 
plasmid was constructed expressing the !-galactosidase reporter gene fused to 
the virB promoter, the downstream DNA target of VirF, and the tac promoter-
controlled MalE-VirF fusion.  We report VirF-specific activation of !-galactosidase 
activity in the virulence plasmid-cured strain Shigella flexneri BS103.  The 
positive control for VirF inhibition was measured by expression from a plasmid 
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with a deletion in the malE-virF open reading frame.  Approximately 42,000 small 
molecules were tested in a high-throughput, cell-based assay measuring !-
galactosidase activity with the colorometric substrate, CPRG (chlorophenol red !-
D-galactopyranoside) [9].  We have identified 7 small molecules that inhibit the 
VirF – !-galactosidase reporter assay in a dose-dependent manner (typical IC50 
values between 1-100 #M).  Further studies are pending to address the 
mechanism of action for each compound. 
In conclusion, we have identified two potential avenues for TGT 
modulation of VirF expression, acting at the level of tRNA and virF mRNA 
modification.  We have also developed a high-throughput, cell-based assay to 
measure transcriptional activation by the VirF protein in Shigella.  We are 
working to identify small molecule inhibitors that may be transformed into new 
antibiotics in the treatment of shigellosis.  These experiments will hopefully lead 
to an increased understanding of VirF from Shigella flexneri and ultimately this 
complex class of AraC-type transcriptional activators. 
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